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Abstract
The coordination of events and cellular interactions within the uterus is vital to the
establishment of pregnancy, a process constrained to a narrow window of time within
the ovarian cycle. The transformation of the endometrium into decidua is one such
event and is considered essential to embryo implantation and to the maintenance of
pregnancy. In humans these changes are most dramatic in the stromal compartment and
are influenced by progesterone, secreted by the Corpus Luteum (CL). This hormone is
believed to be the main factor inducing such differentiation in the oestradiol-primed
stroma. However, mediators with the ability to activate the protein kinase A/cAMP
pathway, such as Prostaglandin E2 (PGE2) and relaxin, are potent inducers of
decidualisation when administered alongside progesterone in endometrial stromal cells
(ESCs) in vitro. Uterine Natural Killer (uNK) cells increase in number in secretory
phase endometrial stroma, implying the control of progesterone on their expansion.
However, they lack the nuclear progesterone receptor and growth and differentiation
may depend on interactions with ESCs. uNK cells replicate upon Interleukin-15 (IL-15)
administration in vitro and this cytokine is expressed in the epithelial and stromal cells.
The aims of this research project have been to investigate in vitro decidualisation of
ESCs and regulation of IL-15 and uNK cells in order to extrapolate how ESCs and uNK
cells may interact during the secretory phase and early pregnancy.
The present study has explored the factors involved in decidualisation using primary
human ESC cultures. Quantitative real-time PCR (Q RT-PCR) and Enzyme-linked
Immunoabsorbant Assays (ELISA) have been used to investigate effective in vitro
stimuli of decidualisation. A combination of treatment with a progestin and either 8-
Bromo cAMP or PGE2 was capable of stimulating decidualisation in ESC cultures as
determined by increases in two markers of this process, prolactin and insulin-like growth
factor-binding protein-1 (IGFBP-1). Further analysis has revealed the changes taking
place within the PGE2 pathway in decidualising ESCs, including an upregulation in the
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EP2 prostaglandin receptor messenger RNA (mRNA) upon treatment with 8-Bromo
cAMP plus a progestin.
The results present here have demonstrated a rise in IL-15 mRNA levels in parallel with
in vitro decidualisation. It appears that both progesterone and the intracellular
messenger, cAMP, are involved in decidualisation and IL-15 expression. IL-15
secretion from the cells is shown to be IFN-y dependent. The expression of IL-15 and
interferon-y (IFN-y) mRNA across the menstrual cycle has been established.
Immunohistochemistry was used to determine IL-15 expression during simulated early
pregnancy compared with normal luteal controls and has shown that secretions of the
CL, including progesterone and/or relaxin, have the ability to increase IL-15 expression
in vivo. Primary cultures of human uNK and peripheral blood NK cells have been used
for studying the T helper 2-type cytokine IL-10 which is believed important for the
support of early pregnancy. In response to PGE2 treatment, uNK cells expressed and
secreted raised levels of IL-10, an anti-inflammatory cytokine.
Further investigation into the interactions between the convergence of the cAMP and
progesterone intracellular pathways and their receptors would be important in clarifying
the exact mechanisms controlling ESC decidualisation and IL-15 regulation. The
interactions between ESCs and uNK cells need to be clarified further to assess the roles
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1.1 The Uterus and the Menstrual Cycle
The uterus has the role of supporting and retaining the fetus throughout pregnancy. The
organ is lined by a glandular tissue layer termed the endometrium and in the non¬
pregnant state the functional layer of the human endometrium undergoes cyclical
regeneration and degeneration. This takes place over a 28 day period and is primarily
determined by the ovarian hormones, oestrogen and progesterone. A progressive and
sequential maturation of the endometrium is essential preparation for implantation of the
blastocyst. There are three major phases, namely menstruation, proliferation and
secretion (figure 1.1). The secretory phase is surprisingly highly regular in length, even
if there is individual variation in proliferative phase length. The functional layer of the
endometrium is shed via the process of menstruation if implantation fails to occur. This
layer is then replenished from the basal endometrial layer and the process begins once
more. The major cyclical changes in response to progesterone and oestrogen have been
described by Noyes et al 1950 (Noyes et al., 1950) (figure 1.2).
1.1.1 The Proliferative Phase
The proliferative phase lasts from day 4 to day 14 of the cycle and is oestrogen
dominated. Oestrogen receptors are present in the glandular and stromal compartments
as are progesterone receptors during the follicular phase (Lessey et al., 1988; Snijders et
al., 1992; Wang et al., 1998). The primary source of oestrogen is the developing
Graaffian follicle. Follicle stimulating hormone (FSH) released from the pituitary gland
stimulates maturation of one or more of these follicles. The oestrogen released
stimulates proliferation of the endometrium and this is reflected by a variety of changes.
New glands form and are straight and tubular in structure and along with the stroma,
regenerate from the residual basal endometrium. The nuclei of the glands become
prominent and increase in mitotic activity. In the compact stromal compartment mitoses
are also abundant. The stroma becomes highly vascularised and the arteries become
14
spiral in formation. As the luteinising hormone (LH) surge on day 14 approaches the
glands become pseudo-stratified and tall and columnar in shape.
1.1.2 The Secretory Phase
The secretory phase commences from day 16 to 25 and is progesterone dominated. The
continued release of LH from the pituitary induces the luteinisation of the theca and
granulosa cells of the corpus luteum (CL). The granulosa lutein cells secrete
progesterone, maintaining the secretory transfonnation of the endometrium.
In the early secretory phase the glands develop subnuclear vacuoles of glycogen and
they become convoluted. The gland mitoses decrease at this point and are absent after
day 18. The glandular glycogen deposits begin to appear on the apical side of the cells
around day 18 of the cycle and continues to increase with maximal secretions being
released around days 20 and 21 before exhausting their stores. The tortuosity of the
glands increases in the mid to late secretory phase. Stromal oedema increases across the
secretory phase, peaking in the mid-section. During the mid to late secretory phase the
stromal cells begin to change both structurally and functionally. This predecidual
change is initially observed around the spiral arterioles before it spreads to other regions
of the stroma. The stromal cells undergo a decidual reaction in preparation for
implantation and progressively forms the decidua during pregnancy. Pinopodes are
expressed on days 19-21 on the apical surface of the luminal uterine epithelium. The
timing of their appearance is progesterone-dependant and they appear around the time of
implantation (Martel et al., 1991; Nikas et al., 1995; Nikas et al., 1997).
In the late secretory phase, an infiltration of leukocytes invades the endometrium.
Although macrophages and lymphocytes accumulate, the major leukocyte cell type in
the secretory phase is the uterine Natural Killer (uNK) cell. These cells remain abundant
in the first trimester of pregnancy and will be discussed in more detail in section 1.2.2.
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Figure 1.1
Diagrammatic representation of the cyclical nature of degeneration and regeneration of
the functional endometrial layer with the major stages being highlighted. This is based
on the "classic" 28 day cycle in humans.
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Figure 1.2
The changes that take place in the human endometrium across the menstrual cycle basec
on the "classic" 28 day model as described by Noyes et al 1950 (Noyes et al., 1950).
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1.1.3 Oestrogen and Progesterone
The co-ordinated actions of the steroid hormones, oestrogen and progesterone, are
pivotal to succinct female reproductive functions. They act throughout the reproductive
tract, including the hypothalamus, pituitary, uterus and ovary. The effects of oestrogen
are not restricted to the reproductive system proving to be crucial in bone remodelling
(Prior, 1990) and is involved in peripheral vasoreactivity (Hashimoto et al., 1995). The
effects of hormones and hormone replacement therapy on vascular function is discussed
by Ganz (Ganz, 2002).
Oestrogens act on the uterus to increase cellular proliferation across the proliferative
phase and also act to prime progesterone receptors (PR) during this phase. The presence
of a functioning PR is crucial to fertility in mice with PR knockouts being infertile
displaying defective ovulation, implantation and stromal cell decidualisation (Conneely
et al, 2002). The actions of oestrogen and progesterone are mediated via their cognate
receptors located intracellularly in the nuclear compartment primarily, and in turn, the
ligand may act to control levels of receptor expression. Thus, the hormones themselves
are capable of modifying the concentration of receptors at the end-organ and this will
partly determine the extent of their actions. Hormone-bound receptors interact to
modulate gene transcription resulting in a function change. There are two types of
oestrogen receptor (ER), ERa (Green et al, 1986) and ERp (Kuiper et al., 1996;
Mosselman et al., 1996), and two isoforms of the progesterone receptor (PR) exist, PR-
A and PR-B (Horwitz et al., 1983; Lessey et al., 1983). PR-A and PR-B arise from
different promoters of the same gene located on chromosome 11 (Clarke et al., 1990;
Kastner et al., 1990). PR-B is identical to PR-A with the exception that it differs in
length by being an additional 164 amino acids in length than PR-A (Horwitz et al,
1983). Upon binding its receptor, progesterone triggers a conformational change and
receptor dimerisation. Heat shock proteins also become dissociated from the receptor in
the binding procedure. A third PR has been identified and termed PR-C and may be able
to alter the transcriptional activity of PR-A and PR-B (Wei et al, 1990; Wei et al,
19
1996). In addition, more recently a fourth novel, truncated PR has been cloned from
human adipose and aortic cDNA libraries and is believed to have a non-genomic action
(Saner et al., 2003). The functional importance of this receptor with context to the
endometrium is currently under investigation.
1.1.3.1 Receptor Cross-talk
Communication also takes place between the oestrogen and progesterone receptors. PRs
are under the dual control of both oestrogen and progesterone. Experiments involving
rat uterine cells demonstrated that when either a progestin or anti-progestin is bound to
either PR-A or -B a resulting inhibition in oestradiol's ability to stimulate ER activity is
reported (Katzenellenbogen, 2000). Exposure of the endometrium to high dose
progestins, as with the Levonorgestrel-releasing intrauterine system (LNG-IUS), down-
regulates the ER and PR-A and PR-B in both the glands and stroma (Critchley et al.,
1998b) implying a dependency of ER levels on progesterone and its receptors.
1.1.3.2 Immunohistochemical Localisation
Immunohistological studies within the human endometrium have described the cyclical
variation of oestrogen (ER) and progesterone receptor (PR) levels in both functional and
basal regions and within the epithelial and stromal compartments (Garcia et al., 1988;
Lessey et al., 1988; Critchley et al., 1993; Snijders et al., 1996; Wang et al., 1998)
(Summarised in table 1.1). They have demonstrated the nuclear locality of both steroid
receptors. PR-A and PR-B are located in the glands and stroma during the proliferative
phase but only the PR-A isoform is present in the functional layer across the secretory
phase and early pregnancy and is localised to the stromal cells (Wang et al., 1998). This
implies that PR-A is responsible for the luteal phase actions of progesterone within the
stroma and in particular on decidualisation. Immunoexpression of ERa increases in the
functional layer across the proliferative phase and reaches a peak in the late proliferative
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endometrium. The ER in the glands is down-regulated in the secretory phase by the
rising progesterone levels. This reduction of ER can be blocked by administration of the
anti-progestin, RU486, when applied early in the secretory phase confirming the role of
progesterone (Maentausta et al., 1993; Cameron et al., 1996). A decline in ERa occurs
in glandular and stromal compartments of the functional layer across the secretory
phase. In situ hybridisation has located the two ER isoforms within the human
endometrium (Matsuzaki et al., 1999). The same expression pattern for ERa was
observed as with the immunohistological studies. ERp mRNA was detected in both
glands and stroma with decreased expression in the glandular region in the late secretory
phase functional layer (Critchley et al., 2001a; Lecce et al., 2001). The ERp was also
localised to endothelial cells implying an influence on vascular regulation. In women
with compromised fertility and receiving clomiphene citrate "anti-oestrogen" therapy,
the low pregnancy rates achieved were correlated with low oestrogen receptor
concentrations in the preovulatory endometrium (Ohno et al., 1998).
A study in vitro has shown that during decidualisation the PR-A is more abundant than
PR-B. However, they found a reduction in the PR-A with progression of the
decidualisation process and this reduction was accelerated by addition of a synthetic
progestin (Brosens et al., 1999). In addition, transient transfection of either PR-A or
PR-B caused an inhibition of decidual prolactin (Prl) promoter-reporter construct in
response to cAMP. Following insertion of LNG-IUS both isoforms of the PR are
downregulated in the glands and the stroma (Critchley et al., 1998b) implying regulation
of both isoforms by their ligand. It appears to be PR-A that is essential to uterine and
ovarian reproductive processes, at least in the murine uterus (Conneely et al., 2002).
They discovered that in the chick oviduct PR-A and PR-B are produced by translation at
two distinct AUG signals encoded by a single gene and could therefore selectively ablate
either of these isoforms (Conneely et al., 1987). Mouse knock-outs for PR-A exhibited
infertility, whilst the necessity of the PR-B isoform is restricted to the mammary gland
(Conneely et al., 2002).
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Table 1.1
Relative immunostaining intensity for oestrogen and progesterone receptors in the
functional and basal endometrium across the proliferative and secretory phases of the
cycle. Negative immunostaining is represented by (-), positive immunostaining is
represented by (+) or (++) depending on intensity. Adapted from Critchley 2000
(Critchley, 2000).
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Proliferative phase Secretory phase
Glands Stroma Glands Stroma
Functional
PR-A+B ++ ++ - ++







PR-A+B ++ ++ + ++
ERa ++ ++ + +
ERp ++ ++ ++
++
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1.1.4 Regulation of Menstruation
If implantation fails to occur, the functional layer of the endometrium is shed by the
process of menstruation in response to declining progesterone levels as a result of CL
demise. The work of Markee 1940 on the rhesus monkey provides much of our present
understanding of the vascular changes occurring during menstruation with the
determination that progesterone and oestrogen are major controlling factors over these
structural changes. It was known that progesterone acts following oestrogen priming
and then is withdrawn in the lead up to menstruation. The effects of these hormonal
changes were studied in endometrial fragments transplanted into the eye of the rhesus
monkey, where changes in the vasculature could be observed (Markee, 1940). Vessels
become coiled across the luteal phase to form the spiral arterioles and upon withdrawal
of progesterone these become vasodilated followed by vasoconstriction (Markee, 1940).
This results in lesions and breakdown of the tissue. The vasoactive products found in
menstrual fluid have been identified as being PGE2 and PGF2a (Lumsden et al., 1983).
Hormones have been implicated in regulating production of these prostaglandins (PG) in
the human endometrium via explant studies (Abel et al., 1980; Abel et al., 1983) and a
more detailed account of their regulation is discussed in section 1.4.1. PGF2a is a
vasoconstrictive agent and has been implicated in the initiation of menstruation (Baird et
al., 1996). During the mid luteal phase prostaglandin dehydrogenase activity (PGDH) is
high relative to the proliferative phase and therefore mediates metabolism of PGE2 and
PGF2ct (Casey et al., 1980; Critchley et al., 1998a).
1.1.4.1 Menstruation and Inflammation
The process of menstruation appears to be multi-factorial and in addition to hormonal
control, the process is considered to be an inflammatory event (Finn, 1986; Kelly et al.,
1994). Leukocytes infiltrate into the endometrium in the pre-menstrual phase, in
addition to providing defence against pathogens at this vulnerable time, they are also
likely to be involved directly in tissue breakdown via production of proteases, and
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indirectly by the release of chemokines and cytokines. Infiltration and the roles of these
different cells will be discussed in section 1.2.1. These leukocytes include macrophages,
neutrophils and uNK cells and all lack genomic steroid receptors (Poropatich et al.,
1987; Henderson et al., 2003) and therefore paracrine control over these cells must be
occurring. Neutrophils are expressed across the cycle in very low numbers but rise
dramatically in the immediate premenstrual phase to sites of uterine inflammation
(Noyes et al., 1950; Kamat et al., 1987; Poropatich et al., 1987). An important
chemotaxis stimulus for neutrophils is IL-8 (neutrophil chemotactic factor) (Rampart et
al., 1989; Colditz et al., 1990).
1.1.4.2 Matrix Metalloproteinases (MMPs)
Matrix metalloproteinases (MMPs) are enzymes released by both the invading immune
cells and by the stromal cells. The breakdown of the extracellular matrix has been
attributed to the actions of MMPs (Schatz et al., 1997; Lockwood et al., 1998;
Salamonsen et al., 1999) and their role in menstruation implied by the timing of their
expression within the human endometrium (Rodgers et al., 1993; Hampton et al., 1994;
Rodgers et al., 1994). MMPs are likely to be under progesterone-control since
withdrawal of progesterone in cultures of endometrial stromal cells (ESCs) enhances
proMMP-2 (Irwin et al., 1996) and proMMP-3 (stromelysin-1) production (Schatz et al.,
1994). A culture system of human ESCs was used to mimic the luteal phase and
demonstrated upregulation of MMP-1, -2, -3 and -4 in latent form upon progesterone
withdrawal (Salamonsen et al., 1997). Their tissue inhibitors (TIMPs) were also
analysed and showed no regulation of TIMP-1, -2 and -3 upon withdrawal of
progesterone, thus implicating a greater complexity to MMP regulation beyond that of
being solely progesterone-determined. Leukocytes are another source of MMPs and via
stromal and epithelial interactions, MMP release and action from this source may be
being controlled (Salamonsen et al., 2000).
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1.1.4.3 Vascular Endothelial Growth Factor (VEGF) and Hypoxia
The type 2 receptor for vascular endothelial growth factor (VEGF), KDR, is expressed
only in endometrial endothelial cells until the premenstrual phase when expression is
observed in the superficial stroma (Nayak et al., 2000). VEGF is expressed across the
menstrual cycle (Zhang et al., 1998a) and is upregulated during the menstrual phase via
a hypoxic stimulus (Sharkey et al., 2000). Flypoxia has been shown to raise VEGF
levels in cultures of human ESCs (Popovici et al., 1999) and the presence of the
response element for the hypoxia inducible factor has been located on the VEGF
promoter (Goldberg et al., 1994). In vitro decidualised ESCs express greater levels of
VEGF compared with controls using Microarray Technology (Popovici et al., 2000).
VEGF has been shown to increase the expression of MMPs (Unemori et al., 1992; Wang
et al., 1998) and may be acting as an additional control on MMP production during the
premenstrual phase (Nayak et al., 2000; Critchley et al., 2001b).
As discussed by Salamonsen et al 1999 menstrual degeneration is focal and not
ubiquitous throughout the endometrium, with the regeneration and repair of the
endometrium beginning to occur 36 hours after the onset of menstruation. During this
repair process no scarring is evident as with normal tissue repair although the exact
mechanisms are not yet understood it may be relevant in understanding pathologies such
as menorrhagia (Salamonsen et al., 1999).
1.1.5 Decidua and Pregnancy
Decidualisation is unique to species that undergo haemochorial placentation and in the
human endometrium is considered an essential pre-requisite for establishment of
pregnancy. The decidua is the transformed endometrium that is morphologically and
functionally distinct. The endometrial cells differentiate and an infiltration of lymphoid
cells occurs. Specific products are secreted by decidual cells, for example prolactin and
IGFBP-1, and their potential functions, with regard to pregnancy, are discussed in
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section 1.3.1.1. With regard to humans it is difficult to assess the direct necessity of
decidualisation to implantation. However, it occurs in every menstrual cycle in advance
of implantation and it may be that products of decidua are involved in this process.
Conditions involving disturbance of stromal differentiation, such as endometriosis and
luteal phase defect (LPD) can result in reduced fertility and menstrual irregularity
(Vanrell et al., 1986; Ronnberg, 1990; Lessey, 2002) and this evidence implicates
decidualisation in being critical to the implantation process. LPD affects 3-4% of
infertile women and can be defined as a lag of greater than 2 days histological
development compared to the cycle day. This condition is believed to be due to either
inadequate action or secretion progesterone, an essential stimulus for decidualisation.
Decidual cells may play significant roles in controlling the extent of trophoblast invasion
(Pijnenborg et al., 1981). If implantation occurs in regions deficient of decidua, due to
scar tissue, over-invasion occurs and conversely if under-invasion occurs the result
could be the development of pre-eclampsia. Recently alpha-2 macroglobulin (a-2M), a
product of endometrial endothelial cells, has been shown to be involved in decidual
regulation of trophoblast invasion in mice (Esadeg et al., 2003).
A 50% pregnancy loss occurs at the time of implantation and therefore it is apparent that
this is a critical time for the endometrium to either continue with decidualisation or to
breakdown by the process of menstruation. Decidual cells are also thought to be
important in preventing uterine bleeding in the peri-implantation phase of the cycle and
have been associated with spontaneous abortion and pre-term birth (Schatz et al., 2001).
Decidualisation initially occurs in the perivascular stromal cells and it may be that these
decidual cells are involved in the control of menstruation (Kelly et al., 2002). This close
association with the blood vessels may allow control over the vasculature and the
decision to stabilise or degenerate. These cells have been shown to produce IL-8
(Critchley et al., 1994) thus stimulating neutophil influx and tissue breakdown via
production of enzymes. The decision of the endometrium to breakdown or to fully
differentiate is likely to be related to secretion of cytokines and other factors during
implantation.
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1.2 The Uterine Immune Environment
1.2.1 Leukocyte Infiltration in the Endometrium
According to the criteria of Noyes et al 1950, there is an infiltration of leukocytes in the
late secretory phase (Noyes et al., 1950) (figure 1.2). The major leukocyte populations
located in human endometrium and decidua are macrophages, T cells, B cells and uNK
cells and the uNK cell numbers alter in a cyclical manner (Loke et al., 1997). The
proliferative phase and early secretory phases have a relatively low abundance of
leukocytes, as demonstrated by immunohistochemical staining with the surface marker,
CD56, with an increase in the late secretory phase and into early pregnancy (Bulmer et
al., 1991). In addition to these CD56 positive leukocytes, an influx of neutrophils
occurs in the perimenstrual period at which point they comprise approximately 6-15% of
total cells, and they are thought to be important in menstruation (Salamonsen et al.,
1999). Eosinophils also rise immediately prior to menstruation and make up around 3-
5% of endometrial cells at this point (Salamonsen et al., 2000). Macrophages show a
small rise in number from the proliferative phase to the secretory phase (Bonatz et al.,
1992) although their expression of MHC class II does not appear to vary (Bulmer et al.,
1988). Macrophages are also raised in number in endometrium taken from women 48
hours after controlled progesterone withdrawal compared to decidua from pregnant
women (Critchley et al., 1999). T and B lymphocytes are located in the basal layer in
lymphoid aggregates and do not vary in number across the menstrual cycle (Bulmer et
al., 1991). In addition, T lymphocytes are also located throughout the functional layer in
intra-epithelial locations (Loke et al., 1995). These cells become activated during
pregnancy at the site of large lymphoid cell clusters and it is possible they are acting to
provide constitutive immune defence at this critical time or control trophoblast invasion
(Mincheva-Nilsson et al., 1994).
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How these immune cells are regulated with regard to their recruitment in the human
endometrium has not been fully established. Cells may be migrating from peripheral
blood (Marzusch et al., 1993) or be proliferating within the tissue itself (Klentzeris et
al., 1992). Endometrial chemokines may be responsible for the up-regulation of
monocytes in the secretory phase (Kamat et al., 1987) and high numbers of these cells
are observed around the time of implantation (Bonatz et al., 1992). Chemokines are
chemotactic cytokines that act via G protein-coupled receptors (GPCRs) (Murphy, 1996)
and their roles as chemoattractants for leukocytes will be discussed in this section.
Chemokines consist of four cysteine residues and two disulphide bonds and are split into
four sub-groups according to the separation of the first two cysteines by amino acids: C,
CC, CXC and CXXXC (Zlotnik et al., 2000).
1.2.1.2 Interleukin-8 (IL-8)
In addition to chemotaxis, IL-8 is implicated in angiogenesis (Koch et al., 1992) and
mitogensis of epidermal cells (Tuschil et al., 1992). In the human uterus, IL-8 has been
located to the perivascular cells in the late secretory phase and first trimester decidua
(Critchley et al., 1994; Critchley et al., 1996; Critchley et al., 1999; Milne et al., 1999).
It is also present in choriodecidual cells (Kelly et al., 1992) and in amniotic fluid
(Laham et al., 1993). In endometriotic tissue it fails to vary with the menstrual cycle
implicating persistent recruitment of leukocytes in this pathological tissue that may be
under IL-8 control (Akoum et al., 2001). Cultures of human ESCs and epithelial cells
have demonstrated that IL-8 production can be regulated by IL-la and TNFa (Arid et
al., 1993). Cell surface peptidases such as aminopeptidase N (APN) are expressed in
human endometrium and their regulation of growth factors, peptide hormones and
growth factors has been suggested previously (Imai et al., 1992; Imai et al., 1996). It
has been proposed that IL-8 levels in vivo may be controlled via APN (Seli et al., 2001).
Progesterone is thought to be a main regulator of IL-8 expression. In human
endometrial explant studies, progesterone acted to inhibit IL-8 secretion (Kelly et al.,
1994). This is in agreement with in vivo data that demonstrates an increase in IL-8
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immunostaining in human endometrium 48 hours after progesterone withdrawal in a
study designed to mimic the late secretory phase (Critchley et al., 1999). This
implicates IL-8 for a role in menstruation but it has also been proposed as a cervical
ripening agent (Kelly et al., 1992). IL-8 is able to synergise with PGE2 to recruit
neutrophils (Rampart et al., 1989; Colditz et al., 1990) which in turn aid the breakdown
of collagen therefore softening the cervix at labour (Junqueira et al., 1980).
1.2.1.3 Monocyte Chemotatic Protein-1 (MCP-1)
Monocyte chemotactic protein-1 (MCP-1) is an example of a CC chemokine and is a
product of an array of cell types including fibroblasts (Yoshimura et al., 1990),
endothelial cells (Sica et al., 1990) and monocytes (Yoshimura et al., 1989) and, as its
name implies, is chemotactic for monocytes (Rollins et al., 1991). MCP-1 is co-
expressed along with IL-8 in perivascular cells in the human endometrium in the late
secretory phase (Jones et al., 1997). This study also confirmed that the expression of
these two chemokines coincides with COX-2 expression and implicates these factors in
perimenstrual functions. Cultures of human ESCs and epithelial cells secrete MCP-1
(Arici et al., 1995) and have been shown to respond to the T helper-1 cytokine, IFN-y,
by releasing MCP-1 after 24 hours of treatment (King et al., 2001). Oestrogen has been
shown to inhibit its secretion by ESCs (Arici et al., 1999). MCP-1 production by
choriodecidual cells and the breast cancer cell line, T47D, is suppressed by progesterone
(Kelly et al., 1997) further implicating a hormonal control over MCP-1. However, a
more recent study failed to show the inhibitory effects of progesterone on either MCP-1,
-2 or -3 mRNA levels in cultured human ESCs or epithelial cells (DeLoia et al., 2000).
1.2.2 Uterine Natural Killer (uNK) Cells
Natural Killer cells are lymphocytes and have been shown to be critical in innate
immune host defence (Bancroft, 1993; Scharton-Kersten et al., 1997; Biron et al, 1999;
Cooper et al., 2001b). They are present in peripheral blood, accounting for
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approximately 10% of total blood lymphocytes (Robertson et al., 1990). There is one
important division with category according to their cell surface marker expression as
either CD56bnght CD 16" or CD56Dim CD16+. However, the CD56bnght variety is scarce,
comprising of less than 2% of total blood lymphocytes and approximately 10% of total
blood NK cells (Lanier et al., 1986). Upon activation CD56bnght NK cells produce an
array of cytokines such as IFN-y and GM-CSF, (Cooper et al, 2001a) and also develop
cytotoxic activity upon IL-12 or IL-2 activation (Ellis et al., 1989; Gately et al., 1991;
Robertson et al., 1992). It has been demonstrated that the CD56bnght NK variety produce
far greater levels of cytokines compared with CD56Dlm cells (Cooper et al., 2001a).
1.2.2.1 Uterine Expression and Functions of uNK Cells
Within the uterus, NK cells were originally termed Large Granular Leukocytes (LGLs)
due to their size and abundance of cytoplasmic granules (King et al., 1991). They
express CD56 on their cell surface making them distinct from the major blood NK cell
population. However, a study comparing cytokine production by peripheral NK cells
and decidual NK cells reported a very similar cytokine repertoire (Saito et al., 1993).
Through their secretion of cytokines it is likely they are having immunoregulatory
effects. Their density is low throughout the proliferative phase but their abundance
increases across the secretory phase, particularly around the time of implantation (Loke
et al., 1997). In the late secretory phase they comprise approximately 15-25% of the
ESCs (King et al., 1989b). Peripheral NK cell number is raised in women with recurrent
spontaneous miscarriage of unknown aetiology, and this implies a role in controlling
pregnancy maintenance (Ntrivalas et al., 2001). uNK cell levels remain high into the
first trimester of gestation but then decline and they also disappear in the non-pregnant
endometrium prior to menstruation, possibly undergoing apoptosis (King, 2000). The
first trimester appears to be a critical time for a successful pregnancy with highest
miscarriage rates prevailing in this stage with approximately 50% of total human
conceptions failing before the first missed menstrual period. The exact functions of
these uNK cells in humans have yet to be elucidated.
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How uNK cells are regulated is not yet fully understood. Their expansion across the
secretory phase when progesterone levels are rising implicates progesterone as a central
regulator of their growth and this is compounded by evidence that ovariectomised
women lack uNK cells (Loke et al., 1995). However, uNK cells lack the genomic PR
and the ERa (King et al., 1996), although they do express ERp and the glucocorticoid
receptor (Henderson et al., 2003). This absence of the genomic PR suggests they are not
controlled directly by progesterone across the secretory phase but that it is likely that
regulation is via paracrine signalling with non-leukocyte ESCs since these cells persist
to express the PR-A isoform at this stage of the cycle (Wang et al., 1998). Studies in
vitro have demonstrated that uNK cells proliferate upon treatment with IL-15 but other,
as of yet, unidentified products of ESCs appear to increase their proliferation further
(Verma et al., 2000). Murine uNK cells express mRNA for an array of cytokines
including CSF-1, TNF-a, IL-1, LIF and TGF-p (Croy et al., 1991). A study on isolated
human decidual NK cells revealed these cells express mRNA and secrete the protein for
G-CSF, GM-CSF, M-CSF and LIF (Saito et al., 1993). This demonstrates that a role, in
addition to or in place of an immune function, exists for uNK cells although the function
of these cytokines remains unclear. A close association exists between uNK cells and
trophoblast cells in vivo providing circumstantial evidence for a role in trophoblast
invasion (Loke et al., 1997). In culture experiments, isolated human cytotrophoblast
cells have been shown to attract CD56bnght cells via secretion of Monocyte Inflammatory
Protein la (MlP-la) and implies a role for MlP-la in attracting uNK cells (Drake et al.,
2001). This is in contrast to the situation in mice where those genetically-ablated for
MlP-la show no difference to wild type mice with regard to uNK cell density at the
implantation site (Chantakru et al., 2001). However, in mice, uNK cells are present only
in the metrial gland (Croy et al., 1993), the triangle at the apex of the placenta where
blood vessels feeding the placenta are close together. In contrast, in humans uNK cells
are present throughout the endometrium and it may therefore be necessary to "attract"
these cells specifically towards the implantation site.
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1.2.2.2 uNK Cells and Decidualisation
uNK cells may be linked with decidualisation. These cells were found to be specifically
located in regions of stroma exhibiting pseudodecidual alterations (Bulmer et al., 1988).
It has been proposed that uNK cells are required in mice for maintenance of the decidual
reaction rather than its initiation (Croy et al., 2002). Evidence from studies on mice
lacking IFN-y implicates this cytokine, a major product of uNK cells, in the decidual
reaction and conversion of the uterine vasculature (Ashkar et al., 1999; Ashkar et al.,
2000). Rat splenocytes can be primed by prolactin to express the IL-2 receptor and
therefore allows these cells to respond to IL-2 stimulation (Mukheijee et al., 1990). In
the human endometrium prolactin is secreted by decidualised stromal cells and mRNA
expression of its receptor on these cells is under progesterone control (Tseng et al.,
1999). A recent study has illustrated uNK cells as a novel target for prolactin action by
detection of the prolactin receptor and this may represent a functional link between uNK
cells and ESCs, which produce prolactin upon decidualisation, and provide the indirect
connection between progesterone control on uNK cells (Gubbay et al., 2002). PGE2 has
inhibitory actions on NK cell IL-15 receptors via down-regulation of the common y-
chain (Joshi et al., 2001). PGE2 has also been shown to reduce IL-2 receptor expression
on NK cells and reduce their proliferation and activity (Parhar et al., 1989). Using IL-2
activated mouse uNK cells, PGE2 stimulated an increase in the size and granularity of
the cells and enhanced the proportion of 4H12 expressing cells (Linnemeyer et al.,
1993). The uNK cells accumulating at implantation sites immuno-stain for the 4H12
antibody and they were able to demonstrate in culture that these cells were less cytotoxic
than NK cells negative for 4H12. The described effects of PGE2 are likely to be
mediated via cAMP since this second messenger was able to augment the same
responses.
Angiogenesis is a critical process in the human endometrium and ensures that vascular
remodelling of the spiral arterioles and regeneration of the vasculature following
menstruation can take place. A major angiogenic stimulus is VEGF and it is a member
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of the vascular endothelial growth factor family, of which there are six members. VEGF
protein and mRNA have been localised within the endometrium across all phases of the
menstrual cycle in both the glandular epithelial cells and in the stroma (Chamock-Jones
et al., 1993). In cultures of human ESCs progesterone treatment resulted in a rise in
VEGF, isoform VEGFigg, secretion (Ancelin et al., 2001). Hypoxia and cAMP have
also been identified as stimuli for VEGF production in ESCs in vitro as demonstrated by
ELISAs and Northern Blot analysis (Popovici et al., 1999). uNK cells are present in the
stroma across the menstrual cycle and increase in number across the secretory phase and
into the first trimester of gestation (Loke and King, 1997). Across the secretory phase
uNK cells have been shown to express VEGF-C and placenta growth factor (PIGF)
mRNA (Li et al., 2001). Additionally, in the late secretoy phase uNK cells express
mRNA for the angiopoietin, Ang2. This study also demonstrated the ability of IL-15 to
up-regulate VEGF-C mRNA levels in uNK cells. The specific locality of uNK cells
within the stroma is in close proximity to the glands and the blood vessels and therefore
their production of angiogenic factors may be having a direct influence on the blood
vessels. This supports a possible involvement in menstruation or in the stabilisation of
blood vessels during implantation and early pregnancy (King and Loke, 1990).
1.2.3 Glandular Cells in Immune and Reproductive Functions
The epithelium is considered central in intestinal immune function (Gewirtz et al., 2002)
and in the control of lymphocyte trafficking in, for example, the skin and small intestine
(Kunkel et al., 2002). Within the endometrium the glands are composed of epithelial
cells and they undergo cyclical variation as described in sections 1.1.1 and 1.1.2. Figure
1.3 illustrates the structure of a gland in the early secretory phase. Infiltrating
leukocytes in the mid and late secretory phase are situated immediately adjacent to
glands in the human endometrium (Bulmer et al., 1985). Macrophages send long
processes into the epithelium of the glands of human endometrium (Kamat et al., 1987)
and intraepithelial T-lymphocytes have been identified (Loke et al., 1995). The
glandular cells are also HLA-DR-positive in the secretory phase but not in the
34
proliferative phase (Chiang et al., 1997) and an increased accumulation of extracellular
immunoglobulin is apparent within glands with progression of the menstrual cycle
(Bjercke et al., 1993) implying a specific immune function in secretory endometrium.
Lymphocytes have been characterised in early human decidua and located as either
clusters, forming aggregates, near to the glands or as intraepithelial lymphocytes within
the glands themselves (Mincheva-Nilsson et al., 1994).
In addition to the leukocyte populations, endometrial epithelial cells are believed to be
important in host defence. Defensins are small cationic proteins that confer anti¬
bacterial, anti-fungal and anti-viral properties and human beta-defensins 1-4 (HBD1-4)
mRNA is expressed in the human endometrium (Valore et al., 1998; Fleming et al.,
2003; King et al., 2003). Secretory leukocyte protease inhibitor (SLPI) is also a product
of human endometrial epithelial cells (King et al., 2000) and has been reported to have
antibacterial, antiviral and antifungal effects (Tomee et al., 1998). Both HBD-1 and
SLPI increase in the mid secretory phase although SLPI expression rises further in the
late secretory phase and into pregnancy (King et al., 2000; Fleming et al., 2003). They
may have important functions at the time of implantation and in early pregnancy but
since the glands lack the progesterone receptor at this time, stromal-derived factors may
be important in controlling their production since the stroma in the functional layer
retains the PR-A receptor (Wang et al., 1998).
The COX enzymes are involved in regulation of PGE2 synthesis and are discussed in
section 1.4.1. Both isoforms have been located in the human endometrium with COX-1
expression being predominant in the luminal and glandular epithelial cells (Rees et al.,
1982) and COX-2 being expressed in the glands and perivascular cells in the luteal
phase (Jones et al., 1997; Marions et al., 1999). Treatment with the antiprogestin,
RU486, in the luteal phase reduced the expression of both isoforms in the epithelial cells
and a role in endometrial receptivity was proposed (Marions et al., 1999). Studies on
mice knock-outs for the COX enzymes have implicated COX-2 in ovulation,
fertilisation, implantation and decidualisation (Lim et al., 1997). In the COX-1 knock-
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Photomicrograph of a gland in the early secretory phase endometrium at high power
magnification in human endometrium stained with toluidine blue and acid fuschsin. G =
gland; S = stroma; GL = glycogen deposits. Scale bar represents 40pm.
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1.3 Establishment of Pregnancy
1.3.1 Decidualisation
The transformation of the human endometrium into decidua begins around post-
ovulatory day 9 in oestrogen-primed stromal cells surrounding the spiral arterioles. This
reaction then spreads throughout the stroma completing the pre-decidual transformation
of the endometrium. If pregnancy is established, these decidual changes become more
widespread creating three layers: decidua compacta, decidua spongiosa and a basal
undifferentiated layer, allowing regeneration following menstruation or birth. Studies in
rats and mice identified three types of decidual cell: anti-mesometrial decidual cells,
mesometrial decidual cells and granulated metrial gland cells (De Feo, 1967). However,
decidualisation differs between humans and rodents with regard to its stimulus and
locality. In humans, the stromal differentiation is spontaneous and occurs in preparation
for implantation across the secretory phase whereas in rodents it is initiated only upon
the physical stimulus of implantation. Decidualisation is apparent throughout the human
endometrium but only occurs at the implantation site(s) in mice and rats.
1.3.1.1 Decidualisation Markers
Term decidual fibroblasts from humans have been shown to express desmin (Oliver et
al., 1999). In addition, decidualised ESCs express raised levels of fibronectin and
laminin compared with control cultures (Irwin et al., 1989). Rat decidual cells contain
large quantities of intermediate fibres. These are made up of vimentin, which is also
present in non-decidualised stromal cells, and desmin, specific to decidualised cells
(Glasser et al., 1986). However, two other products of the decidual reaction, prolactin
and IGFBP-1, are more commonly used to mark this process in culture experiments
using human ESCs. In addition to this a further marker of this process is tissue factor
and these will be discussed each in turn.
38
Prolactin is an anterior pituitary hormone, but was first detected being produced outside
the pituitary, by decidualised endometrial cells (Riddick et al., 1978). It was then
confirmed that prolactin synthesis correlated with the extent of stromal decidualisation
in a study of human endometrial explants from the various stages of the menstrual cycle
(Maslar et al., 1979). Prolactin is widely expressed and has been located in dermal
fibroblasts, epithelial cells of the prostate and breast, Leydig cells of the testis and by
certain immune cells as summarised in Ben-Jonathan et al 1996 (Ben-Jonathan et al.,
1996). Mouse gene knock-outs have confirmed that prolactin is critical to reproductive
processes and fertility and particularly with regard to implantation and pregnancy
maintenance (Binart et al., 2000). Within the endometrium, prolactin protein is
expressed primarily in stromal cells in the late secretory phase but epithelial cells were
also immunoreactive for prolactin at this point in the cycle (Bryant-Greenwood et al.,
1993). Whilst the protein has also been confirmed in both stromal and epithelial cells,
mRNA has only been detected in the stromal cells (Dimitriadis et al., 2000). Prolactin is
considered to be important in human implantation and early pregnancy, as discussed in
Jabbour and Critchley 2001 (Jabbour et al., 2001). A novel target cell of prolactin has
been identified as uNK cells since these cells express the prolactin receptor (Gubbay et
al., 2002). Prolactin has also been shown to regulate the expression of interferon-
regulatory factor (IRF-1), which is located in the glands and upregulated in the secretory
phase (Jabbour et al., 1999).
The insulin-like growth factor system consists of peptide growth factors (IGFs) and their
receptors but also specific binding proteins (IGFBPs) that regulate the availability of
IGFs to their receptors (Lamson et al., 1991). Six types of soluble IGFBPs exist and
these have a degree of tissue specificity (Shimasaki et al., 1991). Within the human
endometrium, mRNA for all six IGFBPs were located and with the exception of IGFBP-
5, all increased in the secretory phase compared with the proliferative stage (Zhou et al.,
1994). The production of IGFBP-2 and -3 by cultures of ESCs with oestrogen and
progesterone treatment has been demonstrated (Giudice et al., 1991).
Immunohistochemical studies have demonstrated an increase in IGFBP-1 levels in
39
human endometrium in the secretory phase (Bryant-Greenwood et al., 1993) and
IGFBP-1 was found to be a secretory product of secretory phase endometrium and early
decidua (Bell et al., 1989). IGFBP-1 is considered a marker of decidualisation and is
used to assess this process in cultures of ESCs (Irwin et al., 1989; Bell et al., 1991;
Giudice et al., 1992). The specific function of IGFBP-1 in the uterus in unknown
although it may be regulating IGF-1, a stimulator of cell growth, and IGF-1 mRNA
levels are up-regulated in the rat uterus following oestrogen treatment (Murphy et al.,
1987). In women using LNG-IUS mRNA levels of IGFBP-1 are upregulated, consistent
with immunohistochemical stromal staining, and IGF-1 levels were found to be
decreased (Rutanen, 2000). It was speculated that the inhibitory action of IGFBP-1 on
IGF-1 levels could partially account for the progestogenic and anti-oestrogenic effects of
LNG-IUS.
Tissue factor is a membrane-bound glycoprotein. It has an extracellular domain that acts
as a receptor for factor VII that is involved in the thrombin pathway and it thought to
maintain an equilibrium between haemostatic and fibrinolytic pathways as discussed in
Schatz et al 2001(Schatz et al., 2001). This knowledge, along with in utero
haemorrhage of tissue factor knockout mice, (Carmeliet et al., 1996) implies a role for
tissue factor in regulation of bleeding. In women using Norplant, the observed decline
in endometrial tissue factor protein and mRNA levels may partially account for their
irregular bleeding patterns (Runic et al., 1997). Tissue factor has also been implicated in
angiogenesis via induction of VEGF (Abe et al., 1999). Experiments on human ESCs in
culture have confirmed hormonal control over the increase in tissue factor expression
and withdrawal of oestrogen and progesterone resulted in a return of tissue factor levels
to those similar to pre-treatment levels (Lockwood et al., 1993). Cyclical changes in
tissue factor mRNA and protein are observed in humans with greatest levels of
expression in luteal phase stroma and in decidua (Lockwood et al., 2001). Its presence
may be important in having a primary stabilisation function during the destructive
process of trophoblast invasion and paralleled vascular remodelling (Schatz et al., 2001).
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1.3.1.2 Progesterone and cAMP
Progestins stimulate the production of prolactin and its receptor in stromal cell primary
cultures and this can be inhibited by addition of the anti-progestin, RU486 (Tseng et al.,
1999). Studies on ESC decidualisation in vitro have demonstrated that progesterone
treatment alone is a weak inducer of the decidual transformation and can only achieve
this conversion after prolonged exposure (Huang et al., 1987; Zhu et al., 1990; Tseng et
al., 1992; Mizuno et al., 1998). It has also been reported that women with low serum
progesterone levels at four weeks gestation can have successful pregnancies following
assisted reproductive technologies (ART) treatment (Azuma et al., 1993) and it may be
the case that other factors are important, in addition to progesterone, to decidualisation.
Synthetic progestins, such as medroxyprogesterone acetate (MPA), are usually used in
place of progesterone because they are metabolically stable and thus more effective at
inducing prolactin expression (Zhu et al., 1990). However, addition of cAMP in
combination with progesterone produces this conversion on a greatly reduced time scale
(Tang et al., 1993a; Tang et al., 1993b; Brar et al., 1997) and these actions are probably
via the protein kinase A pathway (Brar et al., 1997).
1.3.1.3 Relaxin
Relaxin is similar in structure to insulin and insulin-like growth factors (Blundell et al.,
1980) and consists of two chains, A and B chains, which are covalently linked by two
disulphide bonds (Schwabe et al., 1978; Schwabe et al., 1978). It is synthesised as a
precursor form, preprorelaxin (Kemp et al., 1984). Relaxin is primarily a product of the
corpus luteum in reproductive tissue but has been isolasted from human decidua by
chromatographic elution (Bigazzi et al., 1980). It has been localised to the glands and
stroma of human endometrium and decidua, as shown by immunohistochemistry
(Bryant-Greenwood et al., 1993). Relaxin is secreted by the ovary and is present in the
blood and therefore some of the immunoreactivity for relaxin in the endometrium may
be from this source. However, if the sole source of relaxin in this tissue was from
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outside of the endometrium it may be expected that highest concentrations of relaxin
immunoreactivity would be observed surrounding the blood vessels. In fact, highest
immunoreactivity intensity is found in the glandular cells. In addition, two molecular
forms of relaxin exist, HI and H2 and are encoded by different genes (Hudson et al.,
1983; Hudson et al., 1984). H2 is the main form produced by the ovary whereas HI and
H2 are produced by decidua (Bryant-Greenwood, 1991; Hansell et al., 1991). Within
the stroma, relaxin was immunolocalised in decidualised cells in the late secretory phase
and throughout early and late gestation. ESCs themselves have very few receptors for
relaxin, approximately 1000 per cell (Osheroff et al., 1995), however, in cultures of
human ESCs relaxin both acutely and permanently elevates intracellular cAMP levels in
concert with induction of prolactin secretion (Telgmann et al., 1998) and produces
maximal stimulus on prolactin production when added in combination with a synthetic
progestin (Huang et al., 1987; Zhu et al., 1990). In these early studies porcine relaxin
was used in the treatment of human ESCs. Whether this is an exact mimic of human
relaxin actions has not been confirmed due to a lack of availability. However, relaxin
does have the effect of raising cAMP and the direct application of cAMP to cultures
results in prolactin secretion by human ESCs in a similar fashion (Tang et al., 1993a;
Tang et al., 1993b; Brar et al., 1997). It has further been demonstrated that the induction
of raised cAMP levels by relaxin treatment is due to its action to inhibit
phosphodiesterase activity and therefore inhibit cAMP destruction (Bartsch et al., 2001).
1.3.1.4 Interleukin-ll (IL-11)
IL-11 is a member of the gpl30 cytokine family along with LIF (Gadient et al., 1999).
It has actions in a wide range of environments from haematopoietic cells to the nervous
system (Hawley, 1994) but also has anti-inflammatory actions in the gastrointestinal
tract (Sands et al., 1999). Within the human endometrium IL-11 is expressed in all cell
types with greatest immunostaining intensities apparent in decidualised stroma and
appears in these cells before prolactin (Dimitriadis et al., 2000). Human ESCs produce
IL-11 and express IL-11 receptor a (IL-llRa) in culture during progesterone-induced
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decidualisation and upon treatment with an anti-human IL-11 antibody a reduction in
prolactin and IGFBP-1 levels were observed implicating IL-11 in induction of
decidualisation (Dimitriadis et al., 2002). Production of IL-11 by cultured human
epithelial cells and stromal cells was enhanced by IL-la, TNF-a and TGF-p and these
results suggest a role for IL-11 in implantation (Cork et al, 2001). In the murine uterus
IL-11 is essential to female fertility as shown by IL-llRa gene knockout studies in
which a defective uterine response to blastocyst fails to trigger normal maternal decidual
transformation (Bilinski et al., 1998; Robb et al., 1998).
LIF may also have a role in the process of decidualisation since LIF null mice fail to
exhibit decidualisation (Stewart et al., 1992b). The reproductive roles of LIF are
discussed further in section 1.3.2.2. Recently, mRNA and protein for ghrelin, a peptide
hormone, have been shown to increase in human decidualised stroma and in addition,
enhanced cAMP-induced decidualisation of cultured human ESCs (Tanaka et al., 2003).
The mechanisms and factors involved in decidualisation are complex and it is likely that
other factors that are involved have not yet been identified.
1.3.1.5 Decidualisation and Cell Growth
Decidualisation treatments affect the growth rate of ESCs. For example, MPA
stimulates cell growth and prolactin production in human ESCs in culture whereas
relaxin does not promote cell growth (Zhu et al., 1990). IL-11 increases tritiated
thymidine uptake by human ESCs in culture (Karpovich et al., 2003). In rat ESCs both
progesterone and prostaglandins have been postulated to exert effects on the rate of
DNA synthesis with progesterone stimulating it and PGE2 reducing it (Peleg, 1983).
This is consistent with the finding that in rats treated with RU486, division of stromal
cells during pregnancy was inhibited compared with untreated controls (Rider et al.,
1994). The proliferative effects of basic fibroblast growth factor (bFGF) are dependent
on the presence of progesterone in cultures of human ESCs (Irwin et al., 1991). In
addition to this the insulin-like growth factor (IGF) system has been directly implicated
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in human ESC decidualisation (Irwin et al., 1994). This study demonstrated the
necessity of IGF plus epidermal growth factor (EGF) in combination for promotion of
cellular proliferation. However, the presence of growth factors was not essential to
stimulate prolactin and IGFBP-1 production. It has been shown that term decidua
contains undifferentiated ESCs that can be stimulated in vitro to decidualise and it is
speculated that these represent a proliferating population of ESCs that are maintained




The main influences on the sequential maturation of the endometrium are oestrogen and
progesterone with the latter being dominant in the luteal phase of the cycle. Imbalances
of these hormones and/or their receptors can result in an out-of-phase development that
may be significantly detrimental to the implantation process (Bonhoff et al., 1990).
Studies in rodents demonstrated a maternal implantation window controlled by the
steroid hormones (Psychoyos, 1986). In humans, implantation occurs around day LH +
6 and LH + 7 (Hertig et al., 1956; Bergh et al., 1992) and the concept of the
"implantation window" specifies that the blastocyst can only implant whilst the
endometrium is in a receptive developmental stage (Navot et al., 1989; Li et al., 1991;
Tabibzadeh, 1998). The processes of implantation and decidualisation are likely to be
closely linked, although in humans decidualisation begins prior to implantation on day
LH + 8. However, these two events are likely to be closely coordinated and one
important feature of a receptive endometrium is decidualisation. In a review of oocyte
donation success, the optimal window for transferring the fertilized oocyte was between
cycle days 16 and 19 (Rosenwaks, 1987). After this period, no pregnancies were
established. Ultrastructual changes in the luminal epithelial cells are also thought to be
correlated with this receptivity status (Sarani et al., 1999). However, implantation has
been shown to be dependent on embryonic age rather than endometrial maturation in
another study involving IVF treatment of women (Bergh et al., 1992). The receptive
endometrium is thought to balance implantation with excessive trophoblast invasion by
providing appropriate signals (Tabibzadeh et al., 1995) and embryonic signalling may be
essential for the implantation process and maternal acceptance (Edwards, 1994).
The implantation process itself is quite unique in humans in comparison to other species
and is haemochorial (Pijnenborg et al., 1981). The first stage of implantation is
fertilisation of the oocyte within the fallopian tube. The fertilized oocyte then undergoes
successive cleavages during the week-long peri-implantation period. These cleavages
must generate sufficient cell numbers prior to blastocyst formation to allow completion
45
of inner cell mass and trophectoderm formation and are followed by proliferation and
migration towards the uterine cavity around 72-96 hours post fertilisation. On day 5,
the blastocyst hatches from the zona pellucida. The actual process of implantation
occurs in three stages, the first of these being apposition. This is followed by adhesion
of the blastocyst to the luminal epithelium via the trophectoderm and allows the
trophoblast to burrow between the luminal epithelial cells, leaving these luminal
epithelial cells undisturbed. Placenta formation starts once the trophectoderm has
invaded and become embedded in the decidua. Some of the cytotrophoblast cells then
extend into the peripheral syncytium and join to form the cytotrophoblastic shell.
Villous trophoblast cells will eventually form a layer over the placenta and have the
function of nutrient and oxygen transport from maternal blood to the fetus. The
extravillous trophoblast cells penetrate deep into the decidua and transform the spiral
arteries, destroying the muscular walls and converting them into larger vessels allowing
delivery of greater volumes of blood. This is essential for an adequate blood supply for
the fetus and in cases of under-invasion of the trophoblast pathologies such as
miscarriage, pre-eclampsia and fetal intrauterine growth restriction can result (Loke et
al., 1995). This is not only relevant to the short-term with regard to pregnancy
complications but can lead to the development of problems in adult life (Barker, 1997b).
Conversely, when over-invasion of the trophoblast occurs a phenomenon of placenta
percreta, or uterine mpture, can develop. Therefore, it is important for this process to be
under stringent control and a synchrony between the blastocyst and endometrium is
required for it to be implemented successfully.
1.3.2.1 Colony Stimulating Factor-1 (CSF-1)
Signalling between the blastocyst and the endometrium are likely to be essential prior to
adhesion to the epithelium and several soluble factors have been implicated. Colony-
stimulating-factor-1 (CSF-1) is a growth factor and is expressed within the endometrium
in the stroma and epithelial cell and also by the trophoblast along with its receptor, c-fms
(Daiter et al., 1992). Mutant mice lacking CSF-1 are infertile due to implantation failure
46
(Pollard et al., 1991). The cyclical variation of CSF-1 and c-fms in humans is
characterised by rapid rises in expression in the late secretory phase and early pregnancy
(Kauma et al., 1991).
1.3.2.2 Leukaemia Inhibitory Factor (LIF)
LIF is a glycoprotein expressed in endometrial glands just prior to implantation in mice
(Bhatt et al., 1991) and may be involved in blastocyst growth and implantation (Bulletti
et al., 1994; Polan et al., 1995). A targeted mutation of the maternal LIF gene resulted
in impaired implantation in mice. The blastocysts however were viable and able to
implant in wild-type pseudo-pregnant mice implicating LIF specifically in implantation
(Stewart et al., 1992b). In contrast, LIF is not critical to implantation in sheep and cows
as determined by experiments in which animals were immunised against LIF (Vogiagis
et al., 1997). In humans, LIF is present within endometrium and at highest levels during
the time of implantation (Charnock-Jones et al., 1994; Kojima et al., 1994). Isolated
first trimester trophoblast is negative for LIF but positive for its receptor (King et al.,
1995) and it could be speculated that endometrial LIF is acting on its receptors located
on trophoblast cells. Some of the actions of LIF may be via human chorionic
gonadotrophin (hCG) since anti-hCG antibodies have been shown to block LIF-
mediated trophoblast differentiation (Sawai et al., 1995). hCG is secreted by the embryo
and by preventing demise of the CL and therefore maintains luteal progesterone
production. The actions of hCG may not be confined to the CL since hCG receptors
have also been located in the human endometrium (Reshef et al., 1990) and in support of
this, human endometrial stromal cells treated with hCG decidualise (Han et al., 1999).
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1.3.2.3 Cell-matrix Interactions
Interactions between the extracellular matrix and cells provide an essential
communication route. The interactions between extracellular matrix constituents and the
surface of cells are predominantly mediated by integrins. Integrins are a family of cell
surface heterodimeric a/p glycoproteins and are able to bind matrix molecules and to
cell surface receptors (Hynes, 1992). They participate in adhesion, migration,
proliferation, differentiation and cell survival. Several integrins are expressed within the
human endometrium (Lessey et al., 1992; Tabibzadeh, 1992). The expression of many
of these fluctuates in a cyclical manner and those with expression confined to the
window of implantation are aiPi, (X4P1 and avP3 (Tabibzadeh, 1992; Lessey et al.,
1994a). Expression of the fibronectin receptor is delayed in luteal phase defect (Lessey
et al., 1992) and aberrant expression of this receptor has also been associated with
endometriosis (Lessey et al., 1994b).
Matrix metalloproteinases (MMPs) are enzymes that have a range of specificity for
extracellular matrix molecules and are invloved in their degradation. MMPs are
generally considered pathological when detected in connective tissue, however, they
have been localised in human trophoblast (Polette et al., 1994) and are considered to
have a role in the uterus of physiological tissue remodelling (Hulboy et al., 1997).
Tissue inhibitor of MMPs (TIMP) inhibits the invasiveness of trophoblastic cells in situ
(Graham et al., 1991). MMP2 and MMP9 are members of the gelatinase subfamily and
are secreted by the invasive human trophoblast (Shimonovitz et al., 1994). They act to
digest collagen type IV, the major constituent of the uterine basement membrane, and
would be important in uterine invasion during implantation. MMPs are discussed in
more depth in section 1.1.4.2.
The interactions between leukocytes and ESCs via the production of cytokines and
growth factors, such as VEGF, the interferons and TNF-a, are believed to be important
in endometrial tissue breakdown and remodelling (Fraser, 1999). These immune cells
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are believed to play a significant role in establishment of microenvironments via their
production of such factors (Tabibzadeh et al., 1993; King, 2000). uNK cells are located
in the stroma in high concentrations around the blood vessels and are a source of VEGF
and their potential effects on the blood vessels are briefly assessed in section 1.2.2.2. In
addition, uNK cells are also located at the implantation site and this is their only location
within the mouse endometrium (Croy et al., 1991). They may be involved in
modulating trophoblast invasion in humans (King and Loke, 1990) and in mice have
been proposed as having a role in the regulation of placental development whereby
knockout mice for uNK cells exhibit reduced placental size (Croy et al., 2002).
However, a more crtical role in mice is the stabilisation of the vasculature and complete
differentiation of the endometrium into decidua (Ashkar et al., 2000). IFN-y-producing
immune cells, in particular uNK cells, are thought to be involved in modulating ESC
decidualisation in humans (Christian et al., 2001). They demonstrated the ability of
IFN-y to antagonise prolactin protein and mRNA expression in primary ESC cultures.
This provides a role for IFN- y as a modifier of ESC function.
1.3.3 The Role of Cytokines
Cytokines are small glycoproteins with autocrine and paracrine interactions and are
predominantly associated with immune functions. They can be involved in both the
induction and resolution of an inflammatory response and can generally be termed "pro¬
inflammatory" or "anti-inflammatory". Studies on CD4+ T-cells showed that responses
of these cells are polarised and they have been classified on their cytokine production as
either T-helper-1 (Th-1) or T-helper-2 (Th-2) (Mosmann et al., 1986). The Th-1
cytokines include IFN-y, IL-2 and TNFa and whilst examples of Th-2 cytokines are IL-
4, IL-10 and IL-13. In the human endometrium during the peri-implantation phase, a
reduction or absence of Th-1 and a dominance of Th-2 cytokines is observed (Lim et al,
1998). The general hypothesis with regard to pregnancy that has been derived from
mice studies is that a Th-1 response is considered detrimental and a Th-2 response is
thought to be beneficial and supportive of pregnancy and the balance of these responses
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is likely to be critical (Wegmann et al., 1993; Hill et al., 2000), although it is now
apparent that this is an over-simplification (Chaouat et al., 2002). Some of the








Chemotaxis and induction of lymphoid infiltration
Oedema
Induction of PGE2
Activation of T cells
TGF-(3 Gland formation and Angiogenesis
IFN-y




Chemotaxis and induction of lymphoid infiltration
Induction of menstruation
Induction of HLA-DR and ICAM-1
TNF-ot




Chemotaxis and induction of lymphoid infiltration
Oedema
Induction of PGE2
Injury to endometrial vessels
Activation of polymorphonuclear leukocytes
Table 1.2
Cytokine functions in the human endometrium. Table adapted from Tabibzadeh 1994
(Tabibzadeh, 1994a).
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This section will examine IL-1, IL-10 and IFN-y and their functions within the uterus.
IL-8 and IL-15 are discussed in more detail in sections 1.2.1.2 and 1.4.3 respectively.
1.3.3.1 Interleukin-1 (IL-1)
IL-1 is a multifunctional cytokine and exists in two forms: IL-1 a and IL-1 P with a low
sequence homology between them. They have similar action and act on the same
receptor, IL-1 type-1. A second receptor sub-type exists, IL-1 type-2, but it is non¬
functional. In humans, the IL-1 receptor antagonist is located in decidual glands, and in
isolated cells in chorionic villi, the intervillous space and in maternal decidua (Simon et
al., 1994). These decidual cells staining positive for the IL-1 receptor antagonist are
thought to be macrophages (Tabibzadeh et al., 1992). IL-ip is the dominant form and is
secreted by activated murine peritoneal macrophages (Chensue et al., 1989). In the
human endometrium both IL-1 a and IL-P are expressed in the epithelial and stromal
cells (Tabibzadeh et al., 1992) and IL-P mRNA expression is raised in pregnancy
(Kauma et al., 1990). Human serum IL-1 levels vary according to the menstrual cycle
and are found to be highest in the secretory phase, post-ovulation (Cannon et al., 1985).
In contrast, IL-1 receptor antagonist levels decline in the secretory phase (Simon et al.,
1995). IL-1 has also been connected to blastocyst implantation and is found expressed
along with its receptor in both trophoblast and decidual cells (Simon et al., 1994; Simon
et al., 1995). ESCs produce an immune-related response upon treatment with IL-la by
evoking an enhancement in phagocytosis of latex particles and E.coli (Ruiz et al., 1997).
This cytokine may also be involved in menstruation since in cultures of human ESCs,
IL-la stimulates production of MMP-1, a key enzyme in menstruation initiation (Singer
et al., 1997). IL-1 P acts to raise PGE2 levels in decidual and endometrial ESCs (Cole et
al., 1995; Ishihara et al., 1995). IL-la stimulates PGE2 and PGF2aproduction in ESCs
(Kawano et al., 2001). These data support a role for IL-1 in the regulation of
menstruation since PGE2 and PGF2a are believed to be involved in vascular changes
associated with endometrial tissue degradation (Baird et al., 1996). IL-1 has also been
52
associated with endometriosis. Women with endometriosis have elevated IL-1 (3 in their
perintoneal fluid (Fakih et al., 1987) although a later study determined raised IL-1
receptor antagonist in association with endometriosis as opposed to IL-1 (3 (Mori et al.,
1992). IL-1 has been demonstrated to activate an angiogenic phenotype in human ESCs
from endometriotic lesions via its receptor (Lebovic et al., 2000).
1.3.3.2 Interleukin-10 (IL-10)
IL-10 is a homodimeric cytokine expressed by naive and memory T cells (Chabot et al.,
1999). In blood NK cells, IL-2 alone or synergistically with IL-12, can act to induce IL-
10 expression (Mehrotra et al., 1998) and this has also been demonstrated in uNK cells
(Vigano et al., 2001). In mice, IL-10 is only expressed by Th-2 cells but in contrast this
cytokine is expressed by both Th-1 and Th-2 cells although the latter express it more
strongly (Romagnani, 2001). IL-2-induced CD56bnght NK cells proliferate and produce
cytokines upon treatment with IL-10 (Carson et al., 1995). Within the pregnant uterus,
trophoblastic villi do not secrete IL-10 (Kelly et al., 1995), however, mononuclear cells
in the decidua do so spontaneously in culture (Ekerfelt et al., 2002). The specific roles
of IL-10 in reproduction are unclear. Double-deficient mice for IL-10 and IL-4 have
successful pregnancies, although this study did not assess fetal or maternal development
(Svensson et al., 2001). A more recent study on IL-10 null mice has demonstrated
abnormal placental development in the absence of IL-10 and has suggested a role for
this cytokine in implantation and fetal programming (Roberts et al., 2003). In women
with missed abortion, a reduction of IL-10 immunostaining was observed in uNK cells
compared with those from elective terminations (Plevyak et al., 2002). These results
may actually represent post-miscarriage inflammatory changes and it is therefore
difficult to rely on this data alone. In contrast to this, IL-10 production was greater in
stimulated peripheral blood mononuclear cells from women with recurrent pregnancy
loss than controls (Bates et al., 2002). This may, however, represent a compensatory
mechanism by which IL-10 counteracts other not yet understood malfunctions. This
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study was also assessing NK cells from blood and whether they have any impact on
uNK cells has not been confirmed.
1.3.3.3 Interferon-y (IFN-y)
The interferon family are cytokine mediators that are involved in alterting the immune
system to the presence of viral infections. The family comprises of three members in
humans: IFN-a, ~P and -y. Components of the same receptor are shared by IFN-a and
IFN-P and they are therefore referred to as type I interferons. Since IFN-y uses a
separate receptor system it is termed a type II interferon. In addition to distinct
receptors, type I and II interferons also differ with regard to which chromosome they are
located on and their structure differs. IFN-y is distinct due to its sensitivity to pH and
temperature extremes (Arai et al., 1990) and is expressed by many cell types including
Natural Killer cells and macrophages, but predominantly by T cells (Sugawara et al.,
1986). In contrast, type I interferons are secreted by vims-infected cells (Le Page et al.,
2000).
IFN-t is a member of the interferon I family. It is not present in humans but is
expressed by ruminant trophoblastic cells although it has structural and biological
functions similar to those of IFN-a and -P, both present in humans (Roberts et al.,
1999). IFN-t is believed to be the maternal recognition of pregnancy signals in
ruminants. IFN-t is also secreted by the bovine conceptus and is considered to be
involved in rescue of the corpus luteum via limitation of PGF2a release (Thatcher et al.,
1995).
The source of IFN-y within the human endometrium is thought to be the lymphoid
aggregates (Tabibzadeh, 1994b) but is also synthesised by uNK cells in first trimester
decidua (Saito et al., 1993) and by macrophages (Gessani and Belardelli, 1998). IL-12
can stimulate IFN-y production in cultures of uNK cells and acts synergistically with IL-
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2 to provide this response (Marzusch et al, 1997). IFN-y levels remain consistent across
the menstrual cycle in non-pregnant endometrium (Yeaman et al., 1998) but during
pregnancy it can only be detected in supernatants from first trimester decidua and not in
the later pregnancy stages (Lin et al., 1993). IFN-y acts on the epithelial cells to induce
human leukocyte antigen (HLA)-DR molecules of MHC and triggers morphological
changes in addition to a reduction in growth (Tabibzadeh et al., 1986; Tabibzadeh et al.,
1988). This cytokine also has actions on ESCs to induce an increase in the levels of IL-
6, MCP-1 and MCSF production and reduce IL-8 levels (Nasu et al., 1998).
55
Table 1.3
Summary of the reproductive phenotypes exhibited by mutated mice genetical
deficient in endometrial cytokines or their receptor. This table is adapted fro
Robertson and Hudson 2002 (Robertson et al., 2002).
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Seymour et al 1997
(Seymour et al., 1997)
Robertson et al 1999
(Robertson et al., 1999)
IFN-y
Dysregulation of uNK cells
Decidual necrosis
Inadequate transformation of endometrial
vessels during decidualisation
Increased fetal reabsorption
Ashkar and Croy 1999
(Ashkar et al., 1999)
IL-1R Reduced litter size
Abbondanzo et al 1996




Robertson et al 2000




Robb et al 1998 (Robb et
al., 1998)
IL-2 Ry Fail to develop uNK cells
Miyazaki et al 2002





Stewart et al 1992
(Stewart et al., 1992b)
Ware et al 1995 (Ware et
al., 1995)
TGF-pl Lethal in embryogenesis
Shull and Doetschman
1994 (Shull et al., 1994)
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1.3.3.4 The mouse as a model
In order to evaluate the relevance of different pathways and compounds to an overall
system the mouse proves to be a versatile tool to use. In this respect, knockout mice
offer exploration to the function of specific genes and their products whereby such an in
depth study cannot be carried out on humans. Examples of mouse knockouts that are
relevant to reproductive processes are summarised in table 1.3. Although these
knockouts give an insight into a physiological situation, these findings in mice cannot be
directly applied to the human situation. With regard to the uterus there are many
differences between the mouse and the human. The process of decidualisation in
humans occurs in anticipation of pregnancy whereas in mice the physical stimulus of
implantation is the trigger. This implies that the control of this process in humans is
divergent to that in mice. In addition, decidualisation only occurs at the sites of
implantation in mice, which is highly specific compared to the dispersed decidual
transformation within the human endometrium. Therefore to what extent, for example,
IL-11 is essential to decidualisation and implantation in humans may not directly
correlate to that occurring in mice (Robb et al., 1998). However, studies using cultures
of human ESCs have also indicated IL-11 having a role in decidualisation (Cork et al.,
2001; Dimitriadis et al., 2002) therefore illustrating the use of the mouse model as
starting place. In the case of the COX-1 knock-out mouse it appears that COX-2 is
compensating for the absence of COX-1 and therefore the exact roles of this enzyme
become unclear (Reese et al., 1999). This could be occuring in other mouse knock-outs
and therefore should be taken into consideration when assessing the results.
With regard to uNK cells the mouse has been used as a model to assess their function in
several studies (Ashkar and Croy, 1999; Ashkar et al., 2000; Croy et al., 1991; Croy et
al., 2002; Zhang et al., 2003). These studies have focused on knock-out models in
particular and the possible functions of uNK cells in humans are discussed in section
1.2.2. However, more recently IL-15 knock-out mice, which are deficient in uNK cells,
have demonstrated that these cells are not essential to pregnancy (Barber and Pollard,
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2003; Ashkar et al., 2003). What these studies did show was that birth weight was
compromised, probably the result of inadequate conversion of the uterine vasculature,
(Barber and Pollard, 2003) and this deficiency in weight continued into adulthood
(Ashkar et al., 2003). This could have implications on coronary function in the
longterm. The work of Barker demonstrated a greater incidence of coronary heart
disease and stroke in individuals who had suffered from retarded fetal growth (Barker,
1997a, b and c). In humans the uNK cell may be of greater relevance to the
establishment and maintenance of pregnancy than in mice but it may also have
implications to intrauterine programming due to its role in blood vessel modification.
The distribution of uNK cells is different between mice and humans with them only
located at the metrial triangle in mice whereas in humans they are distributed throughout
the stroma. These uNK cell knock-out mice do exhibit defective decidualisation
(Ashkar et al., 2000) and since this decidual transformation is a pre-requisite to
implantation in humans this lack of uNK cells may have a more significant contribution
to establishment of pregnancy in this species.
As discussed in Enders, 2000, the mouse proves an economic animal to use as a model,
however, differences including the mechanism of implantation and the shape of the
lumen exist (Enders, 2000). The mouse is a useful tool and provides a rational starting
point for the exploration within the human system or within other animal models more
closely related to humans.
1.4 Molecular Contributions to Pregnancy
1.4.1 The Prostaglandin Cascade
Prostaglandin (PG) E2 and PGF201 are the most abundant PGs in the human
endometrium. The major site of production is the glandular epithelial cells both in the
endometrium and in early pregnancy (Smith et al., 1988). The production of
prostaglandins (PGs) is controlled by two rate-limiting steps, phospholipase A2 activity
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and activity of the two cyclooxygenase enzymes, COX-1 and -2 (figure 1.4). Initially,
arachidonic acid (AA) must be liberated from the phospholipid membrane of the cell via
PLA2. This free AA can then be converted to prostaglandin H2 (PGH2) by COX-1 and -
2. The next stage in the cascade is the action of specific synthases on PGH2 to direct the
production of the five primary prostanoids, namely PGD2, PGE2, PGF2a PGI2 and TXA2
(Smith et al., 1996; Smith et al., 1996). Three PGE synthases (PGES) have been
identified to date, and these include a cytosolic PGES (cPGES) (Tanioka et al., 2000)
and two microsomal PGESs, mPGES-1 (Murakami et al., 2000; Mancini et al., 2001)
and mPGES-2 (Tanikawa et al., 2002). Aberrant expression of mPGES-1 in conjunction
with COX-2 has been postulated to have a role in tumourigenesis (Kamei et al., 2003).
In reproductive tissue, PGES has been located in bovine endometrium and its expression
correlated with that of COX-2 (Parent et al., 2002). Studies in mice have demonstrated
the high expression of mPGES in the stroma that immediately surrounds the blastocyst
and have implied a role for this synthase in decidualisation and implantation in rodents
(Ni et al., 2002). Conversely, PGs are metabolised and thus deactivated by
prostaglandin dehydrogenase (PGDH) enzymes. In the uterus, PGDH has been
speculated to have a role in maintaining low concentrations of PGs in the fetal
membranes during the majority of pregnancy (Cheung et al., 1992). In some cases of
idiopathic preterm labour, a reduction in PGDH expression in the chorionic trophoblast
resulting in reduced PG regulation, has been implicated as a causative factor (Sangha et
al., 1994). In support of a role for PGs in pre-term labour, inhibition of COX-2 can
prevent inflammation-mediated pre-term labour in mice (Gross et al., 2000b). Within
the human endometrium, PGDH is located within the cytoplasm of gland cells and levels
were found to be highest in the secretory phase but lowest pre-menstrually and during
menstruation (Casey et al., 1980). Raised levels in the secretory phase versus the
proliferative phase were confirmed in a later study and it was also demonstrated that
PGDH activity was significantly increased at 12 months post-insertion of a LNG-IUS
and coincided with a rise in PR-A and -B immunostaining (Critchley et al., 1998b).
This correlates with the control of endometrial bleeding, implicating both receptor levels
and PGs in the process. The role of PGs is supported additionally by a further study that
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has demonstrated a decline in PGDH immunostaining in the glands and stroma in
women 36-48 hours after receiving the antiprogestin, mifepristone (Hapangama et al.,
2002).
PGs have a short half-life and are metabolised rapidly. It is therefore likely that their
actions are local to their production site. PGs are classified by their cyclopentane ring
and TXA contains an oxane ring. Each group acts via its own distinct receptors
(Coleman et al., 1994; Narumiya et al., 1999). These receptors are G protein-coupled
receptors with 7 transmembrane domains, located on the plasma membrane. Sequence
homology between the different receptors is low, ranging from 20 to 30%, although
homology of the specific receptors between species is far higher, 76 - 97% (Narumiya et
al., 1999). There are 4 different PGE2 receptors and these are referred to as EPt _4. The
EP2 and EP4 receptors act via Gs proteins and have the effect of raising cAMP levels.
The EP3 receptor exists as 7 splice variants (Adam et al., 1994; Sugimoto et al., 2000)
with the predominant effect of decreasing cAMP levels. EPi acts via a different second
messenger, Ca2+, to exert its effects (Kennedy et al., 1982; Watabe et al., 1993).
COX-1 is constitutively expressed in most tissues and in contrast COX-2 is normally
absent and only present in a pathological state, for example, COX-2-dependent pathways
have been implicated in development of colorectal cancers (Williams et al., 1999) and in
eutopic and ectopic pregnancies (Ota et al., 2001). COX-2 can be induced by factors
such as lipopolysaccharide (Inoue et al., 1995) and IL-1 (Thomas et al., 2000; Tamura et
al., 2002). However, it is becoming apparent that COX-1 can also be induced and it has
been shown to be upregulated in cervical carcinomas (Sales et al., 2002). Both of the
COX isoforms are inhibited by non-steroidal anti-inflammatory drugs (NSAIDs) and it
has been demonstrated in mice and humans that some NSAIDs are preferentially
selective for one or other of the COX enzymes (Meade et al., 1993; Gierse et al., 1995).
The cause of luteinised unruptured follicle from animal and clinical studies may be
related to COX-2 inhibition and a link between NSAIDs and reversible female infertility
has been proposed (Stone et al., 2002). In the human endometrium around the time of
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implantation, COX-1 and COX-2 are expressed in glandular and luminal cells, and in the
luminal and perivascular cells respectively (Marions et al., 1999). When mifepristone
was administered, epithelial immunostaining of COX-1 and —2 declined. In addition to
illustrating a connection between the PG pathway and steroid hormone action, a function
in endometrial receptivity has been suggested (Marions et al., 1999). COX-2
immunoreactivity levels are greater in the premenstrual phase than the mid-secretory
phase and this coincides with the recruitment of leukocytes into the endometrium
immediately prior to menstruation (Jones et al., 1997).
A variety of PG antagonists have been shown to reduce the implantation site number in
mice and it has been suggested that PGs exert effects on both mother and fetus (Biggers
et al., 1981). Many studies have assessed the effects of the PG pathway on female
fertility and reproductive processes by generating gene knockouts for the various aspects
of the cascade. Some of these will be discussed here although it is important to
remember that reproductive events such as decidualisation and parturition (Gross et al.,
2000a) differ between mice and humans. A double knock-out for COX-1 and COX-2 is
lethal, caused by patent ductus arteriosus (Loftin et al., 2001), and therefore it is not
possible to study the reproductive consequences in mice of complete COX absence.
Targeted disruption of COX-2 in mice leads to problems with the key processes of
ovulation, fertilization, implantation and decidualisation (Lim et al., 1997). Studies in
mice show two distinct pathways for COX-1 and -2 within the uterus implying
independent contributions to uterine PG production but these were also shown to overlap
to some extent (Reese et al., 2001). In a previous study on knock-out mice for COX-1 (-
/-), on pregnancy day 4 demonstrate reductions in vascular permeability and PG
concentration (Reese et al., 1999). However, these reductions were less than those
predicted and further investigation revealed a compensatory response by COX-2
demonstrating interaction between the two enzymes. Mice deficient in the EP2 receptor
exhibit a reduced ovulatory number and a reduced fertility rate (Hizaki et al., 1999). No
alterations in uterine development are apparent. The lack of EP4 receptor expression in
mice knockouts proves to be fatal soon after birth due to malfunction of the ductus
62
arteriosus. Mice deficient in cytosolic PLA2 have reduced fertility, smaller litter sizes
and delayed initiation of labour (Bonventre et al., 1997; Uozumi et al., 1997).
1.4.1.1 PGE2 as an Immune Modulator
PGs have been implicated as modulators of immunity (Harris et al., 2002) and in support
of this PGE2 can inhibit many immune cells such as T cells (Goodwin et al., 1983) and
neutrophils (Fantone et al., 1983). Within human semen high concentrations of PGE2
are contained and this is believed to aid reproductive success via inhibition of female
immune responses (Kelly, 1991). Decidual stromal cells are a source of PGE2 and this
PG has been shown to have an inhibitory effect on NK cells via the IL-2 and IL-15
receptors (Parhar et al., 1989; Joshi et al., 2001). Addition of indomethacin or anti-
PGE2 antibody to NK cells in situ revealed an up-regulation of the IL-2 receptor a chain,
IL-2 production and an increased anti-trophoblast killer activity (Parhar et al., 1989).
PGE2 also has the ability to alter the cytokine profile of cells and favour a Th-2 response
in preference to a Th-1 reaction by stimulating IL-10 and inhibiting IL-12 production in
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Figure 1.4
The prostaglandin cascade illustrating the two rate-limiting stages (i) PLA2 activity to
liberate free arachidonic acid (AA) from membrane phospholipids and (ii) COX-1/-2
activity in the conversion of AA to PGH2. The PGs and TXAs then act on their specific
GPCRs.
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1.4.2 Cyclic Adenosine Monophosphate (cAMP)
Intracellular second messengers allow the transmission of signals to pass within a cell
and produce an amplification of the signal. One of these important messengers is
cAMP. It is produced from ATP when adenylyl cyclase is activated. The original signal
is then amplified via a stimulated protein kinase cascade. Phosphodiesterases act to
breakdown cAMP and thus counteract the effects of this second messenger. Levels of
cAMP can be raised by the presence of phosphodiesterase inhibitors such as rolipram.
Activators of adenylyl cyclase including forskolin also produce the end result of
increasing cAMP levels. Within the endometrium PGE2 is an activator of adenylyl
cyclase and relaxin inhibits phosphodiesterases (Bartsch et al., 2001) thus raising cAMP
levels. The connection between cAMP and the ovarian sex hormones could be partly via
the progesterone receptor. In the breast cancer cell line, T47D, CAT assays have shown
the ability of cAMP to potentiate the progesterone-dependent activation of the
progesterone receptor but only in the presence of progesterone (Edwards et al., 1993).
In post-menopausal women the antiprogestin, RU486, can act as an agonist in the
endometrium but only when in the presence ofprogesterone (Gravanis et al., 1985). The
effects of RU486 on the endometrium of castrate monkeys has been studied, and RU486
was found to have weak progestational effects in the proliferative phase but strong anti-
progestational effects in the secretory phase (Koering et al., 1986). Experiments on
T47D cells also demonstrated that when RU486 was added in combination with cAMP a
partial agonist activity was produced. This implies cross-talk between a second
messenger signal transduction pathway and a nuclear receptor but whether this also
occurs within the endometrium has yet to be established.
Within the human endometrium, cAMP is the main second messenger involved in the
PGE2 signal transduction pathway (Frank et al., 1994). Evidence for the involvement of
cAMP and its analogues in the decidualisation of human endometrium has been
proposed (Tang et al., 1993a; Brosens et al., 1996; Brar et al., 1997; Brosens et al.,
1999). Experiments using cultures of ESCs have shown that prolactin expression is
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dependent on activation of the PKA pathway (Brar et al., 1997; Telgmann et al., 1997).
Direct use of cAMP results in an increase in prolactin mRNA expression and protein
release (Tang et al., 1993a; Brosens et al., 1996; Brar et al., 1997; Brosens et al., 1999)
and this elevation is a permanent response (Telgmann et al., 1998). They demonstrated
the ability of cAMP to synergise with a synthetic progestin to result in stromal
differentiation and an increase in prolactin levels. Progesterone treatment alone proved
to be a weak inducer of the decidualised phenotype. High intracellular cAMP levels
appear essential by sensitising the cells to progestins and thus providing maximal
prolactin expression. Deletion of the region between position -332 and -270 in the dPrl
promoter caused a strong reduction in the ability of cAMP to induce prolactin expression
implying the importance of this particular region in its activation (Telgmann et al.,
1998).
1.4.3 Interleukin-15 (IL-15)
IL-15 was initially discovered as a stimulator of T-cell proliferation (Grabstein et al.,
1994). It has a molecular weight of 14-15 kDa and is a member of the 4 a-helix
cytokine family. The receptor complex for IL-15 is composed of three subunits. The a-
chain is unique to its receptor but both the (3- and y-chains are also common to the IL-2
receptor (Carson et al., 1994; Grabstein et al., 1994). Two forms of IL-15 exist due to
alternative splicing resulting in a long signal peptide (LSP), 48-AA in length, and a short
signal peptide (SSP), 21-AA long (Fehniger et al., 2001) (figure 1.5). The SSP IL-15 is
restricted to the nuclear and cytoplasmic compartments of the cell whereas the LSP has
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The generation of the two isoforms of IL-15, SSP and LSP, from the human IL-15 gene
locus. Diagram recreated from Waldmann et al 2001 (Waldmann et al., 2001).
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1.4.3.1 Systemic IL-15
Human IL-15 has 97% sequence homology compared with simian IL-15 and 73%
homology with murine IL-15 (Anderson et al., 1995). This conservation in IL-15
between species suggests an important biological role. This is compounded by its wide
tissue distribution within humans including skeletal muscle, heart, kidney, placenta and
uterus (Grabstein et al., 1994). Inappropriate production of IL-15 can lead to the
manifestation of a number of human diseases. An implied involvement of IL-15 in
autoimmune and inflammatory diseases such as rheumatoid arthritis and inflammatory
bowel disease support an immune connection with IL-15 (Fehniger et al., 2001). In
contrast, the functions of IL-15 stretch beyond the immune system. In skeletal muscle it
appears to have anabolic properties associated with skeletal muscle fiber hypertrophy
(Quinn et al., 1995). However, knockout mice studies have shown no defects in muscle
development implying a non-critical role in this tissue (Kennedy et al., 2000). Detection
of IL-15 has been reported in human cortical tubular epithelial cells. Both the message
and protein levels are increased by the Th-1 cytokine IFN-y and by ligation with CD40
and it has been suggested that this knowledge may be important in kidney
transplantation (Weiler et al., 1998; Weiler et al., 2001).
1.4.3.2 The Reproductive Relevance of IL-15
Although the actions of IL-2 and IL-15 are reported to be similar, their tissue
distribution is distinct. The uterus and placenta were found to be negative for IL-2
(Jokhi et al., 1994b; King et al., 1995) and so further investigation into other cytokines
that could stimulate uNK cells was undertaken. The novel cytokine, IL-15 was
discovered via detection of both the mRNA (Okada et al., 2000b; Verma et al., 2000)
and protein (Kitaya et al., 2000). Gene profiling has demonstrated an upregulation of
IL-15 during the human "implantation window" compared with the late proliferative
phase. The IL-15 precursor, IL-15 and the a chain of the IL-15 receptor are all
increased by at least three-fold (Kao et al., 2002) and this supports the role of IL-15 in
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the process of implantation. Other studies have also confirmed higher levels of IL-15
mRNA expression in the secretory phase versus the proliferative phase with highest
expression levels in the mid-late secretory phase (Kitaya et al., 2000; Okada et al.,
2000b; Verma et al., 2000; Chaouat et al., 2002). Immunohistochemistry localised IL-
15 to the glandular and luminal epithelium during the proliferative phase and in the mid-
late secretory phase to the perivascular stromal cells (Kitaya et al., 2000). Studies on
stromal cells grown in vitro imply that production of this cytokine is partly under
hormonal control (Okada et al., 2000a). However, the presence of IL-15 is not limited
to the menstrual cycle but is also abundant in first trimester decidua (Kitaya et al., 2000;
Okada et al., 2000b).
The human placenta is an important source of IL-15. Studies utilising a trophoblast
invasion model, JEG-3, discovered IL-15 has the ability to enhance trophoblast invasion
and migration in vitro (Zygmunt et al., 1998) and it is postulated to be involved in this
process in vivo. It is apparent that the ratio of IL-13: IL-15 is important in controlling
this process in vivo since it has been discovered that women experiencing recurrent
spontaneous abortion (RSA) expressed raised levels of IL-13 and IL-15 in endometrial
stromal and epithelial cells with the ratio being in favour of IL-13 (Chegini et al., 2002).
In general terms it is accepted that a Th-2 response is beneficial to pregnancy (Wegmann
et al., 1993), however, the rise in IL-13 expression over that of IL-15 in RSA
endometrium implicates complexity to this classification (Chegini et al., 2002). The
general hypothesis that Th-1 cytokines are detrimental and Th-2 cytokines are beneficial
to pregnancy is probably an over-simplification (Chaouat et al., 2002). This is of
particular importance given the role of IFN-y in the establishment of normal pregnancy
in the mouse (Ashkar et al., 1999; Ashkar et al., 2000).
1.4.3.3 Studies on IL-15 Null Mice
Knockout mice for IL-15 (-/-) have no NK cells present and this suggests a role for IL-
15 in the development and maturation of these cells (Kennedy et al., 2000). Studies
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specifically within the uterus have shown with knock-out studies in mice that mutant
mice lacking uNK cells display irregular oestrous, deficient decidual formation and
thickened blood vessel walls (Miyazaki et al., 2002). In addition to these defects, a
reduced placental size occurs in uNK cell deficient mice (Greenwood et al., 2000). This
supports the theory that these cells are involved in transformation of uterine vasculature
(King et al., 1990). In humans, inadequate artery transformation can result in pre¬
eclampsia, intra-uterine growth retardation (IUGR) and still birth and with the case of
IUGR this programming in utero can be associated with cardiovascular diseases in adult
life (Barker, 1997a; Barker, 1997b).
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1.5 Hypothesis and Aims
Previous studies have identified various factors that are involved in the decidualisation
of endometrial stroma, a process that is essential to a successful pregnancy in humans.
The accumulation of uNK cells across the secretory phase coincides with this decidual
transformation of the stromal compartment. The regulation of uNK cells and their
specific functions in the human uterus are not fully understood although it is likely they
are closely linked to the ESC that is under progesterone control. From the results of
previous research discussed in section 1.2.2.1, a hypothesis of these speculative actions
has been summarised in figure 1.6.
Paracrine interactions between uNK cells and ESCs via cytokines are likely to be
essential to the respective development and functions of both cell types. Specific
products of uNK cells, including IFN-y and IL-10, may be modulating the function of
ESCs in addition to maintenance of inflammatory and immune homeostasis. At this
point in time the ESC cell will be transforming via decidualisation and products of the
uNK cells may be modulating this conversion reaction. Reciprocally, cytokine
production by ESCs will provide communication with uNKs and possibly amend their
cytokine production. Feedback between these cell types will be essential to fine-tuning
the control of these actions and thus establish an environment correctly prepared for
pregnancy.
Prostaglandins are considered important to many of the key reproductive events in the
human uterus although their exact effects are not yet clearly defined. Their actions are
controlled at multiple levels within cells by the activity of various enzymes and this
represents a complex cascade of events. PGE2 is involved in decidualisation of the
endometrial stroma, a process in humans essential to successful implantation.
Expansion in our knowledge of the changes occurring to the PGE2 pathway will provide
a greater understanding of the mechanisms controlling the decidual transformation. This
process is likely to be tightly regulated with modifications at a number of control points
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along the cascade. The transport of PGE2 across the cell membrane is a further control
mechanism post-translationally and will be relevant to transport out of and into cells. In
addition to actions on ESCs, PGE2 can act to modify the actions of IL-15 on the cell
surface of NK cells at the receptor level. PGE2 may also be regulating the production of
cytokines by uNK cells via actions on the IL-15 receptor or directly on its own receptors
at the surface of the cell.
The Main Aims of this Research Project:
1. Further investigate decidualisation of human ESCs in vitro and explore the
functional link between IL-15 and decidualisation.
2. Assess the changes in the prostaglandin cascade during decidualisation of ESCs.
3. Assess the potential factors that are involved in the regulation of IL-15 mRNA
expression and protein secretion in ESCs in vitro and in the human endometrium
and decidua.




The hypothesised interactions between uNK cells and ESCs in the human
endometrium/decidua during the secretory phase and in early pregnancy implicating
the indirect action of progesterone on uNK cell function via the ESC. Studies on
blood NK cells demonstrated that it is the CD56br'8ht NK cells that may be the major
producers of cytokines (Cooper et al., 2001a). uNK cells may therefore represent an





2.1 Collection, Processing of Human Uterine Tissue and Ethics
Human endometrial specimens were collected from women of reproductive age (n = 77)
who were undergoing gynaecological procedures for benign indications. All women had
regular menstrual cycles with a length of between 25-35 days and had not received
exogenous hormones or used an intrauterine contraceptive device in the 3 months prior to
surgery. For all endometrial biopsies analysed, the stage of the menstmal cycle was
consistent with the patient's reported last menstrual period and histological dating using the
criteria of Noyes et al (Noyes et al., 1950). Samples were classified as menstmal (M),
proliferative (P), and early (ES), mid (MS) and late secretory (LS) phases for the purposes of
Taqman Q RT-PCR. Any cases with severe uterine pathology, for example, polyps or large
fibroids, were excluded. All subjects had a serum sample collected at the time of surgery for
the determination of circulating oestradiol and progesterone levels by RIA. All samples
were consistent with the designated cycle stage based on morphological criteria and last
menstrual period (see table 2.1) (Critchley et al., 2002).
Decidual tissue was collected by two different methods for varying experimental
procedures. For the purpose of the analysis of mRNA expression across the cycle
decidual (n = 5) and trophoblast (n = 4) specimens were obtained from women who had
undergone surgical termination by vacuum aspiration, during the first trimester of
pregnancy. All patients had the termination performed under general anaesthesia. Prior
to vacuum aspiration, decidual tissue distant from the implantation site was removed by
gentle curettage of the uterine lining. Presence and absence of decidual parietalis and
trophoblast respectively was confirmed by examination of haematoxylin and eosin
stained tissue sections. Tissue sections were also stained with cytokeratin to confirm the
presence or otherwise of trophoblast cells within the decidual tissue (Critchley et al.,
1996). The endometrial tissue was collected in sterile Roswell Park Memorial Institute
(RPMI) 1640 medium (Sigma, Poole, Dorset, UK). The decidual tissue samples were
processed for messenger RNA (mRNA) extraction alone. The endometrial samples
were divided and processed as follows: (i) homogenisation in Tri Reagent® (a
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monophase solution containing phenol and guanidine thiocynate) to allow mRNA
isolation from DNA and protein; (ii) fixation in 10% neutral buffered formalin (NBF)
overnight at 4°C followed by storage in 70% ethanol preceding wax embedding; and
(iii) separation of endometrial stromal cells (ESCs) by sedimentation (see section 2.2).
A second method of decidua collection was utilised in order to collect tissue for the
uterine Natural Killer cell separation procedure. Insufficient amounts of tissue could be
collected via the former method. In order to collect larger volumes of decidual tissue the
total tissue yield from the suction curettage procedure (used to evacuate uterine
contents) were collected. Decidual tissue (n = 15) was selected by macroscopic
inspection from the products of the termination aspiration procedure (this process was
performed by our trained, Research Sister). Thereafter decidual tissue was collected in
sterile RPMI 1640 medium (Sigma, Poole, Dorset, UK) in preparation for the uterine
Natural Killer cell separation procedure. A small section of tissue was placed in RNA
Later (Ambion Europe Ltd., Cambridgeshire, UK) in order that mRNA could be later
extracted. A second small section of tissue was placed into 10% NBF and following
fixation for 24 hours samples were placed in 70% ethanol preceding wax embedding.
Decidua was only collected from women with a pregnancy of gestation age between 7
and 10 weeks.
Informed patient consent was obtained prior to all tissue collection by a dedicated
Research Nurse. Ethical local research approval had been previously granted by the



























































Details of the endometrial and decidual biopsies studied in this research project. The
median and range of serum oestradiol and progesterone concentrations are included.
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2.2 Endometrial Cell Culture
Endometrial specimens (n = 28) were separated into epithelial and stromal cell
populations by a sedimentation procedure. Specimens were initially washed in
phosphate buffered saline and sliced into l-2mm pieces using scalpel blades. These
were re-suspended in 2ml PBS and digested in collagenase (Sigma) for 80 minutes at
37°C. An 18 gauge needle was used to facilitate tissue breakdown. The cells were then
pelleted by centrifugation and re-suspended in 12ml RPMI 1640 and left for 5 minutes
to settle. The top 10ml were removed as the population of endometrial stromal cells
(ESCs). A Fluorescence Activated Cell Sorter (FACS) had been used to verify the
purity of cells separated by this technique (see section 2.3). The ESCs were further
cultured in RPMI 1640 medium (Sigma) supplemented with 10% foetal calf serum
(FCS) (Mycoplex; PAA, Teddington, UK), penicillin (50 pg/ml; Sigma), streptomycin
(50 pg/ml; Sigma) and gentamycin (5 pg/ml; Sigma). The endometrial specimens used
in the cell culture experiments were predominantly from the proliferative phase.
However, due to a shortage of specimens it was necessary to use some from the early
secretory phases also. These specimens will have been exposed to progesterone in vivo
although those from the proliferative phase had not. It was therefore necessary to grow
all of the cultures in the prescence of progesterone prior to being used in the experiments
so that all cultures had been exposed to progesterone. Cells were cultured in 75cm3
culture flasks (Coming Incorporated, Coming, NY) for a minimum period of 5 days and
allowed to reach confluence in the presence of oestradiol (10"7 M),
Medroxyprogesterone acetate (MPA) (10"6 M) and basic fibroblast growth factor (bFGF)
(5ng/ml). These supplements also provide optimum conditions for ESC growth (Irwin et
al., 1991).
2.3 Fibroblast Cell Purity
Cultures of ESCs were grown for two weeks before the purity of fibroblasts in the
cultures (n = 6) was determined by a Fluorescence Activated Cell Sorter (FACS)
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(Beckmann Coulter). This was achieved by using a human fibroblast antigen Ab-1
(Oncogene). About 1 million ESCs were taken from an ESC culture following
trypsinisation, re-suspended in 200pl Cell Separation Media (CSM) (PBS 0.5% bovine
serum albumin; 2mM EDTA) and split between three 1.5ml Eppendorf tubes. Into one
tube 2pl of the fibroblast antibody was added and mixed and the tubes were left on ice
for 30 minutes. The tubes were spun at 4000rpm for 1 minute to pellet the cells, which
were re-suspended in 1ml CSM. This wash was repeated twice more. To two tubes
lOOpl CSM and lOpl anti-mouse IgG whole molecule with FITC conjugated (Sigma)
was added and cells re-suspended. The remaining tube is used as a "blank". The tube
exposed to only the anti-mouse IgG whole molecule with FITC conjugated is the
negative isotype-matched control. The tubes were wrapped in foil to prevent light
exposure and kept on ice for 30 minutes. Tubes were washed as before and re-
suspended in 500pl FACs buffer (PBS 0.1% Azide; 1% FCS). Before passing the cells
through the FACS machine the cell suspensions were passed though cell strainers
(Becton Dickinson Labware Europe, France) to ensure a single cell suspension. See
figure 2.1 for an example of the FACS reports.
2.3.1 Fluorescence Activated Cell Sorter (FACS)
A Coulter ® EPICS® XL™ Flow Cytometer was the FACs machine used to measure the
purity of the cells. This machine allows the purity of a specific cell type within a mixed
population of cells to be measured. The cells are passed through an aperture as single
cells. The laser beam detects cells and registers them as an event. The laser beam is
able to determine two properties of each cell: the granularity and cell size. The
granularity is read by the amount of side scatter of the laser beam and the cell size
determined by the degree of forward scatter. The third measurement made by the laser
beam is fluorescence, in this case fluorescein. The three measurements combined
illustrate the distinct populations of cells that are present and the percentage of
fluorescent gives the percentage of fibroblast-positive cells in the sample.
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Figure 2.1
A representative example of the FACS recordings for the fibroblast purity of ESCs after
2 weeks in culture. The isotype-matched negative control (A) and the sample incubated
with the fibroblast antibody (B). On graph (i) the y axis is the log of the forward scatter
and the x axis is the log of the side scatter. The total number of counts is illustrated on
this graph and the region within the red line represents the gated area of cells analysed.
The remainding points that are outside of this region are likely to be cell debris or red
blood cells and are therefore excluded from analysis. On graph (ii) the y axis is the total
cell count and the x axis is the FITC value - the total level of fluorecence detected on
the cells counted within the gated region in graph (i). The region represented by the
green line indicates the number of cells that are positive for FITC. This is minimal in
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2.4 Messenger RNA Extraction and Reverse Transcription-Polymerase Chain
Reaction (RT-PCR)
2.4.1 Messenger RNA Extraction
The medium on the treated cell cultures was pipetted off and either frozen at -20°C or
maintained at 4°C if being used immediately. Cells were washed in PBS twice to
remove the remnants of medium. Onto each well of a 12-well plate, 0.5ml tri-reagent
was added whereas if 6-well plates or small flasks had been used, 1ml of tri-reagent per
well or flask was added. Cells were left for 5 minutes to allow rupture of cell
membranes to take place. The contents of the wells/flasks were then transferred to phase
lock gel tubes (Eppendorf, Hamburg, Germany) and kept on ice for the remaining
extraction. Chloroform was added at 200pl/ml and the tubes shaken vigorously for
several seconds. They were spun in a pre-cooled, refrigerated centrifuge at 4°C,
14000rpm for 20 minutes to remove the organic phase containing protein and DNA that
become trapped beneath the gel layer. The top aqueous phase containing the mRNA
was poured into labelled 1.5ml eppendorfs. Into each tube 500pl of isopropanol was
added and tubes were inverted a couple of times before being left on ice for 1 hour.
They were spun in a pre-cooled, refrigerated centrifuge at 4°C, 14000rpm for 15 minutes
to pellet the mRNA. The majority of the isopropanol was removed using a sterile
Pasteur pipette and 500pl of 70% ethanol added to each Eppendorf. After being
inverted the tubes were spun for 5 minutes in a pre-cooled, refrigerated centrifuge at
4°C, 14000rpm. The ethanol was removed from each tube and between 20-50pl RNA
Storage Buffer (RSB) was added depending on the size of the mRNA pellet. Samples
were left to dissolve in the RSB for a minimum of 30 minutes.
The concentration of total RNA in the samples was then measured using a Biotech
photometer (WPA, Cambridge, UK). Each sample was vortexed and 2.5pl removed,
which in turn was diluted in 2ml distilled water. All tubes were thoroughly mixed
before measuring the wavelength at both 260nM and 280nM on the photometer. A
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blank used to zero the machine consisted of 2.5pl RSB diluted in 2ml of distilled water.
All samples were then diluted in Diethylpyrocarbonate-treated water (Depc water) to a
concentration of lOOng/pl.
2.4.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Messenger RNA samples (at lOOng/pl) were reversed transcribed using a multiscribe
reverse transcriptase (1.25 IU/p.1), random hexamers (2.5 pmol/1), MgCB (5.5 mmol/1),
dNTPs (lmmol/1) and an RNAase inhibitor (0.4 IU/p.1) was added (PE Biosystems,
Warrington, UK). All reactions consisted of 16pl of reverse transcription mix per tube
and 4pl of mRNA. Once the contents of the tube were mixed, 50pl of mineral oil was
added to prevent evaporation of the reaction mix during the reverse transcription
process. Samples were incubated for 20 minutes at 25°C, 60 minutes at 42°C and then at
95°C for 5 minutes (Omnigene PCR machine, UK). The resulting cDNA was then
diluted 2.5x with TE buffer (10mmol/l Tris pH8.0 and lmmol/1 EDTA in DEPC water)
and were stored at 4°C.
The precision of the reverse transcription (RT) reaction was calculated by a colleague,
Elena Faccenda (laboratory research support). An mRNA sample was taken and 8 RT
reactions set up in 8 separate tubes. These were compared in a single PCR run on one
primer and probe set. The precision was found to be 3.65%.
2.5 Quantitative Real-time-PCR (Q RT-PCR)
This procedure allows the quantitative detection and measurement of a specific sequence
of complementary DNA (cDNA). Primers and probes were designed individually for
each DNA target sequence using the Primer Express computer program. The probe has
a reporter dye and quencher dye attached to the 5' and 3' ends respectively. Whilst
intact, the close proximity of the reporter to the quencher suppresses fluorescence of the
reporter. If the target sequence is present the probe anneals to the cDNA in between the
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forward and reverse primer sites and this is referred to as the polymerisation step. The
sequence of either strand must be complementary to the probe for it to attach. The Taq
polymerase has nuclease activity in the 5' to 3' direction and cleaves the probe in
between the reporter and quencher. This can only take place if the probe has hybridised
to the target sequence of cDNA. Cleavage of the probe allows separation of the reporter
dye from the quencher dye with the result being an increase in fluorescence. This
increase in fluorescence allows the accumulation of PCR products to be measured
directly.
The FAM Ct is the cycle number when the fluorescent signal crosses an arbitrary
threshold value. The 18-S is a measure of the mRNA content of the sample and is used
as an internal control for mRNA variation between samples. The ACt is the difference
between the FAM Ct and the 18-S reading and enables the amplified signal to be
normalised against the total mRNA content. The mean ACt between the duplicates on
the PCR plate was calculated. This was then used to calculate the AACt which is the
difference between the ACt of a treated sample relative to the control in that experiment.
Within each experiment the ACt was related to its own control. The 2"AACt is then
calculated which shows the fold increase or decrease in mRNA expression of the
samples in relation to their control with each control always having a 2"AACt of 1.
All primer and probes sets used on the ABI Prism 7700 PCR machine were purchased
from Biosource (Belgium). The sequences for these are listed in table 2.2. Primers were
diluted to 250pM and probes to 50pM in TE buffer (lOmM Tris; ImM EDTA in Depc
FI2O). A PCR master mix was made up using the Stratagene Brilliant Quantitative PCR
Core Reagent kit (Amsterdam, Netherlands) (7.2mM MgCh; 1.6mM Stratagene dNTP
mix; 1.6mM Boehringer dNTP mix; 0.05U/pl Taq Polymerase; 2x PCR Buffer and
0.06% Reference dye diluted in Depc H2O). Sample to be tested were ran in duplicate
wells on the PCR plate (Applied Biosystems, UK). For each sample, a tube containing
45pl PCR Master Mix and 5pl cDNA was mixed and 23pl pipetted into two separate
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wells on the PCR plate. Two wells containing 5pl of Depc H2O in place of cDNA were
added to each run to serve as a negative control.
The primer and probe sets used were validated with respect to the linearity of the
response. Graphs of the log of total RNA in ng were plotted against the mean ACt value
of three replicates. The regression line of the graph (y) needed to be < 0.1 in order that
the primers and probe could be validated (Figure 2.2). The intra-assay variation was
calculated as a precision value (relative standard deviation) calculated from the mean of
six replicates of identical cDNA ran on the PCR machine in the same run. This value is
expressed as a percentage. (See table 2.3).
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Table 2.2
Details of the primer and probe sets used in Q RT-PCR in this study. The accession









































































































































































y = 0.062x + 13.82
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log ng total mRNA
Figure 2.2
An example of a linearity plot for the primer and probes used for Q RT-PCR. This
figure is the plot for the prolactin primer and probes. The y value for this particular plot
is 0.062 and is an indication of the linearity.
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Validation and precision values for the primer and probe sets used in the present study.
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To ensure that no genomic DNA contamination was present in the mRNA samples, the
P-actin level was measured in the controls from each experiment and in all the RNA
samples used for analysis across the menstrual cycle. The samples were not processed
for the reverse transcription stage and were measured directly by Q RT-PCR in place of
adding cDNA. An arbitrary level of 27, which was 3 standard deviations away from the
mean of all samples, was set and any endometrial samples falling below this level were
excluded from analysis. One sample was excluded for this reason. Figure 2.3 represents
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Figure 2.3
The P-actin levels for the experimental control mRNA samples and for the samples used
in across the menstrual cycle analyses. The cycle number represents the fluorescence
threshold level for all of the samples. Any samples with a value below 27 were
excluded from the study. Therefore, the sample circled in red was omitted.
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2.6 Enzyme-linked Immunoabsorbant Assay (ELISA)
An enzyme-linked immunoabsorbant assay, an ELISA, can be used to detect and
measure various proteins released by cells during in vitro culture. The media in which
the cells have been grown and treated was collected and stored at -20°C. The ELISA
detects the amount of a particular protein present and measures this against a standard
curve to give the concentration of protein present in the media sample. There are two
types of ELISA that will be discussed: the Two-site sandwich ELISA (section 2.6.1) and
the Competition ELISA (section 2.6.2). Both types are run on Maxisorp 96-well plates
(Nunc, Denmark). Method files for each ELISA were constructed in Assay Zap and
contained information concerning the range of standards used and the level of non¬
specific binding. This allows a standard curve to be produced against which the samples
can be measured against.
2.6.1 Two-site Sandwich ELSIA
Prior to the assay, plates are coated with a capture monoclonal antibody that is specific
against the protein of interest. Blocking and protecting medium (2% Polyvinyl
Pyrollidone; 5mg/ml BSA; 0.5ml/litre Preservatives (200mg/ml 5-bromo-5-nitro-l, 3-
dione and 200mg/ml 2-methyl-4-isothiazolin-3-one in DMF/DMSO 1:2); 5mM EDTA;
50mM EDTA) is added to prevent non-specific binding and reduce background
recordings across all samples. The samples are incubated with the standards, quality
controls (of a set concentration in multiple replicates), non-specific binding wells and
finally the media samples to be assayed. Any free, specific protein in the wells will
spontaneously bind to the capture antibody on the base and sides of the well. Excess
media is discarded and washed away before a biotinylated detection antibody
(secondary) is added. This will bind to the protein already bound on the plate and this is
detected with streptavidin peroxidase conjugate (SPC), diluted in assay buffer (see
specific assays for details). After washing the plates once more to remove any unbound
SPC, substrate is added. The peroxidase substrate consisted of 20ml sodium acetate
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(pH 6; lOOmM), 2ml 0.5% urea hydrogen peroxidase (pH 6) and 2ml tetramethyl
benzidine (3mg/ml). Any bound peroxidase will metabolise the hydrogen peroxide
present in the substrate and the tetra methyl benzidine will be converted into a coloured
product. The reaction is stopped by addition of 2N sulphuric acid. The colour is then




The capture antibody is bound to the
base and sides of the wells.
Stage 2:
Any antigens in the media specific to







A biotin-labelled detection antibody is
added and it binds to the bound antigen.
Stage 4:
Streptavidin peroxidase conjugate is
added to the wells and this converts the
substrate to a coloured product that can
be measured.
Figure 2.4
Description of the stages and principles of a two-site sandwich ELISA.
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2.6.2 Competition ELISA (PGF2aand PGE2)
A Competition ELISA (see figure 2.5) works on a different basis to the Two-site
sandwich ELISA. Initially plates are coated with a purified donkey anti-rabbit antibody
(Sapu, Scotland, UK). Blocking and protecting medium is added to block any non¬
specific binding and reduce background. For the PGE2 ELISA, a PGE2 anti-sera (AS)
raised in rabbit is added to the wells and this will bind to PGE2. Since the coating
antibody is anti-rabbit, this will also bind with the AS. Biotinylated labelled PGE2 is
added at the same time and this is referred to as the Link. Samples are added in this
same step and this allows the PGE2 protein in the sample to compete with the Link for
binding sites on the AS. As in other ELISAs, a standard curve and quality control wells
are added to the plate. The standard contains unlabelled PGE2 that will compete for
biding sites on the AS in the same way as for the unknown samples. The maximum
binding is measured by addition of the Link and AS in duplicate wells and this is
referred to as the Bo value. The assay works on the principle that the greater the level of
PGE2 in the sample the greater the amount of displacement of the Link. This results in
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Description of the stages and the principles of a Competition ELISA.
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2.7 Immunohistochemistry
The immunohistochemical method used was a standard avidin-biotin peroxidase (ABC)
method allowing specific proteins within formalin fixed and paraffin embedded
endometrial tissue sections to be detected and visualised. Avidin and biotin have a high
affinity for one another and it is this property that is the basis of the method. A primary
antibody is added and will bind specifically to the protein of interest in the tissue
section. A biotinylated secondary antibody that is specific to the species in which the
primary antibody was raised is added and will thus bind to the primary antibody.
Addition of an avidin-biotin and horseradish peroxidase enzyme complex will result in
any free sites on the avidin molecule binding to the biotin on the secondary antibody.
When 3,3 diaminobenzidine (DAB) is added it becomes oxidised the resulting colour
change of the chromagen causes an insoluble brown precipitate to form at the site of the
protein of interest.
2.7.1 Preparation
Tissue sections and cultured cells embedded in agarose and then in paraffin wax were
dewaxed in histoclear for 5 minutes. Slides were transferred into a second vial of
histoclear for a further 5 minutes. The sections were dehydrated in an alcohol series
starting in absolute ethanol for 20 seconds, then into 95% ethanol and finally 70%
ethanol, each for 20 seconds. Slides were transferred into dtBO and washed once in
PBS.
2.7.2 Scoring of Immunohistochemistry
A semi-quantitative scoring system was used to measure the location and intensity
immunostaining. The sections were scored blind and individually by two observers.
The following system was employed: 0 = no immunoreactivity; 1 - faint
immunoreactivity; 2 = moderate immunoreactivity; 3 = strong immunoreactivity. All of
the slides analysed were included in the same immunohistochemical run and therefore a
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fair comparison could be made between them. Initially all of the slides were examined
briefly to assess the extremes in staining intensity. The staining intensity and area of
staining across each slide was considered as a whole before deciding on the score value
to give it. The two observers then came together and compared the scores they had
asigned. If there were any discrepancies the slides were re-examined and a mutal
decision made on the score that should be given.
2.8 Statistical Analysis
Significant difference of the Q RT-PCR and ELISA data was determined by analysis of
variance (ANOVA) using the computer package Statview 3.0. Individual differences
were assigned using Fisher's protected least square differences (PLSD) test.
The IL-15 immunohistochemistry results were analysed by Kruskal-Wallis analysis and
Dunn's Multiple Comparisons Test used to assign significance (Instat 2.03). This
approach was necessary since the data is non-continuous.
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3. Features of Endometrial Decidualisation - in vitro studies
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3.1 Introduction
The sequential development of the human endometrium is a prerequisite for successful
implantation and continued pregnancy (Wilcox et al., 1999; Lessey, 2000). In humans,
the stromal compartment of the endometrium experiences a transformation across the
mid- and late-secretory phases of the menstrual cycle referred to as decidualisation.
This begins within the perivascular stromal cells and spreads throughout the stromal
region contributing to the formation of decidua in pregnancy. The cells become larger
and more rounded in appearance (figure 3.1) with intracellular structural rearrangements
and increasing stromal oedema. The major in vivo trigger of these adaptations is
considered to be progesterone acting upon oestrogen-primed cells (Milligan et al., 1995;
King, 2000). The differentiation of these cells runs parallel with the rise in progesterone
levels across the secretory phase. Studies in vitro on primary cultures of human
endometrial stromal cells (ESCs) have revealed that this process is complex implicating
the involvement of other factors such as PGE2 (Frank et al., 1994), relaxin (Tabanelli et
al., 1992; Lane et al., 1994) and cAMP (Tang et al., 1993a; Yee et al., 1993; Brar et al.,
1997) in addition to progesterone. More recently, Activin A, a member of the TGF-p
superfamily, has been implicated as another inducer of decidualisation in ESC at least in




Diagrammatic illustration of the various factors thought to be involved in decidualisation
of human ESCs to decidualised stromal cells (DSC), highlighting the multi-factorial
nature of the process.
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PGs are synthesised from the intermediate, PGH2, (see sections 1.4.1 and 2.1 for details)
by specific PG synthases (Smith et al., 1996; Smith et al., 1996; Murakami et al., 2003).
PGE2 and PGE2 synthase are located in glandular, stromal and epithelial cells in the
functional layer of the human endometrium at all cycle stages with a reduction in
stromal staining in the late secretory phase (Milne et al., 2001). Prostaglandins may be
important in the secretory phase and specifically during the implantation window since
the EP2 receptor is up-regulated 4-fold compared with the late proliferative phase as
shown by gene profiling (Kao et al., 2002). There are four sub-types of the PGE2
receptor, EP1-4 and activation of the EP2 and EP4 receptors (section 1.4.1) leads to
stimulation of adenylate cyclase and the cAMP/protein kinase A pathway (Narumiya et
al., 1999). Relaxin is a phosphodiesterase inhibitor and therefore has the ability to
maintain intracellular cAMP levels by inhibiting the action of phosphodiesterases, which
breakdown cAMP. The principal source of relaxin in the female reproductive tract is the
corpus luteum in the luteal phase and throughout pregnancy (Weiss et al., 1978;
Blankenship et al., 1994; Bani, 1997; Sunder et al., 2000). Relaxin is also expressed in
the endometrium and decidua (Bryant-Greenwood et al., 1993). Epithelial and stromal
cells have been reported to display immuno-reactivity for relaxin with an increase in
intensity across the secretory phase and throughout pregnancy.
It is not only the morphology of the stromal cells that transforms with decidualisation,
but also their function. The stroma provides more extensive functions than a mere
supportive structural role. It is believed that decidualised stromal cells are important in
providing homeostasis during implantation and trophoblast invasion (Lockwood et al.,
1999). Progesterone receptor knock-out mice fail to exhibit decidualisation and this is
associated with implantation failure (Rider, 2002). Trophoblast invasion in humans is
significantly deeper in areas where the uterus is deficient in decidua caused by scar
tissue. Imbalances in implantation and placentation can result in uterine rupture or the
later development of pre-eclampsia (Loke et al., 1997) highlighting the necessity for
tight regulation of these events. The depth of trophoblast invasion in humans is under
the influence of hCG, progesterone and oestradiol (Mitreski et al., 2003) and in ectopic
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pregnancies, the extent of trophoblast infiltration has also been shown to be influenced
by hCG levels (Natale et al., 2003). In humans, whether the process of decidualisation
is irreversible is a matter for discussion and will be addressed in this chapter. Relaxin
has previously been shown to acutely and permanently raise intracellular cAMP levels in
cultured ESCs, resulting in prolactin secretion (Telgmann et al., 1997).
Documented markers of the decidualisation process include prolactin (Maslar et al.,
1979; Tseng et al., 1999) and IGFBP-1 (Bell et al., 1991; Bryant-Greenwood et al.,
1993; Lee et al., 1997) and these can be used as guidelines to observe and identify
decidualisation in vitro. In humans, prolactin levels start to increase in early secretory
phase endometrial stroma reaching maximal levels in decidua as shown by
immunohistochemistry (Bryant-Greenwood et al., 1993). This study also revealed a rise
in IGFBP-1 immuno staining with a different timing of appearance to that of prolactin.
IGFBP-1 was absent from proliferative and early secretory phase endometrium but
began to appear in the mid secretory phase followed by a dramatic rise in the late
secretory stroma (Figure 3.2). Other markers of decidualisation that have been
identified in human and rat decidual stroma include vimentin, desmin, laminin and
fibronectin (Glasser et al., 1986; Glasser et al., 1987; Van Muijen et al., 1987) and
these represent structural rearrangements within the cells.
The number of uNK cells present in the human endometrium increases across the
secretory phase, particularly in the mid-secretory phase. This implies hormonal control
over these cells (King et al., 1989b) although they do not express the nuclear
progesterone receptor (King et al., 1996; Henderson et al., 2003). Studies on uNK cells
have demonstrated the ability of the cytokine IL-15 to stimulate proliferation of these
cells in vitro (Verma et al., 2000). A relationship between IL-15 and progesterone-
induced decidualisation of human ESCs in vitro has been proposed (Okada et al.,
2000a). This provides a link between the functions of ESCs and uNK cells within the
endometrium that may be important to successful embryo implantation and early
pregnancy maintenance.
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This chapter examines decidualisation in ESC cultures in vitro, studying the effects of
treatment with a synthetic progestin, PGE2 and 8-Bromo cAMP on the expression and
release of prolactin and IGFBP-1. Using these data as an indication of decidualisation in
these cultures a comparison between IL-15 mRNA expression and decidualisation in
vitro has been made. Levels of the genomic progesterone receptor expression in these
cells have been established. The effect of withdrawing decidualisation treatment on
prolactin expression is also examined.
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Figure 3.2
Photomicrographs of non-decidualised ESC (a) and decidualised ESC (b) primary
cultures. The decidualised ESCs were treated for 6 days with a synthetic progestin,
MPA, (10"6 M) plus 8-Bromo cAMP (250pM) and have become much rounder in
appearance compared with the non-decidualised ESCs. Scale bar represents 300pm.
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Figure 3.3
Schematic diagram of the variation in stromal immuno staining intensity ofprolactin and
IGFBP-1 across the human menstrual cycle and throughout pregnancy. Based on data
from Bryant-Greenwood et al 1993 (Bryant-Greenwood et al., 1993).
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3.2 Materials and Methods
3.2.1 Human Uterine Tissue Collection
Proliferative (n = 5) and early secretory (n = 4) endometrial biopsies were collected and
processed as described earlier (section 2.1). All samples were processed to separate the
ESCs from the glands, as described in section 2.2. The cells were grown for a period of
two weeks prior to commencing experiments in the presence of Medroxyprogesterone
acetate (MPA) and bFGF.
3.2.2 in vitro Primary Cell Culture Studies - Decidualisation
ESCs were seeded in 12-well plates at a concentration of 1.4x105 cells/ml and allowed to
adhere overnight. The following treatment regimes were employed as detailed in tables
3.2 and 3.3. The experiments were designed to study in vitro decidualisation of ESCs.
MPA is a synthetic progestin and is relatively stable. It was selected as a treatment to
analyse the effects of a progestin alone on in vitro decidualisation. Both PGE2 and
synthetic cAMP analogues have previously been acknowledged as stimulators of
decidualisation in vitro and were therefore included in the treatment regime (see section
3.1). 8-Bromo cAMP is a cAMP analogue and was selected because it is readily
absorbed by cells and partially resistant to phosphodiesterases. In addition, the
combined effects of MPA plus PGE2 or 8-Bromo cAMP were assessed. The experiment
detailed in table 3.3 was designed to determine whether a continuous supply of
treatments was required to sustain decidualisation in ESCs in vitro. Relative levels of
prolactin mRNA will be analysed to assess this (see 3.2.5).
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Table 3.2
Experiment 1: Decidualisation of ESCs (n = 4)
Treatment Concentration Incubation time
Control n/a






pge2 + mpa 10~6m+ 10~6m
8-Bromo camp 250pm
8-Bromo camp + mpa 250pm + 10~6m
Table 3.3
Experiment 2: Decidualisation of ESCs and treatment removal (n = 5)
Treatment Concentration Incubation time
Control N/A 5 days, 5 days followed
by 5 days with treatment
withdrawal, 10 days
continuous treatment
PGE2 + MPA 10~6M+ IO-6M
8-Bromo cAMP + MPA 250pM+ 10"6M
3.2.3 Prolactin ELISA
Media collected from experiment 1 at the termination of the time-points, (4, 8 and 12
days), was assayed on a commercial Wallac DELFIA® Prolactin kit (PerkinElmer™
Life Sciences, Wallac Oy, Turku, Finalnd). The kit instructions were adhered to with
the exception that 150pl of sample media was added in place of the suggested 25pil to
increase the sensitivity of the assay.
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3.2.4 IGFBP-1 ELISA
Media collected from experiment 1 at the termination of the time-points, (4, 8 and 12
days), was assayed for IGFBP-1 using a two-site sandwich ELISA (section 2.6.1) (R &
D Systems). Plates were coated with the IGFBP-1 capture antibody and incubated
according to the IL-15 ELISA method. The antibody was added at 2pg/ml and lOOpl
per well. The plates were washed prior to use and a standard curve added in single wells
to each plate consisting of eight standards starting with a top standard of 8ng/ml. 1:2
dilutions were performed until the bottom standard of 0.06ng/ml was obtained. Buffer
plus Tween (B+T) was used to dilute samples and NSB wells were added as lOOgl of
B+T. A quality control was made up at 700pg/ml from the IGFBP-1 standard and added
in quadruplicate wells to each plate. All media samples to be tested were added in
quadruplicate wells, lOOpl per well. Plates were sealed and incubated for 2 hours on a
plate shaker at room temperature. The plates were washed in wash buffer four times
each and tapped dry. The IGFBP-1 detection antibody was then added at 0.1 gg/ml and
lOOpl per well and incubated at room temperature for 2 hours on a plate shaker. Plates
were washed as before and tapped dry. Streptavidin peroxidase conjugate (Roche) was
diluted in B+T to 0.125U/ml and lOOpil pipetted into all wells. Plates were sealed and
incubated for 20 minutes on a plate shaker at room temperature. The plates were then
washed as before and lOOpl of substrate added per well. Plates were allowed to develop
for 15 minutes before stopping the reaction with 50pl of 2N sulphuric acid per well. All
plates were read on a plate reader at 450nM. The computer program Assay Zap was
used to analyse the results and construct a standard curve against which the samples
could be judged.
3.2.5 RNA Extraction and Q RT-PCR
The RNA was extracted and cDNA prepared from the ESC experiments 1 and 2.
Prolactin, IGFBP-1, IL-15 and progesterone receptor mRNA levels were measured by Q
RT-PCR as described in section 2.5.
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3.2.6 Statistical Analysis




3.3.1 Decidualisation of ESC Studies
3.3.1a Prolactin mRNA Expression and Release by ESCs
The mRNA expression of prolactin after 4 days is almost 4-fold greater than controls
with MPA or with 8-Bromo cAMP treatment. Treatment with a combination of MPA
and 8-Bromo cAMP stimulated a 22-fold increase in prolactin mRNA levels (P <
0.017). Prolactin protein released into the media after 4 days was below the minimum
detection limit (250pg/ml) of the ELISA. After 8 days of treatment the combined
treatment of PGE2 and MPA had caused a 40-fold rise in prolactin mRNA relative to
controls. A 163-fold increase in prolactin mRNA was produced by treatment with 8-
Bromo-cAMP and MPA in combination (P < 0.006). This was comparable with the
ELISA data that recorded 3-fold and 9-fold increases in prolactin release with PGE2 plus
MPA and 8-Bromo-cAMP plus MPA (P < 0.009) treatment respectively. The same
pattern of prolactin mRNA expression and protein release were observed after 12 days
of treatment. PGE2 plus MPA stimulated an 11-fold rise in mRNA and a 9-fold increase
in protein levels. 8-Bromo-cAMP plus MPA triggered a 29-fold increase in prolactin
mRNA levels (P < 0.03) and a 22-fold increase in protein release (P < 0.028). Modest




Relative levels of prolactin mRNA expression after 4 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, ap < 0.017.
Figure 3.4
Relative levels of prolactin mRNA expression after 8 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, bp < 0.006.
Figure 3.5
Relative levels of prolactin mRNA expression 12 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same




Prolactin protein release by human ESCs over 48 hours after 8 days of treatment with a
variety of treatments designed to stimulate decidualisation in ESCs in vitro. Same
letters denote significant difference, a p < 0.009. The lower detection limit of the
ELISA was 0.25ng/ml.
Figure 3.7
Prolactin protein release by human ESCs over 48 hours after 12 days of treatment with a
variety of treatments designed to stimulate decidualisation in ESCs in vitro. Same





























3.3.1b IGFBP-1 mRNA Expression and Release by ESCs
The mRNA expression for IGFBP-1 was increased considerably by treatment of ESCs
with PGE2 plus MPA (1766-fold increase) and 8-Bromo cAMP plus MPA (9075-fold
increase) (P < 0.019) after 4 days. Treatment with PGE2 alone resulted in a 32-fold rise
in IGFBP-1 mRNA expression relative to controls. 8-Bromo cAMP promoted a fold
increase of approximately 800. These results were consistent with the IGFBP-1 ELISA
data, illustrating a 25-fold increase in protein release on day 4 with PGE2 plus MPA
treatment and an 85-fold increase following incubation with 8-Bromo-cAMP plus MPA
(P < 0.034). After 8 and 12 days of incubation with the treatments corresponding
patterns in mRNA expression and release were observed.
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Figure 3.8
Relative levels of IGFBP-1 mRNA expression after 4 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, a p < 0.019
Figure 3.9
Relative levels of IGFBP-1 mRNA expression after 8 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, bp < 0.015,
Figure 3.10
Relative levels of IGFBP-1 mRNA expression after 12 days of treatment with a variety
of treatments designed to stimulate decidualisation in ESCs in vitro. The numbers
located above the error bars indicate the fold increase in expression relative to controls.




IGFBP-1 protein release (pg/ml) by human ESCs over 48 hours after 4 days of treatment
with a variety of treatments designed to stimulate decidualisation in ESCs in vitro.
Same letters denote significant difference, a p < 0.034. The lower detection limit of the
ELISA was 60pg/ml.
Figure 3.12
IGFBP-1 protein release (pg/ml) by human ESCs over 48 hours after 8 days of treatment
with a variety of treatments designed to stimulate decidualisation in ESCs in vitro.
Same letters denote significant difference, b p < 0.011. The lower detection limit of the
ELISA was 60pg/ml.
Figure 3.13
IGFBP-1 protein release (pg/ml) by human ESCs over 48 hours after 12 days of
treatment with a variety of treatments designed to stimulate decidualisation in ESCs in
vitro. Same letters denote significant difference, c p < 0.034. The lower detection limit
of the ELISA was 60pg/ml.
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3.3.2 Decidualisation State of ESCs Following Treatment Removal
After 5 days of treatment the mRNA expression of prolactin was 77-fold and 261-fold
greater compared with controls proceeding treatment with PGE2 plus MPA and 8-Bromo
cAMP plus MPA (P < 0.017) respectively. Treatment of ESCs for 5 days and then a
further 5 days of culture with removal of treatments gave rise to a 44-fold increase in
those initially incubated with PGE2 plus MPA and a 139-fold increase following 8-
Bromo cAMP plus MPA (p < 0.04) pre-treatment. After 10 days of continuous
incubation with the treatments, PGE2 plus MPA and 8-Bromo cAMP plus MPA




Relative levels of prolactin (prl) mRNA expressed in ESCs treated for 5 days with
decidualising stimuli. The numbers located above the error bars indicate the fold
increase in expression relative to controls. Same letters denote significant difference, a
p< 0.017.
Figure 3.15
Relative levels of prolactin (prl) mRNA expressed in ESCs treated for 5 days with
decidualising stimuli followed by 5 days of treatment withdrawal. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, b p < 0.04.
Figure 3.16
Relative levels of prolactin (prl) mRNA expressed in ESCs treated for 10 days with
decidualising stimuli. The numbers located above the error bars indicate the fold




3.3.3 IL-15 mRNA Expression in ESCs Treated with Decidualising Stimuli in vitro
After 4 days of treatment with PGE2 plus MPA an 11-fold increase in IL-15 mRNA
expression was observed relative to controls and a 22-fold rise in ESCs treated with 8-
Bromo cAMP plus MPA {p < 0.023). After 8 days of treatment with PGE2 plus MPA
and 8-Bromo cAMP plus MPA (p < 0.028) 26- and 60-fold increases in IL-15 mRNA
expression were recorded. Following a further 4 days of treatment on day 12, PGE2 plus
MPA and 8-Bromo cAMP plus MPA (p < 0.028) had stimulated 20- and 168-fold
increases in IL-15 mRNA levels compared with controls. MPA added alone produced a
2-fold increase in expression and 8-Bromo cAMP on its own stimulated 4-, 18- and 25-
fold rises in IL-15 mRNA levels on days 4, 8 and 12 respectively.
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Figure 3.17
Relative levels of IL-15 mKNA expression after 4 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, a p < 0.023
Figure 3.18
Relative levels of IL-15 mRNA expression after 8 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, bp < 0.028
Figure 3.19
Relative levels of IL-15 mRNA expression after 12 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, cp< 0.028.
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Figure 3.20 Correlation between prolactin and IL-15 mRNA levels on day 4
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 4 and found to be 0.92. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
Figure 3.21 Correlation between prolactin and IL-15 mRNA levels on day 8
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 8 and found to be 0.97. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
Figure 3.22 Correlation between prolactin and IL-15 mRNA levels on day 12
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 12 and found to be 0.97. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
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3.3.5 Progesterone Receptor (nuclear) mRNA Expression in ESCs Treated with
Decidualising Stimuli in vitro
No significant changes in the genomic progesterone receptor (PR) mRNA levels were
observed after ESCs were treated for 4, 8 or 12 days (figure 3.23, 3.24 and 3.25). All
treatment groups expressed PR mRNA levels similar to controls values.
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Figure 3.23
Relative levels of genomic progesterone receptor (PR) mRNA expression after 4 days of
treatment with a variety of treatments designed to stimulate decidualisation in ESCs in
vitro.
Figure 3.24
Relative levels of genomic progesterone receptor (PR) mRNA expression after 8 days of
treatment with a variety of treatments designed to stimulate decidualisation in ESCs in
vitro.
Figure 3.25
Relative levels of genomic progesterone receptor (PR) mRNA expression after 12 days































































Table 3.4. Summary of Results for Experiment 1 (Day 4)
Numbers represent fold increases in levels relative to controls with significance values
given in the brackets were applicable.
Treatment Prl Prl igfbp-1 igfbp-1 il-15 PR
mRNA protein mRNA protein mRNA mRNA
Control 1 N/A 1 1 1 1
MPA 4 N/A 4 0.8 2 1.5
pge2 2 N/A 31 7 1 1.1
pge2 +
MPA
4 N/A 1766 25 11 0.9
8-Bromo
cAMP















Table 3.5. Summary of results for experiment 1 (Day 8)
Treatment Prl Prl IGFBP-1 IGFBP-1 IL-15 PR
mRNA protein mRNA protein mRNA mRNA
Control 1 1 1 1 1 1
MPA 2 1 10 1 2 0.8
pge2 4 1.3 14 7 6 1.3
pge2 +
MPA
40 3.1 2153 299 26 0.9
8-Bromo
cAMP















3.6. Summary of results for experiment 1 (Day 12)
Treatment Prl Prl IGFBP-1 IGFBP-1 IL-15 PR
mRNA protein mRNA protein mRNA mRNA
Control 1 1 1 1 1 1
MPA 1 1 1 0.1 2 0.7
pge2 1 1.3 15 9 3 1.0
pge2 +
MPA
11 9.1 2438 39 20 1.1
8-Bromo
cAMP

















Using an in vitro system to study decidualisation in ESCs the results in this chapter have
demonstrated the synergistic actions between a synthetic progestin, MPA, and either
PGE2 or 8-Bromo cAMP in inducing prolactin and IGFBP-1 expression and release.
These synergistic actions were required for inducing a rise in IL-15 mRNA expression.
There was a correlation between the decidualisation status in these cells and IL-15 levels
suggesting that IL-15 mRNA levels rise upon decidualisation in vitro. Genomic
progesterone receptor levels remained consistent between treatment groups and controls.
In ESC cultures that were pre-treated for 5 days followed by withdrawal of treatment for
5 days the levels of prolactin remained high in the ESCs treated with MPA and either
PGE2 or 8-Bromo cAMP. These data indicate that over this time period the decidual
state of cells remains in place and that suggests a permanent transformation of these
cells that cannot be reversed.
In humans, decidualisation occurs in the endometrial stroma during the mid- to late-
secretory phases and involves both morphological and biochemical changes in this cell
type. This transformation is thought to be essential to embryo implantation and to
pregnancy maintenance. Two of the major products of the decidualised stromal cell are
IGFBP-1 and prolactin and are believed to have important roles in pregnancy although
their specific functions are still not clear. Women with reduced serum IGFBP-1 levels
have been shown to have a predisposition to developing pre-eclampsia (Grobman et al.,
2001) suggesting a possible role of IGFBP-1 in placentation. Although knock-out mice
for the prolactin receptor (Prl-R -/-) show evidence of failed implantation, it was
established that the corpus luteum was unable to produce progesterone and
administration of a progestin counteracted these defects in the early stages of pregnancy
(Binart et al., 2000). However, late pregnancy loss could not be rescued, thereby
implicating a discrete function of prolactin in the maintenance of pregnancy in late
gestation.
135
Prolactin and IGFBP-1 are well documented as markers of stromal decidualisation since
decidual cells express raised levels versus non-decidualised ESCs (Maslar et al., 1979)
(Bryant-Greenwood et al., 1993). The results in this present chapter illustrate further the
synergistic ability of cAMP plus a progestin to induce decidualisation in vitro. PGE2
acts via EP2 and EP4 receptors to raise intracellular cAMP and alongside the rising
progesterone levels across the secretory phase, this provides one mechanism by which
decidualisation can be triggered (figure 3.26). How these separate pathways
communicate is unclear. However, experiments using the breast cancer cell line, T47D,
have demonstrated a form of cross-talk between cAMP and the progesterone receptor
(Edwards et al., 1993). If a similar process occurs in decidualising ESCs this would
provide such a link. The results in this chapter showed that no change in the nuclear
progesterone receptor mRNA level occurred in concert with decidualisation but this does
not exclude the possibility that cAMP is interacting with the progesterone receptor via
more discrete mechanisms. In in vitro experiments treatment of human ESCs with
progesterone plus oestradiol resulted in induction of the EP2 receptor mRNA compared
to untreated controls (Brar et al., 1997). It is therefore possible that via the upregulation
of this PGE2 receptor that some of the effects of progesterone may be driven.
The cAMP analogue used in the experiments detailed in this chapter is 8-Bromo cAMP
which is absorbed by cells but also resists the destructive actions of phosphodiesterases
thus acting as a cAMP mimic. This may explain the potency of this treatment versus
PGE2. Relaxin is a physiological product that acts to raise cAMP levels and has been
proposed to be an inhibitor of phosphodiesterases (Bartsch et al., 2001) thus preventing
breakdown of intracellular cAMP. It is produced by the corpus luteum (Weiss et al.,
1978) and in both secretory endometrium and decidua (Bryant-Greenwood et al., 1993).
The possible mechanisms by which progesterone, PGE2 and relaxin may be converging
to induce decidual transformation are illustrated in figure 3.26. In the Hoxa-10 knock¬
out mouse, defective decidualisation is observed and aberrant expression of the PGE2
receptors, EP3 and EP4, is apparent (Lim et al., 1999) implicating PGE2 further in
decidual transformation. The timing of appearance of prolactin and IGFBP-1 in the
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human uterine stroma as shown by immunohistochemistry is both cyclical and divergent
(Bryant-Greenwood et al., 1993) (figure 3.3) and it therefore likely that in vivo other













A model for the potential mechanisms by which intracellular cAMP, via the PKA
signalling pathway, may be playing a central role in ESC decidualisation. This
illustrates a possible convergence of the separate pathways of progesterone (Prog),
PGE2 and relaxin during transformation of the stroma.
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Several studies have utilised gene array technology to analyse changes in gene
expression within the human endometrium and many of these are relevant to the time of
decidualisation. These studies provide information on a wide range of genes that are
being either up- or down-regulated at specific times in the menstrual cycle. Genes
thought to be important in the decidualisation reaction are summarised in table 3.7. The
regulation of these genes during the luteal phase and early pregnancy has been explored
by the different research groups. For example, the up-regulation of IGFBP-1, known to
be a product of decidualising stromal cells, between day LH + 2 and LH + 7 has been
confirmed by use of this technology (Riesewijk et al., 2003). Phospholipase A2 (PLA2)
is a rate-limiting step in the PG pathway. The levels of PLA2 are increased during the
implantation window compared with late proliferative endometrium (Kao et al., 2002)
and are also raised in first trimester decidua (Chen et al., 2002). In addition, one of the
PG synthases, PGD2 synthase, is more abundant in the secretory phase than the
proliferative based on a ranking system of the 200 most abundant transcripts in each of
the phases (Borthwick et al., 2003). This evidence implies an activation of the PG
pathway at a time where decidualisation will be occurring in the stromal compartment.
VEGF is an endothelial mitogen and produced in the human endometrium. In mid-
secretory phase human endometrium VEGF immuno-staining is observed in the stromal
cells and isolated ESCs expressed significantly raised levels of VEGF mRNA in concert
with decidualisation in these cells (Sugino et al., 2002). This is in agreement with a
study that has shown cAMP-induced decidualisation in vitro induces VEGF mRNA
expression (Popovici et al., 1999). These gene array-based studies on whole
endometrium do not, however, provide information on the specific cellular location of
these regulated genes but are an important starting point and an effective approach to
determine novel factors involved in key reproductive processes.
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Table 3.7





(i) Increased expression in ESCs decidualised in vitro
(ii) 2.8-fold up-regulation during the implantation window
compared to late proliferative endometrium
(iii) Higher gene expression in decidua versus chorionic villi
(i) (Popovici et
al., 2000)
(ii) (Kao et al.,
2002)
(iii) (Chen et al.,
2002)




Rank as the most abundant transcript present is lower in the




(i) Laminin S (33 chain and laminin (31 chain increase in
expression during the implantation window compared to late
proliferative endometrium
(ii) Laminin (33 increases 15-fold between day LH +2 and LH +7





(i) 3.6-fold up-regulation of the prostaglandin receptor EP2
during the implantation window compared to late proliferative
endometrium
(ii) 18-fold up-regulation of PLA2 during the implantation
window compared to late proliferative endometrium
(iii) High level of PLA2 gene expression detected in first
trimester decidua
(i) (Kao et al.,
2002)
(ii) (Kao et al.,
2002)
(iii) (Chen et al.,
2002)
IL-15
(i) 2.2-fold increase in IL-15 gene expression between the early
and mid luteal phases
(ii) Increase in IL-15 expression in ESCs decidualised in vitro
(iii) IL-15, IL-15 precursor and IL-15 receptor a chain precursor
genes are up-regulated during the implantation window





(iii) (Kao et al.,
2002)
VEGF
(i) Increase in VEGF expression in ESCs decidualised in vitro
(ii) 3.4-fold decrease in VEGF gene expression during the
implantation window compared to late proliferative endometrium
(i) (Popovici et
al., 2000)
(ii) (Kao et al.,
2002)
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The results detailed in this chapter demonstrate the up-regulation of IL-15 mRNA
expression in concert with increasing prolactin and IGFBP-1 mRNA and protein levels.
The required presence of progesterone and cAMP together have the ability to induce
both decidualisation and IL-15 mRNA expression effectively. This supports the concept
of a link between decidualising ESCs and IL-15 production. It has previously been
suggested that IL-15 may be linked with progesterone-induced decidualisation in human
ESCs in vitro (Okada el al., 2000a). In agreement with these findings analysis using
Microarray Technology (refer to table 3.7) has revealed a rise in the IL-15 mRNA in
human ESCs treated with decidualising stimuli in vitro (Popovici et al., 2000). Raised
levels of the IL-15 gene have been documented in the mid-luteal phase (Carson et al.,
2002) and in addition the IL-15 precursor and IL-15 receptor a chain precursor genes
are up-regulated during the implantation window (Kao et al., 2002). These data provide
evidence for both amplification of IL-15 production and also in the actions of this
cytokine via an increase in the IL-15 receptor a chain subunit. It is possible that this rise
in IL-15 receptor a chain precursor gene is due to the expansion of uterine natural killer
cells during this cycle stage and it is thought that these cells may have a role in
implantation (King et al., 1990).
The role of PGE2 in decidualisation has been explored in this chapter. It appears that the
presence of progesterone is essential for decidualisation to take place via PGE2. Alone,
neither PGE2 nor MPA had appreciable effects on decidualisation in vitro as determined
by prolactin and IGFBP-1 levels. When they were added together they appeared to act
in synergy proving to be an effective combination for a decidualisation stimulus. This
confirms the findings of a previous study by Frank et al 1994 (Frank et al., 1994). Rats
treated with indomethacin, an inhibitor of COX, exhibit a reduction in the proportion of
pregnant rats and a significant reduction in uterine decidualisation (Sookvanichsilp et
al., 2002). COX exists in two isoforms, COX-1 and-2, and can be a rate-limiting step in
progression of the PG pathway in addition to phospholipase activity. These experiments
have demonstrated further the role of the PGE2 pathway in the process of
decidualisation.
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In summary, PGE2 and the synthetic progestin, MPA, are weak inducers of prolactin and
IGFBP-1 expression. However, when added in combination they appear to have
synergistic actions. The effects of PGE2 are likely to be via its ability to raise
intracellular cAMP levels since addition of a synthetic cAMP analogue that is resistant
to phosphodiesterases in combination with MPA dramatically raises levels of the
decidualisation markers. Decidualisation of human ESCs in vitro is likely to be an
irreversible reaction and therefore one of the reasons that makes menstruation necessary
in humans. The process of ESC decidualisation appears to be linked with IL-15 mRNA
expression. Those treatments with the ability to induce the greatest rises in prolactin and
IGFBP-1 levels also raise IL-15 expression in concert. This relationship between
decidualisation of ESCs and IL-15 provides further evidence of a link between the
stromal cells and uNK cells.
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4. The Prostaglandin Pathway and Decidualisation
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4.1 Introduction
Prostaglandin ligand-receptor interactions are key to many reproductive functions such
as ovulation, implantation, decidualisation and parturition (Lim et al., 1997).
Prostaglandin (PG) production is dependent on a complex intracellular signalling
pathway with two major rate-limiting stages: the availability of free substrate,
arachidonic acid (AA), via the activity of Phospholipase A2 and secondly COX activity,
the enzyme responsible for catalysing the conversion of AA into the intermediate, PGH2.
COX exists in two isoforms, COX-1, which is expressed constitutively, and the
inducible form, COX-2. However, in certain circumstances COX-1 can be induced
(Jackson et al., 1993) (Brannon et al., 1994) and COX-2 can be expressed constitutively
in the absence of pathology (Walenga et al., 1996). These isoforms are encoded by two
separate genes and also differ in their sub-cellular locality and regulation. PGH2 is
converted into the various prostanoids and thromboxanes via specific PG synthases
(Smith et al., 1996) (Smith et al., 1996), which can then act on specific receptors to
mediate their actions. The prostanoid PGE2 acts on the EP-receptors: EPi, EP2, EP3 and
EP4 (Narumiya et al., 1999) (Coleman et al., 1994). The EP2 and EP4 receptor subtypes
exert their effects through raising cAMP (Figure 4.1) (refer to chapter 1.4.1 for further
details). The EP3 receptor also acts via the cAMP pathway and can either result in a rise
or reduction in cAMP levels. However, the overall effect is a reduction in cAMP levels
(Adam et al., 1994; Sugimoto et al., 2000). The EPi receptor acts via the IC Ca2+
signalling pathway upon stimulation (Kennedy et al., 1982; Watabe et al., 1993).
Within the human endometrium PGE2 has been localised to the epithelial, endothelial
and stromal compartments in the functional layer (Milne et al., 2001). The role of PGE2
in female reproductive processes has been analysed via knockout mice for COX-1 and
COX-2. These studies have demonstrated the involvement of COX-2 but not COX-1 in
implantation and decidualisation (Reese et al., 2001) (Chakraborty et al., 1996)
(Langenbach et al., 1995) (Figure 4.2). However, it has been demonstrated that COX-2
may be compensating for COX-1 deficiency during implantation in COX-1 knockouts
145
(Reese et al., 1999). It has not been possible to study double knockout mice for COX-1
and COX-2 since they fail to live long postnatally (Loftin et al., 2001).
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Figure 4.1
Illustration of PGE2 acting via the EP2 and EP4 receptors to raise intracellular cAMP
levels. The EP3 receptor exists as multiple splice variants, and acts via Gj proteins to








• Defective ovulation and
fertilisation




The effect of the PG pathway progression on reproductive outcomes in wild type mice
versus COX-2 (-/-) mice illustrating the importance of PGs in female fertility.
Phospholipase A2 (PLA2) is the enzyme responsible for liberating membrane-bound
arachidonic acid (AA). AA is then converted into the intermediate, PGH, via COX-2
enzyme under normal circumstances. Thus, in COX-2 (-/-) mice the PG pathway is
ablated, preventing the formation of any prostanoids.
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A link between the actions of progesterone and PGs in the uterus has been demonstrated
via studies on the effects of the anti-progestin, RU486, in the human endometrium
(Marions et al., 1999). Levels of COX-1 declined whereas COX-2 immunostaining
persisted further illustrating the differences in regulation between these two enzymes.
Endometrial PGs were measured at different times of the menstrual cycle and it was
observed that the PGF2a: PGE2 ratio increase from the proliferative phase, peaking in the
mid-secretory phase and falling again at menstruation (Downie, 1974). PGF2a and PGE2
concentrations were measured in human endometrial biopsies by gas chromatography-
mass spectrometry (Maathuis et al., 1978). The PGF concentration was found to be
greatest in the mid-secretory phase and no variation in PGE2 levels was observed. An
increase in PGF production is also apparent in cultured human ESCs and glandular
epithelial cells following RU486 treatment (Kelly et al., 1986).
The involvement of PGE2 in the decidual transformation of the endometrial stroma has
been previously suggested following in vitro culture experiments using human and rat
ESCs (Frank et al., 1994; Kennedy et al., 1982; Peleg, 1983). They demonstrated that
the combination of PGE2 and progesterone is able to induce decidualisation in these cell
cultures. The exact intracellular mechanisms by which this is occurring have not yet
been analysed. COX-2 (-/-) mice have been shown to exhibit defective decidualisation
(Lim et al., 1997) supporting evidence for the involvement of PGE2 in stromal
differentiation. In studies on cultured human ESCs treated with hCG to induce
differentiation, an increase in COX-2 gene expression was observed via raised transcript
stability (Han et al., 1996) providing further evidence for a role of PGs in
decidualisation.
This chapter examines changes occurring in components of the PG pathway in
decidualised versus non-decidualised human ESCs in vitro. In addition, the effect of
decidualising pre-treatments on the release of PGE2 and PGF2Q protein from human
ESCs in vitro has been explored.
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4.2 Methods
4.2.1 Human Uterine Tissue Collection
Endometrial (n = 14) biopsies (7 proliferative, 6 early secretory and 1 mid secretory)
were collected and processed as described in section 2.1. All samples were processed to
separate the ESCs from the glands, as described in section 2.2. The cells were grown for
a period of two weeks prior to commencing experiments in the presence of MPA and
bFGF.
4.2.2 Human Primary Cell Culture
4.2.2a in vitro Decidualisation of Primary ESCs
ESCs were seeded in 12-well plates at a concentration of 1.4x105 cells/ml and allowed to
adhere overnight. The following treatment regimes were followed as detailed in tables
4.1 and 4.2. The experiments were designed to stimulate in vitro decidualisation of
ESCs (refer to chapter 3) and allow the analysis of alterations in the PG signalling
pathway via Q RT-PCR.
Table 4.1
Experiment 1: Decidualisation of ESCs (n = 4)
Treatment Concentration Incubation time
Control N/A





PGE2 + MPA 10-6M+ IO~6M
8-Bromo cAMP 250pM
8-Bromo cAMP + MPA 250pM + 10~6M
150
Table 4.2
Experiment 2: Decidualisation of ESCs and treatment removal (n = 5)
Treatment Concentration Incubation time
Control N/A 5 days, 5 days followed by
5 days with treatment
withdrawal, 10 days
continuous treatment
PGE2 + MPA 1(T6M+ 1(T6M
8-Bromo cAMP + MPA 250pM + 10~6M
Decidualisation in these treated cell cultures was confirmed by prolactin and IGFBP-1
ELISA and Q RT-PCR (refer to section 3.3).
4.2.2b Effect of Pre-treating ESCs with Decidualising Stimuli on PGE2 and PGF2a
Release
ESCs were seeded in 12-well plates at a concentration of 1.4x105 cells/ml and allowed to
adhere overnight. The following treatment regime adhered to is detailed in table 4.3.
The experimental design was to establish the effects of decidualising stimuli on the
secretion of PGE2 and PGF2a by human ESCs in vitro.
Table 4.3
Experiment 3: Decidualisation Pre-treatment of ESCs (n = 5)
Pre-treatment Concentration Incubation time
Control N/A
4 days pre-treatment




PGE2 + MPA 10"6M+ 10"6M
8-Bromo cAMP 250pM
8-Bromo cAMP + MPA 250pM + 10_6M
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4.2.3 RNA Extraction and Q RT-PCR
RNA was extracted from the ESC cultures at the termination of the experiments 1 and 2
and cDNA prepared as detailed in sections 2.4 and 2.5. Messenger RNA expression of
the following components of the PG cascade was measured by Q RT-PCR: COX-1,
COX-2, Phosphodiesterase3a (PDE3a), Phosphodiesterase4b (PDE4b), Prostaglandin
transporter protein (PGTP) and EP2 and EP4 receptors.
4.2.4 PGE2 and PGF2a ELISAs
Media was collected at the termination of experiment 3 and processed for ELISAs.
Refer to Methods chapter, sections 2.6.2 for a description of a Competition ELISA.
4.2.4a PGF2a ELISA
The general method description for an ELISA is detailed in section 2.6. For
measurement of PGF2a by ELISA a buffer with no Tween added is used. The standard
curve range is 5120pg/ml to lOpg/ml with 1:2 dilutions to give 10 standards in total.
The Quality control is set at 200pg/ml in a minimum of 4 wells per plate. All wells
received 50pl AS, 50pl Link and lOOpl of either a standard or a sample. The link
increases the sensitivity of the assay via proline coupling to a PG, making it more
antigenic. This enables the free PG in the sample to displace the biotin-labelled link for
AS binding sites (Kelly et al., 1989). The well to show non-specific binding (NSB)
receives 50pl Link and 150pl of buffer and the Bo well receives 50pl AS, 50pl Link and
lOOpl of buffer. The plate was incubated at 4°C overnight. The following day plates are
washed four times, once for 30 seconds on a plate shaker. The streptavidin was diluted
in buffer (no Tween) to a concentration of 0.125U/ml and 100pi pipetted into all wells.
Plates were placed on a plate shaker at room temperature for 20 minutes before being
washed as before. The substrate (as in the Two-site sandwich ELISA) was added to the
wells, 200pl per well. Plates were left for 20m before being quenched with 2N
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Sulphuric Acid and read on a plate reader. A method file was designed in Assay Zap
(section 2.6) and used to analyse results. Intra-assay variation was calculated from 10
replicates across the same plate and inter-assay variation was calculated from across a
minimum of 6 different assay plates and these were calculated to be 7.8% and 15.0%
respectively.
4.2.4b PGE2ELISA
For details of the procedure see Competition ELISA and PGF2a ELISA protocol details
above. Exceptions are that all samples were MOXed upon collection 1:1 with Methyl
oximating (MoxB) solution in order to stabilise to PGE2 and prevent conversion to the
PGA form. Standards for the plate were made up in a 25% MOX buffer (MoxB diluted
in B+T). The top standard is 1048pg/ml and the bottom standard is 2.8pg/ml (10
standards in total). A Link and Anti-sera specific for PGE2 were used. Intra-assay
variation was calculated to be 5.2% and inter-assay variation was 18.3%.
4.2.5 Statistical Analysis




4.3.1a COX-1 mRNA Expression in Decidualising ESCs
Treatment of ESC cultures with PGE2 plus MPA stimulated an increase in COX-1
mRNA levels of between 2- and 3-fold relative to controls (figure 4.3). The expression
of COX-1 mRNA was increased between 3- and 4-fold following 8-Bromo cAMP
treatment on days 4, 8 and 12. The combination of 8-Bromo cAMP plus MPA triggered
the greatest rises in COX-1 expression, with 8-, 10- and 16-fold increases observed on
days 4, 8 and 12 respectively (p < 0.010; p < 0.0012; p < 0.0032).
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Figure 4.3
The effects of decidualising stimuli on the expression of COX-1 mRNA in human ESCs
after 4, 8 and 12 days of treatment. Same letters denote significant difference a p <











4.3.1b COX-2 mRNA Expression in Decidualising ESCs
The expression of COX-2 mRNA increased 2.5-fold with MPA treatment compared
with controls (figure 4.4). PGE2 stimulated a 2-fold increase in COX-2 levels on days 4
and 8 and this increased to a 4-fold increase on day 12. The combination of PGE2 plus
MPA resulted in 4- (NS p < 0.07), 7- (p < 0.0022) and 9-fold (p < 0.021) rises in COX-2
mRNA on days 4, 8 and 12 respectively. Alone, 8-Bromo cAMP stimulated a 4-fold
rise in levels but when added in combination with MPA, stimulated a 9-fold elevation
across all time-points (p < 0.0001; p < 0.0001; p < 0.017).
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Figure 4.4
The effects of decidualising stimuli on the expression of COX-2 mRNA in human ESCs
after 4, 8 and 12 days of treatment. Same letters denote significant difference, a p <
0.0022; bp < 0.021; cp < 0.0001; dp< 0.0001 and ep < 0.017.
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Figure 4.4
Control MPA PGE2 PGE2+MPA cAMP cAMP+MPA
Treatment
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4.3.1c COX-1 mRNA Expression in Decidualised ESCs and Pre-decidualised ESCs
after Decidualising Treatment Removal
Figure 4.5 shows the expression of COX-1 mRNA in decidualising ESCs after 5 and 10
days of treatment and also after 5 days of continuous treatment followed by 5 days of no
treatment. A 7-fold increase relative to controls in COX-1 mRNA was stimulated by
both cAMP plus MPA and by PGE2 plus MPA treatments after 5 days of continuous
treatment. However, this result failed to reach significance due to one ESC culture
sample expressing a much higher level of COX-1 than the other 4. If this result is
omitted the results are significant: 8-Bromo cAMP plus MPA p < 0.001 and PGE2 plus
MPA p < 0.05. The same trends were maintained after 10 days of continuous treatment
although were not statistically significant. However, when the decidualising stimuli
were removed for 5 days following 5 days of pre-treatment levels of COX-1 mRNA
declined to those similar to controls.
The statistics used to assign significance was the parametric ANOVA. This test assumes
a normal distribution, as was expected from our samples, and is more powerful than
non-paramentric tests. However, because one of the samples was expressing much
greater levels of COX-1 mRNA compared with its own control than the other samples
were, this made the results insignificant even though the same trend was occurring in all
samples. A Kruskal-Wallis Test (non-parametric ANOVA) was then performed on this
data and Dunn's Multiple Comparisons test used to assign significance. The medians in
each group were compared with each other. This test showed there to be a significant
difference between the control group and the group treated with cAMP plus MPA on
treatment days 5 and 10 (p < 0.01 and 0.05 respectively). With the remaining data that
has been assessed throughout this study no other out-lying results have been present to
affect the possibility of significance. Therefore, because the remaing data appears to
represent a normal distribution the parametric ANOVA test was utilised.
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Figure 4.5
The effects on COX-1 mRNA expression of ESCs treated with decidualising stimuli for
either 5 or 10 days continuously or for 5 days followed by removal of treatment for a
further 5 day period.
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4.3.Id COX-2 mRNA Expression in Decidualised ESCs and Pre-decidualised ESCs
after Decidualising Treatment Removal
Following 5 and 10 days of continuous treatment with PGE2 plus MPA, 2- (p < 0.055
NS) and 4-fold increases in COX-2 mRNA levels relative to controls were observed
respectively (figure 4.6). Treatment of ESCs with 8-Bromo cAMP plus MPA stimulated
a 4-fold rise in COX-2 mRNA expression after 5 days (p < 0.0002) and after 10 days of
continuous treatment this had dropped to a 3-fold increase relative to controls. In those
ESCs subjected to 5 days of decidualising treatment with a subsequent 5 days in the
absence of treatments, COX-2 mRNA levels had returned to control levels.
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Figure 4.6
The effects on COX-2 mRNA expression of ESCs treated with decidualising stimuli for
either 5 or 10 days continuously or for 5 days followed by removal of treatment for a




4.3.1e EP2 Receptor mRNA Expression in Decidualising ESCs
The expression of EP2 receptor mRNA rose 6-fold compared with equivalent controls
after 4 days of MPA treatment (figure 4.7). PGE2 treatment stimulated 2- and 3-fold
increases in expression levels after 4 and 8 days respectively. Treating cells with the
combination of MPA and PGE2 did not stimulate any further increase in EP2 receptor
expression. ESCs treated with cAMP alone exhibited a 4-fold elevation in relative
expression after 4, 8 and 12 days of treatment. Where cAMP was added alongside MPA
the expression levels were elevated by 10-, 8- and 10-fold after 4 (p < 0.003), 8 (p <
0.013) and 12 days (p < 0.013) of treatment respectively.
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Figure 4.7
The effects of decidualising stimuli on the expression of the EP2 receptor in human
ESCs after 4, 8 and 12 days of treatment. Same letters denote significant difference, a p




Control MPA PGE2 PGE2+MPA cAMP cAMP+MPA
Treatment
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4.3.1f EP4 Receptor mRNA Expression in Decidualising ESCs
The expression of the EP4 receptor mRNA was relatively similar to controls across the
treatment regime added to ESC cultures and time points with the exception of treatment
of cells for 4 days with 8 Bromo-cAMP plus MPA (p < 0.05) (figure 4.8). This
significant rise in EP4 receptor appears to be temporal with a reduction on day 8 and




The effects of decidualising stimuli on the expression of the EP4 receptor in human ESCs




Control MPA PGE2 PGE2+MPA cAMP cAMP+MPA
T reatment
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4.3. lg Prostaglandin Transporter Protein (PGTP) mRNA Expression in
Decidualising ESCs
Figure 4.9 illustrates the relative mRNA expression of the PGTP mRNA in treated
ESCs. Levels of expression were similar to controls across all treatment groups at all
time points with the exception of day 12. A 2-fold increase in PGTP mRNA relative to
controls was observed after PGE2 plus MPA or 8 Bromo-cAMP plus MPA treatment but
this was not a significant rise.
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Figure 4.9
The effects of decidualising stimuli on the mRNA expression of the PGTP in human
ESCs after 4, 8 and 12 days of treatment.
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Figure 4.9
Control MPA PGE2 PGE2+MPA
Treatment
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4.3.1h Phosphodiesterase 3a (PDE3a) mRNA Expression in Decidualising ESCs
Figure 4.10 represents the expression of PDE3a mRNA levels relative to controls
following 4, 8 or 12 days of treatment. ESCs treated with PGE2 or MPA exhibited a 2-
fold increase in mRNA expression at all time points. Addition of PGE2 plus MPA had
maximal effects by day 4 of treatment with a 4-fold rise in expression levels (p < 0.038).
On days 4 and 8 those ESCs treated with 8-Bromo cAMP displayed a 4-fold increase in
expression (p < 0.045 and p < 0.021 respectively) with a small decline to a 3-fold rise
after 12 days of continuous treatment. ESCs treated with 8-Bromo cAMP plus MPA for
4 days expressed a 5-fold increase in PDE3a mRNA (p < 0.003) and cultures treated for




The effects of decidualising stimuli on the mRNA expression of the PDE3a in human
ESCs after 4, 8 and 12 days of treatment. Same letters denote significant difference, a p

























4.3-li Phosphodiesterase 4b (PDE4b) mRNA Expression in Decidualising ESCs
ESCs treated with PGE2 or MPA expressed similar levels of PDE4b mRNA levels to
controls although a modest 2-fold increase after 12 days was observed in the PGE2 or
PGE2 plus MPA treated cultures (Figure 4.11). Treatment of ESCs with 8-Bromo cAMP
alone stimulated an approximate 3-fold elevation at all time points and this was
significant on day 4 (p < 0.0003). These results were comparable to the 8-Bromo cAMP
plus MPA treatment values which were significantly different to controls on day 4 (p <
0.003), day 8 (p< 0.044) and day 12 (p < 0.007).
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Figure 4.11
The effects of decidualising stimuli on the mRNA expression of the PDE4b in human
ESCs after 4, 8 and 12 days of treatment. Same letters denote significant difference, a p














Figure 4.12 Release of PGE2 by ESCs pre-treated with decidualising stimuli for 5
days
The decidualising pre-treatments had no effect on the secretion of endogenous PGE2 by
ESCs. However, PGE2 treatment alone stimulated a significant rise in PGE2 secretion {p
< 0.032). Same letters denote significant difference, a p < 0.032. The lower detection





Control MPA PGE2 MPA+PGE2 cAMP MPA+cAMP
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Figure 4.13 Release of PGF2a by ESCs pre-treated with decidualising stimuli for 5
days
ESCs treated with either PGE2 or 8-Bromo cAMP stimulated an increase in the level of
PGF2a protein secretion. Addition of MPA had no additional effect on PGF2a protein
secretion and when added alone levels of secretion were comparable to control values.
Same letters denote significant difference, ap < 0.0003; bp < 0.0003; cp < 0.027 and








Table 4.5 Summary of results for experiment 1 (day 4)
The values in the table represent fold increases in mRNA expression relative to controls
















Control 1 1 1 1 1 1 1
MPA 1.9 2.4 5.6 1.1 0.8 1.9 1.1
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Control 1 1 1 1 1 1 1
MPA 1.5 2.6 5.6 1.5 1.1 1.6 2
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Decidualisation of the human uterine stroma is likely to be a multi-factorial process.
PGE2 has been implicated as one of these factors contributing markedly to
decidualisation of human ESCs in vitro (Frank et al., 1994). PGs are able to raise
intracellular cAMP levels. This chapter has analysed some of the individual components
of the PG pathway in an attempt to assess the effects of decidualisation on it and
ultimately on PG production. The results for this chapter are summarised in figures 4.14
and 4.15.
An increase in both COX-1 and COX-2 mRNA expression was observed after 5 and 10
days with continuous decidualising treatment. This effect was diminished upon removal
of decidual stimuli illustrating the necessity of sustained stimuli for the rise in the COX
enzymes. COX-2 has been implicated in mice decidualisation via studies on COX-2
knockouts where they exhibited defective decidualisation (Lim et al., 1997; Reese et al.,
2001) and suggests at some level a link with decidualisation and COX-2. Historically,
COX-1 has been considered to be constitutively expressed although emerging evidence
shows that it is inducible. In experiments using an embryo lung fibroblast cell line,
COX-1 was demonstrated to be regulated by both IL-ip and TGF-fl (Jackson et al.,
1993). This potential for COX-1 expression to be regulated is in agreement with the
results in this chapter. The second rate-limiting step at this point in the pathway is the
action of PLA2, the enzyme responsible for liberating free AA. If AA levels are limited
then it is reasonable to expect that the actions of COX-1 and -2 have a threshold effect
and therefore the conversion of AA to PGH2 is limited. This is one of the self-regulatory
steps within the PG pathway. The next major stage in the PG pathway is the conversion
of PGH2 to the various prostanoids and thromboxanes via specific PG synthases. PGE
synthases (PGES) catalyse the conversion of PDH2 to PGE2 and three forms of this
enzyme have been identified: cytosolic PGES (Tanioka et al., 2000) and microsomal
PGES-1 and -2 (mPGES-1 and -2) (Jakobsson et al., 1999; Murakami et al., 2000;
Mancini et al., 2001; Tanikawa et al., 2002). A correlation between COX-2 and PGE
synthase expression in bovine endometrial cell cultures has been proposed (Parent et al.,
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2002) and experiments using a human colorectal adenocarcinoma cell lines showed that
abnormally high expression of mPGES-1 and COX-2 together are able to contribute to
tumourigenesis (Kamei et al., 2003). As discussed in Murakami et al 2003 (Murakami
et al., 2003), mPGES preferentially couples to COX-2 over COX-1 and cPGES is able to
couple COX-1. If this is the situation in the human endometrium it adds further
complexity to control of the PG pathway with a feedback scenario occurring between
these two stages.
The results in figure 4.7 show no changes in the PGTP, the protein responsible for
transporting PGE2 across the cell membrane into cells, occurred in ESCs upon
decidualising treatment administration. This suggests that there was no autocrine
feedback to stimulate the uptake of PGE2 upon decidualisation. The ATP-binding
cassette (ABC) transporter family of proteins is involved in active transport of molecules
across membranes. A sub-family of this transporter are the multi-drug resistant proteins
(MRP) and MRP-4 has been implicated in the transport of PGE2 and PGF2ct (Reid et al.,
2003). These transporters facilitate the movement of molecules out of cells and would
be of interest to study in the context of the control of PGE2 secretion from decidualising
ESCs (figure 4.14).
The production of PGE2 and PGF2a has been analysed in this chapter via levels of
secretion. The experiments revealed that in culture, ESCs are secreting both PGE2 and
PGF2ct although levels of PGE2 are about 4 times greater. Also, decidualising stimuli
had no appreciable effects on PGE2 secretion levels. However, PGE2 alone triggered a
significant rise in PGE2 secretion and MPA appeared to inhibit this response to some
extent but this was not significant. Both 8-Bromo cAMP and PGE2 did however give
rise to a moderate and significant rise in the secretion levels of PGF2a from the ESCs.
This suggests that the actions of PGE2 may be due to a rise in IC cAMP via stimulation
of either or both of the EP2 and EP4 receptors. It is possible that the PGF2a synthases are
being stimulated causing a rise in PGF2a production or that PGF2a is being selectively
secreted. Previously it has been demonstrated that cultured bovine luteal cells secrete
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raised levels of PGF2tt following PGE2 treatment (Del Vecchio et al., 1995) confirming
the ability of PGE2 to modify the PGF2« pathway. The functions of PGF2a in the human
endometrium are not understood. It is however known that human secretory
endometrium secretes greater amounts of PGF2tt than proliferative endometrium as
shown by explant culture experiments (Abel et al., 1980) and that PGF2a concentrations
are greatest in late secretory endometrium (Downie, 1974; Maathuis et al., 1978;
Ishihara et al., 1986). These findings are consistent with the proposed function for
PGF2a in the human endometrium as vasoconstrictor in uterine vessels in the pre¬
menstrual phase (Baird et al., 1996). In menorrhagic women, endometrial
concentrations of PGE2 and PGF2a during the luteal phase were found to be raised in
almost half of the women studied compared with healthy controls (Haynes et al., 1980)
and this is likely to be due to a raised availability of AA in the menorrhagic
endometrium (Kelly et al., 1984). It is however, the ratio of PGF2a to PGE2 that is
important in the luteal phase in the control of excessive blood loss in women since
menorrhagia is associated with a shift in endometrial conversion of PGH from PGF2a to
PGE2 (Smith et al., 1981).
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Figure 4.14
A summary of the alterations observed in the PG pathway by MPA, PGE2 and a cAMP
analogue (inducers of in vitro decidualisation) using the results of this chapter (section
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A divergent control over the EP receptors, EP2 and EP4, was revealed by the results
detailed in this chapter. Decidualising stimuli were able to significantly raise EP2
receptor mRNA expression levels on all days. This is in agreement with gene array data
showing the EP2 receptor is raised during the implantation window compared with the
proliferative phase in human endometrium (Kao et al, 2002). In contrast, the data in
this chapter showed EP4 receptor expression levels to be unaffected by the decidualising
treatments with the exception of on day 4 with administration of 8-Bromo cAMP plus
MPA. In order for PGE2 to exert its decidualising effects via the cAMP pathway these
receptors need to be present in the ESCs (see figure 4.15). EP2 receptor null mice have
compromised fertility, manifested as a reduced litter size (Kennedy et al., 1999; Tilley et
al., 1999). However, decidualisation was normal and the lowered litter size found to the
result of an impaired ovulatory process (Matsumoto et al., 2001). It is possible that the
EP4 receptor, under these circumstances, can compensate partially for the loss of EP2
receptor in a similar manner that COX-2 compensates for COX-1 deficiency in COX-1 -
/- mice (Reese et al., 1999). It is also important to consider the differences between the
decidualisation process in humans and mice. In humans the process begins in the non¬
pregnant endometrium in anticipation of pregnancy and is essential to implantation of
the embryo. However, in mice the process only occurs as a result of implantation.
A rise in IC cAMP levels and activation of the PKA pathway results in an increase in
PDE activity and cAMP degradation via a "short-loop" feedback system in rat heart and
fat cells (Gettys et al., 1987) and in rat hepatocytes (Corbin et al., 1985). The cGMP-
inhibited PDE, PDE3, has been implicated in this regulatory mechanism after studies on
human platelets (Grant et al., 1988; Macphee et al., 1988). PDE3a has been located in
rat genitourinary smooth muscle and epithelial cells by in situ hybridisation (Reinhardt
et al., 1995). The atomic structure of the cAMP-specific PDE4b has been established
(Xu et al., 2000) and has been located in human myometrium by mRNA studies (Leroy
et al., 1994; Leroy et al., 1999). In this chapter the relative mRNA expression levels of
PDE3a and PDE4b in response to decidualising stimuli were analysed. Modest
elevations in the expression of both PDE3a and PDE4b were observed in the
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decidualising ESCs (Figure 4.15). Experiments on human ESCs demonstrated a rise in
intracellular cAMP levels during PGE2 plus progesterone-induced decidualisation in
vitro and addition of a PKA inhibitor blocked this cAMP elevation (Brar et al., 1997).
The results in this current chapter illustrate how cAMP levels may be "fine-tuned" so
that levels do not become excessively raised (see figure 4.15). Decidualisation is being
stimulated and influenced by many factors and a further candidate is relaxin. In human
ESC cultures, relaxin has been shown to induce expression of the decidualisation
marker, prolactin (Huang et al., 1987; Zhu et al., 1990; Tabanelli et al., 1992; Tseng et
al., 1999). In addition, cultured human endometrial cells treated with relaxin showed
increased intracellular cAMP levels and this was enhanced by PGE2 and PGF2a (Fei et
al., 1990) and this elevation in response to relaxin is acute and permanent (Telgmann et
al., 1998). These effects of relaxin have been proposed to be via an inhibitory control
over PDE activity (Bartsch et al., 2001), although the specific PDE being regulated are
as yet unconfirmed. The in vivo expression of relaxin has been identified in the human
endometrial stroma by immunohistochemistry (Bryant-Greenwood et al., 1993) (refer to
figure 3.2 in chapter 3). Since relaxin acts to raise intracellular cAMP levels by
inhibition of PDE activity, this is an additional stimulus on cAMP levels and therefore it
will be essential that a regulatory feedback mechanism will be involved to control cAMP
levels (figure 4.15). The increase in PDE3a and PDE4b levels upon raised intracellular
cAMP levels, as demonstrated by the results in this chapter, could be providing some of
this regulation but other PDEs not explored in this chapter could also be involved.
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Figure 4.15
An illustration of the potential mechanisms by which PGE2 may be exerting paracrine
effects on ESCs and how intracellular cAMP levels may be regulated during
decidualisation. The modifications in this pathway that have been explored in this
chapter are highlighted by red arrows.
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The results detailed and discussed in this chapter give an insight into aspects of the PG
pathway that are modified during the decidualisation process of human ESCs in vitro.
This provides information on the intracellular changes that decidualising cells in vitro
undergo. The fine-tuning of some of the PG pathway stages has been addressed here but
gives rise to further questions and also highlights other important mediators to explore.
These include how the external PGTP is regulated and this knowledge would help in the
understanding of how PGE2 secretion is controlled and how it can be upregulated. In
addition, the effects of decidualisation on PGES expression and activity would be of
interest as a further controlling factor in PGE2 production.
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5. IL-15 Regulation in the Human Endometrium
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5.1 Introduction
Cellular interactions and cytokine production within the human endometrium are critical
to the key events of menstruation, implantation and placentation. Cytokines allow
communication between different cell types at the various cycle stages. The major
leukocyte population in the late secretory phase and throughout the first trimester of
pregnancy is the CD56bnght CD 16" uterine Natural Killer (uNK) cell. NK cells are
absent in IL-15 (-/-) knockout mice implying a role for IL-15 in the development and
maturation of these cells (Kennedy et al., 2000). In the human endometrium, in vitro
experiments on isolated human uNK cells demonstrated the ability of IL-15 to stimulate
proliferation of these cells (Verma et al, 2000). During the human "implantation
window" IL-15 and the a chain of the IL-15 receptor are upregulated at least 3-fold
compared with the late proliferative phase (Kao et al., 2002) and supports the role of IL-
15 in the process of implantation. In human peripheral blood at least, IL-15 has been
shown to be essential for the production of type 2 cytokines, such as IL-10, by this sub¬
type ofNK cell (Cooper et al., 2001a).
Localisation of IL-15 within the human endometrium has been confirmed using
immunohistochemistry (Kitaya et al., 2000). During the proliferative phase of the cycle
staining is highest in the glands with stromal staining in the perivascular region
appearing in the secretory phase. The mechanism by which IL-15 is regulated in
epithelial cells has not been explored to date. This chapter will examine, briefly, this
issue using two endometrial epithelial cell lines, HES and Ishikawa. The
immunoreactivity for IL-15 persists in both glands and stroma into the first trimester of
decidua. Treatment of human endometrial stromal cells (ESCs) and decidual cells with
progesterone stimulated the release of IL-15 in vitro (Kitaya et al., 2000; Okada et al,
2000). These results suggest hormonal control of IL-15 mRNA expression and protein
release. Progesterone levels increase across the menstrual cycle, peaking at day 21
before either being maintained at a high level due to continued secretions from the
corpus luteum (CL) or declining as a result of its demise in the absence of pregnancy.
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Due to the timing of IL-15 appearance in the stromal compartment of endometrium and
the in vitro influence of progesterone, the in vivo trigger of decidualisation, a
relationship between IL-15 and the process of decidualisation has been previously
proposed (Okada et al., 2000a). An effective inducer of in vitro decidualisation is a
combination of the synthetic progestin,
medroxyprogesterone acetate (MPA), together with cAMP (Tang et al., 1994; Brosens et
al., 1999). This second messenger is downstream in the PGE2 pathway, a compound
also shown to induce stromal differentiation (Frank et al., 1994), and cAMP levels can
be upregulated by PGE2 via the EP2 and EP4 receptors (Narumiya et al., 1999).
Studies in mice have identified uNK cells as a source of the T helper-1 (Th-1) cytokine,
IFN-y (Ashkar et al., 2000). Further experiments involving knockout mice lacking IFN-
y (IFN-y ~ ~) demonstrated that the normal pregnancy-associated modifications of the
blood vessels failed to occur (Ashkar et al., 1999). In addition to a role in decidual
artery remodelling, it was established that this absence of IFN-y leads to a necrotic
decidua in late gestation implying a role in maintenance of decidual integrity.
This chapter details the in vitro control of IL-15 mRNA expression and secretion by
IFN-y and PGE2 in ESCs and examines the expression of IL-15 and IFN-y across the
menstrual cycle. In addition, a model of progesterone maintenance in vivo has been
used to study the influence of progesterone on IL-15 immunostaining in the human
endometrium.
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5.2 Materials and Methods
5.2.1 Human Uterine Tissue Collection
Endometrial (n = 68) and first trimester decidual biopsies (n = 8) were collected and
processed as described earlier (section 2.1). The samples used in this chapter are
detailed in Table 5.2.
Table 5.2






First trimester decidua 8
Study group A: mid secretory endometrium * 5
Study group F: pregnancy simulation ** 5
* ** Descriptions on the following page.
For the biopsies used in the Q RT-PCR studies to measure IL-15 and IFN-y mRNA
expression across the menstrual cycle and in first trimester decidua the total RNA was
extracted and complimentary DNA prepared from 44 of the endometrial and the 8
decidual samples, utilising the methods detailed in the General Methods and Materials
(sections 2.4 and 2.5). The cell separation procedure was implemented to process 14 of
the endometrial biopsies into cultures of endometrial stromal cells (section 2.2).
The remaining 10 endometrial biopsies were collected as part of a study group of
women:
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Group (i) Normal mid secretory phase endometrium (day LH + 8-10), correlated
with peak serum progesterone concentrations (mean ± SEM (nmol/1): 50 ±11. Range:
28.7-91.6). This is the Control Group. (n = 5).
Group (ii) Simulation of early pregnancy (n = 5). Daily Injections of hCG were
given from day LH + 8 for 14 days, thus maintaining the lifespan of the corpus luteum
(CL) and therefore maintaining progesterone production. Over the 14 days incremental
doses of hCG were given ranging from 125 to 20,000 IU (Illingworth et al, 1990).
5.2.2 in vitro Primary Cell Culture Studies (ESCs)
Proceeding ESC culture preparation as described in section 2.2, cells were seeded in 12-
well plates at a concentration of 1.4xl05 cells/ml. Three experiments were designed and
performed. Treatments administered are detailed in tables 5.2, 5.3 and 5.4. In table 5.2
the time-course experiment of IL-15 mRNA expression is described. This experiment
was designed to determine the ability of IFN-y and PGE2 to increase IL-15 mRNA levels
at different time points. IFN-y was selected as a treatment due to its ability to stimulate
IL-15 expression and secretion in cortical tubular epithelial cells (Weiler 1998) and
PGE2 for its ability to stimulate decidualisation in ESCs (Frank et al., 1994). There is
evidence for a discordance between IL-15 mRNA expression and secretion and it is
considered that post-transcriptional controls are responsible (Tagaya et al., 1996). There
are two splice variants of IL-15, the LSP and the SSP (refer to section 1.4.3). It is
therefore important to note that the primer and probes used in the quantification of IL-15
mRNA levels by Q RT-PCR in this chapter will detect both forms of IL-15 mRNA.
However, only the LSP is secreted and this form is detected in the ELISA. In addition,
the same IL-15 antibody was used in the immunohistochemistry as in the ELISA and
therefore the staining pattern determined within this chapter for IL-15 in the human
endometrium is that of the LSP.
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Table 5.2
Experiment 1: Time-course of IL-15 mRNA expression (n = 4)
Treatment Concentration Incubation time
Control N/A 0, 4, 24, 48 and 72 hours
IFN-y 25ng/ml
4, 24, 48 and 72 hourspge2 10~6M
pge2+ IFN-y 10~6M + 25ng/ml
The experiment detailed in table 5.3 was designed to study the ability of decidualising
treatments (see chapter 3) to stimulate IL-15 mRNA expression and secretion. In
addition, IFN-y was added to study the role of this inflammatory mediator on IL-15
production.
Table 5.3
Experiment 2: IL-15 mRNA expression and secretion (n = 3)
Treatment Concentration Incubation time
Control N/A
3, 6 and 9 days
MPA 10"6M
MPA + 8-Bromo cAMP 10~6M + O.lmg/ml
MPA + 8-Bromo cAMP +
IFN-y
10~6M + O.lmg/ml +
25ng/ml




Experiment 3: IL-15 secretion (n = 7)
Treatment Concentration Incubation time
Control N/A
3 and 6 days
IFN-y O.lmg/ml
MPA + IFN-y 10~6M + 25ng/ml
8-Bromo cAMP + IFN-y O.lmg/ml + 25ng/ml
MPA + 8-Bromo cAMP +
IFN-y
10~6M + O.lmg/ml +
25ng/ml
PGE2+IFN-y 10~6M + 25ng/ml
MPA+ PGE2+IFN-y 10"6M+ 10"6M + 25ng/ml
5.2.3 in vitro Cell Line Culture Studies (Epithelial Cell Lines)
Endometrial epithelial cells also produce IL-15 and the following experiment was
designed to explore whether the regulation of IL-15 production by these cells is similar
to that in ESCs. Two epithelial cell lines were used (due to the lack of availability of
primary epithelial cells). The HES cell line was established from human proliferative
endometrium and was found to express vimentin and cytokeratin but did not produce
prolactin, a marker of ESCs (Desai et al., 1994). It is critical to prevent cross-
contamination from other cell lines once they are established and so they should always
handled with extreme care. Previously it has been reported that the ED27 trophoblast-
like cell line was contaminated by the WISH cell line and both were found to be
genetically identical to the cell line HeLa (Kniss et al., 2001). HES cells (a gift from Dr
Rniss, Ohio State University, Columbus) and Ishikawa cells (a gift from Dr Nishida,
University of Tsukuba, Japan) (epithelial cell lines) were cultured in 162cm2 culture
flasks at a concentration of 1.6x10s cells/ml in complete medium. Cells were incubated
for 24 hours after passaging and seeding of cells in 12-well plates. Treatments were
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then added as detailed in Tables 5.5 and 5.6 to determine whether these cells are
regulated in a similar manner to ESCs.
Table 5.5
IL-15 mRNA expression in HES cells (n = 4)





IFN-y + 8-Bromo cAMP 25ng/ml + 250pM
Table 5.6
IL-15 mRNA expression in Ishikawa cells (n = 4)






pge2+IFN-y 10~6M + 25ng/ml
5.2.4 IL-15 ELISA
At the termination of the experiments, media was collected and either stored at -20°C or
assayed immediately for IL-15 in duplicate using a commercial Enzyme-linked
immunoabsorbant assay. Plates were initially coated with human IL-15 capture
antibody at 2pg/ml diluted in phosphate buffered saline. lOOpl was added to each well.
Plates were left overnight at 4°C before being washed twice in water. To each well,
lOOpl of Blocking and protecting medium was added and left at room temperature for 60
minutes. The blocking and protecting medium was aspirated and plates were allowed to
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air dry, uncovered at room temperature before either being stored in the freezer at -20°C
or used to run an ELISA.
To set-up an ELISA, plates were initially washed in water and wash buffer (dH20 0.05%
Tween; lOmM Tris; 9g/litre NaCl). Any moisture remaining in the wells was removed
by suction. Each well in the plate had a final volume of lOOpl. Non-specific binding
was measured by providing two wells on each plate with the buffer and Tween (Per litre
dH20: 12.1 lg lOOmM Tris; 2g 2mg/ml BSA; 9g NaCl; 0.744g 2mM EDTA; 300pl
Phenol Red Solution; 1ml preservatives; 1.5ml 20% Tween 20 Solution; pH 7.2)
solution alone. A standard curve was added to each plate with a top standard of
500pg/ml. A 1:2 serial dilution was performed down to 3.9pg/ml to create eight
standards in total. Between four and six replicates of a quality control with a
concentration of lOOpg/ml were added to enable intra-assay variability to be monitored.
All test samples were run undiluted, in duplicate wells. Plates were then left overnight
at 4°C.
Plates were washed three times in wash buffer and suction used to remove excess
moisture. An IL-15 detection antibody was diluted to O.lpg/ml and lOOpl pipetted into
each well using a multi-channel pipette. Plates were covered and secured on a plate-
shaker for 90 minutes at room temperature. They were washed as before in a solution of
diluted wash buffer. The streptavidin peroxidase was added at 0.125U/ml, each well
receiving lOOpl. Plates were sealed and placed on a plate-shaker for 20 minutes at room
temperature followed by the standard washing procedure. The substrate was then mixed
and 200pl transferred to each well. Each plate was allowed 20 minutes to develop and
then read on a Multiscan Ex plate reader (Labsystems) using a filter with a 450nM
absorbance value. The computer program Assay Zap was used to analyse the results and
construct a standard curve against which the samples could be judged.
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5.2.5 RNA Extraction and Q RT-PCR
The RNA was extracted and cDNA prepared from the epithelial cell line experiment and
ESC experiments 1 and day 9 samples of experiment 2. IL-15 mRNA levels were
measured by Q RT-PCR as described in section 2.5.
5.2.6 IL-15 Immunohistochemistry
Immunostaining for IL-15 was conducted on the study group tissues. A late secretory
endometrial section was used as a positive control to ensure the procedure had worked.
In addition, three extra slides from the study group tissues were included as negative
controls. Slides were prepared (see section 2.7.1) and then blocked with endogenous
peroxidase (3% H2O2) for 10 minutes. Slides were washed twice in PBS for 5 minutes
each wash. An avidin-biotin step was performed using a kit (Vector, Peterborough, UK)
-15 minutes in avidin, 2 PBS washes, 15 minutes in biotin, 2 PBS washes. The first
non-immune block was performed in normal horse serum (NHS) (150pl NHS diluted in
10ml PBS) for a 20 minute duration. Slides were incubated with the primary antibody
for 60 minutes at 37°C. The anti-human mouse monoclonal IL-15 antibody (R&D
Systems, Abingdon, UK) was diluted 1 TOO and mouse IgG typel was used as a matched
negative control and diluted 1:200. After the incubation the slides were washed in PBS
Tween for 5 minutes twice. Biotinylated horse anti-mouse was the secondary antibody
diluted 1:200 in NHS. Slides were incubated for 30 minutes at room temperature.
Slides had two 5 minute washes in PBS Tween. The tertiary complex was made up in
PBS 30 minutes prior to use from an ABC kit (Vector). Slides were incubated for 30
minutes at room temperature. Slides had two 5 minute washes in PBS Tween before
being stained with DAB (Dako, Cambridgeshire, UK). Slides were washed twice in
dH20 once the brown staining had appeared in the positive controls. Slides were
haematoxylin counterstained for 20 seconds before being dehydrated in graded alcohols
(20 seconds in each). A 5 minute step in Histoclear was followed by 5 minutes in
xylene and slides were then mounted.
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All samples were stained in the same immunohistochemical run to avoid artefactual
variation in staining intensity. Analysis of staining within the groups was performed
blindly by two individuals. Refer to section 2.7.2 for full details of this scoring system.
5.2.7 Statistical Analysis
Q RT-PCR, ELISA and immunohistochemical data were analysed by the methods
described previously in section 2.8.
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5.3 Results
5.3.1 Analyses Across the Menstrual Cycle
5.3.1a IL-15 mRNA Expression
IL-15 mRNA expression was detected in whole endometrial biopsies from all stages of
the menstrual cycle and in whole first trimester decidual biopsies (Figure 5.1). Lowest
levels were detected in the proliferative phase of the cycle. A steady rise in levels into
the early and mid secretory phases was apparent with expression levels rising 3- and 6-
fold respectively compared with the proliferative phase. There is a dramatic rise in the
late secretory phase of approximately a 30-fold increase versus the proliferative phase
and expression of significantly more IL-15 mRNA than each of the cycle phases (p <
0.005). Levels of expression were higher in the menstrual and decidual tissue than in the
proliferative tissue by 8- and 10-fold respectively (although not significantly).
5.3.1b IFN-y mRNA Expression
IFN-y mRNA expression was detected in each of the cycle stages and in first trimester
decidua tissue (figure 5.2). The decidual tissue was found to have the highest level of
expression and this was significantly raised when compared with the early secretory
phase (p < 0.05). The early secretory tissue expressed the lowest levels of IFN-y and
there was a gradual rise across the later cycle stages.
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Figure 5.1
Relative amounts of IL-15 mRNA in proliferative (P), early secretory (ES), mid
secretory (MS) and late secretory (LS) endometrium and first trimester decidua (D).
Numbers in brackets indicate sample number, a p < 0.005.
Figure 5.2
Relative amounts of IFN-gamma mRNA in proliferative (P), early secretory (ES), mid
secretory (MS) and late secretory (LS) endometrium and first trimester decidua (D).
Numbers in brackets indicate sample number, a p < 0.05.
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5.3.2 IL-15 mRNA Expression by Cultured ESCs
The mRNA expression of IL-15 increased throughout the time-course between 0 and 72
hours (Figure 5.3) when ESCs were treated with PGE2 and IFN-y alone or in
combination. The control cells had consistently low levels of expression across all time
points. When compared with controls the PGE2-treated cultures by 72 hours were
expressing significantly greater levels of IL-15 mRNA (p < 0.005). The cultures treated
with IFN-y had significantly raised IL-15 mRNA levels compared with controls at 4, 24,
48 and 72 hour time points {p < 0.05). The PGE2+IFN-y-treated cultures exhibited
significantly raised IL-15 expression at all time points (p < 0.05) and were higher than
those treated with IFN-y alone although this difference was not significant. Refer to
table 5.7 for a comparison with the epithelial cell line data.
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Figure 5.3




5.3.3 IL-15 mRNA Expression and Secretion by ESCs in vitro
Treatment of ESCs with MPA in combination with 8-Bromo-cAMP caused a 50-fold
increase in expression of IL-15 above control values after 9 days of treatment (p < 0.05)
(Figure 5.4). MPA alone had little effect on IL-15 expression. Addition of IFN-y, MPA
and 8-Bromo-cAMP together triggered a 60-fold increase in IL-15 expression above
control levels (p < 0.03).
IL-15 protein levels in the ESC culture media after 3 days of treatment were no different
to controls when treated with either MPA alone or together with 8-Bromo cAMP (Figure
5.5). Cells treated with MPA, 8-Bromo-cAMP plus IFN-y showed a 10-fold increase in
IL-15 secretion relative to controls (p < 0.0001). After 6 days of treatment a similar
pattern was apparent with MPA, 8-Bromo-cAMP plus IFN-y stimulating an 11-fold




IL-15 mRNA expression measured by Q RT-PCR in cultured ESCs following 9 days of




IL-15 protein release from treated ESCs with and without IFN-y after 3 days of
treatment, (n = 3). Same letters denote significant difference, a p < 0.0001. The lower
detection limit of the ELISA was 3.9pg/ml.
Figure 5.6
IL-15 protein release from treated ESCs with and without IFN-y after 6 days of
treatment, (n = 3). Same letters denote significant difference, b p < 0.0003. The lower
detection limit of the ELISA was 3.9pg/ml.
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5.3.4 IL-15 Secretion by ESCs in vitro
As predicted from previous results (section 3.3.3) addition of IFN-y alone stimulated a
rise in IL-15 release from ESCs relative to control values (p < 0.05) (Figure 5.7). When
8-Bromo cAMP was added with IFN-y a significant rise in IL-15 release was observed
and this rose further by 6 days of treatment {p < 0.01). The addition of MPA to the
treatment regime appeared to augment this response at 3 and 6 days, although this was
not significant. ESCs cultured in the presence of PGE2 and IFN-y secreted greater levels
of IL-15 relative to controls on days 3 and 6 but this only became a significant
difference when MPA was supplemented {p < 0.05). Addition of MPA and IFN-y
stimulated a similar level of IL-15 release to treatment with IFN-y alone.
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Figure 5.7
IL-15 protein release from IFN-y treated human ESCs after 3 and 6 days of treatment, (n
= 7) * Depicts group with no IFN-y stimulation. Same letters denote significant
difference. a,dp< 0.01; b, ep < 0.0002; c, f, g p < 0.05. The lower detection limit of






IL-15 mRNA expression measured by Q RT-PCR in cultured HES cells following 2
days of treatment (n = 4). IL-15 mRNA levels were analysed by Q RT-PCR after 48
hours of treatment. IFN-y and 8-Bromo cAMP alone or in combination had no effect on





IL-15 mRNA expression measured by Q RT-PCR in cultured Ishikawa cells following 2
days of treatment (n = 4). IL-15 mRNA levels were analysed by Q RT-PCR after 48
hours of treatment. IFN-y and PGE2 alone or in combination had no effect on the level



















pge2 + IFN-y 3.8 <0.05
HES
Control 1 N/A









pge2 + IFN-y 0.8 N/S
Table 5.7
Summary of comparable primary endometrial stromal cell (ESC) and epithelial cell line




Immunohistochemical localization of IL-15 in the normal mid-luteal (LH day 8-10) (a
and c) and with simulation of early pregnancy (b, e and f). Negative control (d). A
strong intensity of staining was observed in the glandular epithelium (g) of endometrium
from simulated early pregnancy (b and e) and this was significantly greater than in the
control group (a and c) (P < 0.05). The stromal cells showed no immunoreactivity in
the control group (a and c) but endometrium from simulated early pregnancy had strong
stromal (s) immunostaining (b, e and f). Scale bar in photomicrograph d represents
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Figure 5.11
Qualitative scoring of IL-15 immuno staining in human endometrium taken from two
groups of women: Normal mid-luteal (LH peak + 8-10) and simulation of pregnancy










The results in this chapter demonstrated via a study simulating pregnancy that IL-15
immuno expression in the stroma and glands is increased by artificial maintenance
("rescue") of the CL. However, in vitro studies on isolated ESCs demonstrated that a
synthetic progestin alone was not capable of increasing IL-15 mRNA expression or
protein release from these cells. In contrast, both PGE2 and 8-Bromo cAMP were able
to increase IL-15 release in vitro in the presence of IFN-y or in the absence of IFN-y, a
rise in IL-15 mRNA. These responses appeared to be enhanced by addition of a
progestin. IFN-y was essential for IL-15 protein secretion and when added alone,
stimulated a small rise in IL-15 release from ESCs. Stimulation of ESCs with PGE2 or
IFN-y alone or in combination, led to an increase in the expression of IL-15 mRNA in
vitro. Despite protein detected in the glands by immunohistochemistry, an up-regulation
of IL-15 mRNA expression in the HES and Ishikawa human epithelial cell lines was not
achieved by cAMP, PGE2 or IFN-y stimulation over a 48 hour time period. In addition,
expression of IL-15 mRNA in first trimester decidua and in endometrium across the
menstrual cycle was demonstrated. The late secretory stages expressed significantly
greater levels (p < 0.005) in comparison to all other cycle phases. Expression of IFN-y
mRNA across the menstrual cycle and in decidua was also confirmed. Expression in
decidua was significantly greater than that in the early secretory phase (p < 0.05).
IL-15, a pro-inflammatory cytokine, is a potent T cell growth factor and activator and
has been associated with allograft rejection (Baan et al., 1998). It is a member of the
four a-helix family of cytokines alongside IL-2. Although many of the effects of IL-15
and IL-2 are similar, their tissue distribution is distinct and the expression of IL-15
mRNA has been found in a large variety of cell types and tissues. The expression of IL-
15 in a broad spectrum of tissue and cell types, including kidney epithelial cells (Weiler
et al., 1998), skeletal muscle (Quinn et al., 1995) and placenta (Grabstein et al., 1994)
implies that the functions of IL-15 extend beyond that of the immune system. The
possible role of IL-15 in uterine physiology has also recently been explored and the idea
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of hormonal control over this cytokine proposed (Kitaya et al., 2000; Okada et al.,
2000a). The involvement of IL-15 in placental establishment has also been proposed
(Zygmunt et al., 1998). Pre-eclampsia is associated with insufficient invasion of
trophoblast cells at the time of implantation and placentation. The outcome is defective
transformation of uterine spiral arteries resulting in the development of pre-eclampsia.
The results detailed in this chapter suggest that, at the intra-cellular signalling level (at
least in vitro), the second messenger cAMP is a key regulator of IL-15 release from
ESCs and that this response is likely to be linked to the action of IFN-y. The role of
IFN-y in IL-15 release by cells has also been described previously in the kidney (Weiler
et al., 1998; Basok et al., 2001). The mRNA expression for IL-15 is greatest in the late
secretory endometrium and although the level is lower in first trimester decidua it is still
10-fold greater than in the proliferative phase. The simulation of early pregnancy study,
described herein, has demonstrated a rise of IL-15 protein in the stroma. It is the LSP
form of IL-15 that has been detected in the immunohistochemistry. The LSP and SSP
forms of IL-15 were detected by Q RT-PCR across the menstrual cycle. It may
therefore be possible that IL-15 staining would be greater in intensity and distributuion if
it were possible to assess both forms with immunohistochemistry. It may be that these
elevated levels of IL-15 mRNA in the late secretory endometrium represent the
transformation of the stroma from a pseudo-decidualised state into fully decidualised
cells, only relevant at this specific cycle stage. The presence of IFN-y in human
endometrium in lymphoid aggregates and in cells dispersed throughout the stroma has
been confirmed previously by immunocytochemistry (Stewart et al., 1992a). Here we
have confirmed for the first time, quantitative expression of IFN-y throughout the
menstrual cycle and in first trimester decidua and demonstrated a rise in expression in
first trimester decidua by Q RT-PCR. Macrophages can produce IFN-y (Gessani and
Belardelli, 1998) and uNK cells are another important source of IFN-y and are situated
both perivascularly and in close proximity to the glands (King, 2000). A study of
decidual NK cells in vitro has demonstrated the spontaneous secretion of IFN-y by these
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cells (Ekerfelt et al., 2002). There is a further infiltration of uNK cells throughout the
endometrial stroma in the late secretory phase (Bulmer et al., 1991). This pattern of
rising uNK cell numbers post-ovulation, parallels the IL-15 expression demonstrated
across the cycle in this chapter. It has been proposed that IL-15 is the stimulator of uNK
cell proliferation (Verma et al., 2000). These cells are believed to undergo apoptosis
prior to menstruation. However, they appear to be "rescued" if pregnancy is established
and full decidual transformation completed thus implying a link between uterine NK
cells and decidualisation (King, 2000). Communication between the stromal cells and




Communication between the ESCs and uNK cells could be important to the discrete
functions of these cells in vivo. IL-15 and IFN-y are two cytokines that may provide
some of this paracrine cross-talk. R represents the IL-15 receptor which is composed of
three subunits: the common y chain, an a chain specific to IL-15 and the P chain of the
IL-2 receptor.
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In the present chapter it has been demonstrated that PGE2 is also able to stimulate IL-15
expression and release by ESCs. The actions of PGE2 have been established, in part, to
be via the second messenger cAMP through activation of EP2 and EP4 receptors and
this supports the present observations (Coleman et al., 1994). The responses of both
PGE2 and 8-Bromo cAMP appear to be enhanced by addition of a progestin. This is in
agreement with other studies that have suggested progesterone has an involvement in IL-
15 regulation in human endometrium (Kitaya et al., 2000; Okada et al., 2000a) and also
in concordance with IL-15 immunohistochemistry in this chapter. These data also
illustrated a rise in IL-15 in the stroma and glands in vivo. Treatment of human
epithelial cell lines with cAMP, PGE2 or IFN-y alone or in combination failed to
stimulate an increase in IL-15 mRNA expression. Treatment of ESCs with the same
regime significantly raised IL-15 mRNA expression over the same time period. These
data suggest that IL-15 regulation in stromal and epithelial cells in vitro is taking place
via divergent pathways. This is apparent according to IL-15 immunoreactivity across
the menstrual cycle (Kitaya et al., 2000) where in the proliferative phase the glands stain
strongly for IL-15 although stromal staining is weak. The function of IL-15 in the
endometrial epithelial cells has yet to be explored.
Studies using endometrial explant cultures have compounded evidence for hormonal
control of PGE2. Secretory endometrium released greater levels of prostaglandins than
proliferative endometrium, corresponding with the rise in progesterone levels, and from
these results an involvement of PGE2 in menstruation has been proposed (Abel et al.,
1980; Baird et al., 1996). Additionally, synergistic actions between MPA and oestradiol
plus PGE2 on the process of in vitro decidualisation have previously been reported
(Frank et al., 1994). An up-regulation of IL-15 mRNA expression during in vitro
decidualisation (Okada et al., 2000a) supports the link between IL-15 and
decidualisation (refer to chapter 3). Previous studies have demonstrated a central role
for cAMP in increasing the expression of prolactin, a marker of decidualisation (Tang et
al., 1993a; Brosens et al., 1996). In purified blood NK cells the ability of PGE2 to
suppress the actions of IL-15 on NK cells via inhibition of the IL-15 receptor y-chain has
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been demonstrated (Joshi et al., 2001). If a similar effect can be demonstrated in uNK
cells this could offer a possible paracrine regulatory system to restrict uNK cell
proliferation. This would be essential since women suffering from recurrent miscarriage
were found to have significantly raised levels of uNK cells compared with fertile
controls (Quenby et al., 1999). However, these findings were discovered in the non¬
pregnant endometrium in the pre-implantation phase. It is not a direct reflection to what
is happening in the pregnant uterus in the early stages of gestation with regard to uNK
cell number and function. In contrast uNK deficient mice have small placental size
(Ashkar et al., 1999) that may lead to problems such as pre-eclampsia or intra-uterine
growth retardation of the fetus.
In conclusion, this study provides evidence of a role for IFN-y in IL-15 regulation in
concert with the actions of PGE2 and supports the view that IL-15 is closely linked to
decidualisation and uterine NK cell function. Progesterone secretion from the CL in
vivo increases IL-15 expression in both glandular and stromal compartments of the
human endometrium although regulation of IL-15 mRNA expression in vitro is disparate
in ESCs and human epithelial cell lines. A greater knowledge about stromal and uNK
cell interactions in human endometrium and first trimester decidua will benefit our
understanding of key reproductive processes such as decidualisation, menstruation,
placental formation and the establishment and maintenance of early pregnancy.
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6. Characterisation of Uterine Natural Killer Cells
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6.1 Introduction
In the first trimester of pregnancy the major immune cell is the uterine natural killer
(uNK) cell comprising approximately 70% of the bone marrow-derived cells (Loke et
al., 1995) and they have a specific phenotype, CD56bnght CD 16" (Starkey et al., 1988).
In a comparison of IL-10 decidual staining in missed abortion versus elective
terminations, immunostaining intensity was reduced in the majority of the missed
abortion cases (Plevyak et al., 2002). The IFN-y staining pattern did not differ between
the two groups of women. These data suggest that the cytokine profile of uNK cells
may be important in maintenance of the first trimester ofpregnancy.
uNK cells respond to IL-2 (Ferry et al., 1990; Nishikawa et al., 1991; King et al., 1992)
although this cytokine has not been detected in the human endometrium or decidua
(Saito et al., 1993; Jokhi et al., 1994b; King et al., 1995). IL-15 has many functional
similarities with IL-2 although its distribution is distinct with IL-15 being widely
expressed (Grabstein et al., 1994; Quinn et al., 1995; Weiler et al., 1998). The IL-15
receptor is composed of three subunits: IL-15 receptor-a (the molecule binding site),
IL-2 receptor-p and the common y chain (the signal transduction site). uNK cells have
been shown to proliferate in vitro upon treatment with IL-15 (Verma et al., 2000) and
IL-15 null mice have a marked reduction in thymic and peripheral blood (PB) NK cells
(Kennedy et al., 2000). Knock-out mice for Interferon regulatory factor-1 (IRF-1) are
unable to induce IL-15 in the bone marrow and are deficient in NK cells (Ogasawara et
al., 1998) implying a role for IL-15 in the survival and expansion ofNK cells in vivo. In
addition, CD56bnght NK cells in blood have been reported to require IL-15 for their Th-2
cytokine production (Cooper et al., 2001a). Cytokines released by T cells reflect the
mode of dealing with disease that has been programmed into the cell and can be
classified as either T helper-1 (Th-1) or -2 (Th-2), with each group exhibiting divergent
roles. The Th-1 cytokines include IFN-y, IL-12 and IL-2, and are generally classified as
being pro-inflammatory whereas Th-2 cytokines, for example, IL-10 and IL-6, are
considered to be immunosuppressive. However, IL-10 can also be expressed by Th-1
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cells in humans but not in mice (Romagnani, 2001). Immunocompetent cells, of
haematopoietic lineage, such as macrophages, T-cells and NK cells are major sources of
cytokines within the uterus.
There appears to exist an intimate association between the uNK cell and endometrial
stromal cells and the role of uNK cells as a pre-requisite for decidualisation in humans
has been discussed (King, 2000). In mice, the uNK cell has been implicated in the
maintenance of stromal decidualisation but not it's initiation (Croy et al., 2002). In
chapters 3 and 4 the role of PGE2 in decidualisation has been examined. PGE2 can
modify the effects of IL-2 on PB NK cells via inhibition of the IL-2 receptor (Parhar et
al., 1989). Studies on mouse decidual NK cells have implicated PGE2 in controlling
their differentiation and function (Linnemeyer et al., 1993). In this chapter the possible
influence of PGE2 on NK cell function in the human uterine environment will be
examined.
CD40 is a member of the TNF-a receptor family and along with its ligand, CD40L
(CD154), is involved in proinflammatory signalling via the NFkB transduction pathway
(Berberich et al., 1994). CD40 is expressed on a range of cell types including vascular
endothelial cells (Hollenbaugh et al., 1995) and fibroblasts (Fries et al., 1995) and more
recently has been localised to the stromal compartment of the human endometrium, with
a focus in locality in the perivascular region (King et al., 2001). It was demonstrated
that treatment of stromal fibroblasts with IFN-y and CD40L stimulated their secretion of
IL-6, IL-8 (the main neutrophil chemoattractant) and MCP-1 and this may represent a
role in endometrial tissue remodelling. In addition, stimulation of the CD40 system in
lung fibroblasts results in raised COX-2 expression (Zhang et al., 1998b) and if a similar
pathway takes place in endometrial fibroblasts this pathway provides a further
mechanism for inducing PGE2 production by ESCs. IL-2-activated NK cells can express
CD40L (Carbone et al., 1997). uNK cells are located surrounding the blood vessels,
where the CD40 protein has been localised in the stroma (King et al., 2001), and
therefore it may be possible that these two cell types may communicate by cell-cell
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contact via the CD40-CD40L pathway. It is necessary to identify initially whether uNK
cells are able to express CD40L.
Immunodeficient mice lacking uNK cells have an abnormal implantation site including
acellularity of the decidua and decidual arteries with thick walls and a decreased luminal
diameter (Greenwood et al., 2000). Likewise, with IL-2 receptor-y chain null mice, no
uNK cells are present and these mice exhibit poor decidual transformation although they
do experience apparently successful pregnancies (Miyazaki et al., 2002). A link
between uNK cells and decidual transformation in humans has been proposed and their
decline immediately prior to menstruation has implicated them in endometrial
breakdown (King, 2000). The number of uNK cells varies in a cyclical manner with a
progressive rise across the secretory phase, with a marked rise at the time of
implantation in the mid secretory phase (King et al., 1989b) (figure 6.1). Their cyclical
variation indicates they are hormonally regulated although this is likely to be indirect
since they are lacking in the nuclear progesterone receptor (Henderson et al., 2003).
They have also been implicated in human implantation and placentation (King et al.,
1990; King et al., 1991).
This chapter examines the effects of in vitro culture of uNK cells, separated from human
first trimester decidua, with IL-15 and PGE2 treatment. IL-10 production, a cytokine
believed to support pregnancy, has been studied and compared with PB NK cells.
Chapter 5 demonstrated the essential role for IFN-y in IL-15-release from ESCs in vitro.
IL-15 is a known regulator of uNK cell function and in this chapter the effects of IL-15
and PGE2 treatments on IFN-y and CD40L mRNA expression in uNK cells will be
explored. This chapter has also assessed the effect of these treatments on the expression









The cyclical variation in uNK cell number in relation to progesterone levels and ESC
decidualisation in the human endometrium based on the "classic" 28 day cycle. The




6.2.1 Uterine Natural Killer Cell Separation Procedure
Samples of first trimester decidua (n = 9) were collected for isolation of uNK cells
(collection details in section 2.1). The method was obtained from Professor A Moffet-
King, Department of Pathology, Cambridge University, UK. Figure 6.2 is a paraffin-
embedded section of this tissue and illustrates the abundance of uNK cells in first
trimester decidua by the CD56 immunostaining pattern. Samples were washed in RPMI
for 20 minutes upon collection and then chopped into l-2mm pieces using scalpels
(Swann-Morton, Sheffield, Yorkshire, UK) and suspended in 12ml RPMI + 10% FCS in
a 50ml Falcon tube. 7.2mg of Type V collagenase (Sigma) was added to produce a final
concentration of 0.6mg/ml. The tube was then incubated on a turning machine at room
temperature overnight.
On the second day of the process, the falcon tube was topped up to 50ml RPMI + 10%
FCS and re-suspended. The sediment was allowed to settle for 10 minutes and the top
45ml was then passed in turn through 70pm and 40pm sterile filters (Becton Dickinson,
Europe, France). The cells were pelleted by spinning in a centrifuge for 5 minutes at
450xg. The supernatant was discarded and the pellet re-suspended in 50ml RPMI + 10%
FCS. This suspension was divided between two 50ml Falcon tubes, each containing
15ml Histopaque 1077 (Sigma). 25ml was carefully layered on top of the Histopaque
using a sterile pasture pipette. The tubes were spun at 800xg for 15 minutes at room
temperature, ensuring the brake on the centrifuge was switched off. The lymphocyte
band of cells was harvested and diluted in RPMI + 10%FCS at least 1:5 and spun and
washed three more times for 5 minutes at 450xg in order that any Histopaque was
removed. A red cell lysis buffer (RCLB) (ImM NH4HCO3; 114mM NH4CI; in distilled
H2O) was applied to the cells to remove any remaining red blood cells. 1ml of PBS was
added per 15 108 total cells and 4 ml of RCLB was added per 1ml PBS. Cells were
incubated on ice for 10 minutes. PBS was added to produce a 50ml volume and tubes
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were spun for 10 minutes at 1200rpm in order to thoroughly wash the cells and remove
the RCLB. Cells were then re-suspended in RPMI + 10 % FCS and a cell count






CD56 immunostaining in first trimester decidua at low power and high power
magnification. Insert is the negative control, (a) Scale represents 200/^m. (b) Scale
represents 50fim.
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6.2.2 Magnetic Bead Purification
The decidual NK cells were purified by magnetic bead isolation (Miltenyi Biotec Ltd,
Surrey, UK). lOOpl of CD56 MACS microbeads were added per 15 108 total cells
resuspended in 300pl of CSM. The suspension was incubated for 20 minutes at 4°C and
then washed in 10 ml CSM for 10 minutes at 300xg. The cells were resuspended in
500pl of CSM and applied to a LS Column attached to a VarioMACS magnet (Miltenyi
Biotech). The column was removed from the magnet and washed three times and the
positive cells then eluted with CSM. The purity of cells from this method of selection,
as determined by FACS analysis, was on average 75% (see general methods section
2.3.1). Two aliquots of approximately 0.5 million cells was taken prior to incubation
with magnetic beads, one to serve as a "blank" and the second as the negative control,
and again after the positive selection procedure was completed. The "blank" tube was
put through the FACS machine without any further treatment. The other two aliquots
were resuspended in 200pl CSM and 10pl of anti-mouse IgG whole molecule with FITC
conjugated (Sigma) added to each. The tubes were wrapped in foil and kept on ice for
30 minutes before being washed in 1ml of CSM and spun for 1 minute at 4000rpm. The
cells were resuspended in 500pl of FACS buffer. Before passing the cells through the
FACS machine the cell suspensions were passed though cell strainers (Becton
Dickinson) to ensure a single cell suspension. For an example of the FACS recordings,
see figure 6.3. The cells were then either embedded in agarose (section 6.2.4) or used in
cell culture experiments (6.2.6).
245
Figure 6.3
A representative example of the FACS recordings for the purity of the separated uNK
cells. The mouse anti-human matched negative control (A) and the sample incubated
with the mouse anti-human CD56 antibody (B).
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6.2.3 Peripheral Blood (PB) NK Cell Separation
Buffy coats were collected from healthy donors (n = 5) from the Blood Donor Centre,
Edinburgh, UK. The blood was diluted 1:4 with PBS and the peripheral blood monocyte
cells (PBMC) were separated out using Histopaque 1077 as detailed above in section
6.2.1. CD56 positive NK cells were purified using the method described in 6.2.2 and
FACS (section 2.3 and 2.3.1) determined the purity of separation to be > 90%.
6.2.4 Agarose Embedding
The negative and positive column fractions from the uNK cell separation were retained
in order to make comparisons. Aliquots of 0.5 - 1 million cells were taken and washed
in 1 ml of PBS for 1 minute at 4000 rpm. The supernatant was removed and 200pl of
NBF added to briefly fix the cells. Tubes were centrifuged at 1500 rpm for 10 minutes.
The supernatant was discarded and cells were resuspended in lOpl PBS. Agarose gel
(2% agarose MP (Sigma) in PBS) was pipetted onto glass slides in the confinement of a
circle drawn with a hydrophobic pen (Sigma). Before the agarose gel had set, the lOpl
cell suspension was pipetted just below the surface of the gel. The piece of gel was
wrapped in speci-wrap that had been pre-soaked in 70% ethanol and submerged in a vial
of 70% ethanol. Samples were then processed for wax embedding and sections were cut




Photomicrographs of haematoxyiin and eosin stained decidual cells: positive and
negative column fractions- (a and b). Cells from the negative column fraction, (c and
d). Cells from the positive selection column fraction. Scale bar represents 100/rm.
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6.2.5 CD56 Immunohistochemistry
Slides were prepared as in section 2.7.1 (except TBS was used in place of PBS) and then
placed in a pressure cooker for 5 minutes in a solution of 0.01M sodium citrate pH6.
This antigen retrieval step would break the cross-links formed during the fixation
process and allow antibodies to access the previously masked epitopes on the protein of
interest. Endogenous peroxidase activity was blocked with hydrogen peroxide (3%
H2O2) for 30 minutes, followed by two 5 minute washes in TBS. Slides were blocked
with diluted NHS (a non-immune block) (150pl NHS diluted in 10ml PBS) for 20
minutes at room temperature, followed by a 60 minute incubation at 37°C with the
mouse anti-human CD56 antibody (diluted 1:125) and the matched negative control
(anti-mouse IgGi) (diluted 1:500). Slides were washed twice for 5 minutes in TBS. The
secondary antibody, biotinylated horse anti-mouse (1:200 dilution) was added to the
slides and left at room temperature for 30 minutes, followed by two 5 minute washes in
TBS. The tertiary complex was made up in TBS 30 minutes prior to use from an ABC
Elite kit (Vector). It was added to the slides and left for 30 minutes at room temperature.
Two 5 minute washes in TBS were carried out prior to addition of DAB (Dako). Once
staining had developed in the positive control, slides were washed in dH20 and mounted
following haematoxylin counterstain and dehydration stages. The CD56
immunostaining results are represented in figure 6.5.
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Figure 6.5
CD56 Immunostaining in decidual cells: positive and negative column fractions. Cells
from the negative column fraction (n = 2) (a and b). Cells from the positive selection
column fraction (n = 2) (c and d). Negative control for the positive selection column
fraction (e). Scale bar represents 50pm.
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The purified decidual (n = 5) and PB NK cell populations (n = 5) were seeded in 12-well
plates at a concentration of 1.4xl05 cells/ml (see figure 6.6). Treatment regimes were
added in duplicate wells as in table 6.1.
Table 6.1
Treatment of uNK and PB NK cells with PGE2
Treatment Concentration Incubation time
Indomethacin (Control) 5pM
24 hours
IL-15 + indomethacin 5ng/ml + 5pM
PGE2 + indomethacin 10"bM + 5pM
IL-15+ PGE2 +
indomethacin
5ng/ml + 10"6M + 5pM
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Figure 6.6
uNK cells after 24 hours in culture media. Scale bar represents 150pm.
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6.2.7 IL-1Q ELISA
Media collected from the uNK cell (n = 4) and PB NK cell (n = 5) culture experiments
after 24 hours and was assayed for IL-10 using a two-site sandwich ELISA (section
2.6.1). Plates were initially coated with human IL-10 capture antibody (Pharmingen,
Beckton Dickinson Company, Oxford, UK) at 2pg/ml diluted in phosphate buffered
saline. lOOpl was added to each well. Plates were left for 1 hour before being washed
twice in water. To each well, 400pl of Blocking and protecting medium was added and
left at room temperature for 60 minutes. The Blocking and protecting medium was
aspirated and plates were washed four times in wash buffer. A standard curve
(Pharmingen) was added to each plate with a top standard of 500pg/ml made up in PBS
with 10% FCS. A 1:2 serial dilution was performed down to 7.8 pg/ml to create seven
standards in total. Four replicates of a quality control with a concentration of lOOpg/ml
were added to enable intra-assay variability to be monitored. To measure NSB, lOOpl of
PBS with 10% FCS was added to four wells. All test samples were mn undiluted, in
duplicate wells with lOOpl being added to each well. Plates were placed on a plate
shaker for 1 hour at room temperature. The contents of the plates were aspirated and
they were then washed in wash buffer four times. The detection antibody was diluted in
PBS plus 10% FCS to 1.3|xg/ml and lOOpl added to all wells. Plates were left for 1 hour
at room temperature on a plate shaker and then washed four times in wash buffer. The
streptavidin peroxidase was added at 0.125U/ml, each well receiving lOOpl. Plates were
sealed and placed on a plate-shaker for 20 minutes at room temperature followed by the
standard washing procedure. The substrate was mixed (see section 2.6.1) and 200pl
transferred to each well. Each plate was allowed 20 minutes to develop and then read on
a Multiscan Ex plate reader (Labsystems) using a filter with a 450nM absorbance value.
The computer program Assay Zap was used to analyse the results and construct a
standard curve against which the samples could be compared. The intra-assay variation
was calculated from 8 replicates of the same standard on a plate and found to be 15.4%.
The inter-assay variation was calculated across 4 separate assay plates and was
determined to be 18.3%.
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6.2.8 RNA Extraction and Q RT-PCR
The RNA was extracted and cDNA prepared from the cell culture experiments. IFN-y,
CD40L, IL-10 and EP2 and EP4 receptor mRNA levels were measured by Q RT-PCR as
described in section 2.5.
6.2.9 Statistical Analysis




6.3.1 IFN-y mRNA Expression in uNK Cells
The results in figure 6.7 show that following IL-15 treatment for 24 hours IFN-y mRNA
levels had increased almost 4-fold in relation to controls and 4-fold compared with the
PGE2 treatment group (p < 0.04). When PGE2 was added alongside IL-15 the rise in
mRNA levels with IL-15 treatment alone was reduced to just under a 2-fold increase.




The relative IFN-y mRNA expression levels in uNK cells following a 24 hour incubation





6.3.2 CD4Q-Ligand mRNA Expression in uNK Cells
The relative levels of CD40L mRNA was over 2-fold greater in the IL-15-treated cells
than in the controls (p < 0.004) (figure 6.8). When added alone, PGE2 had no effect on
expression levels inducing comparable levels to controls. However, when PGE2 was
added in combination with IL-15 it appeared to inhibit the stimulatory effects of IL-15
modestly although this was not a significant reduction.
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Figure 6.8
The relative CD40L mRNA expression levels in uNK cells following a 24 hour
incubation with IL-15, PGE2 and IL-15 plus PGE2. Same letters denote significant
difference, a p < 0.004 and b p < 0.006.
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6.2.3 EP2 and EP4 Receptor mRNA Expression in uNK Cells
The uNK cells were expressing both the EP2 and EP4 receptor according to mRNA
levels. No change in the EP2 receptor was observed following IL-15 and PGE2
treatments according to the results in figure 6.9. The mRNA expression levels of the
EP4 receptor increased 3-fold relative to controls following IL-15 treatment (p < 0.01)
and PGE2 plus IL-15 triggered a 4-fold rise in the EP4 receptor (p < 0.0006) (figure
6.10). PGE2 added alone had no effect on EP4 receptor expression.
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Figure 6.9
The relative EP2 receptor mRNA expression levels in uNK cells following a 24 hour




The relative EP4 receptor mRNA expression levels in uNK cells following a 24 hour
incubation with IL-15, PGE2 and IL-15 plus PGE2. Same letters denote significant

















6.3.4 IL-10 mRNA Expression and Release by uNK Cells
uNK cells treated with PGE2 stimulated a 3.5-fold increase in IL-10 mRNA levels
compared with controls (p < 0.0004) (figure 6.11). This trend was consistent with IL-10
release from uNK cells although the exact levels detected were variable between the 4
samples (figure 6.12 a-d) and the fold changes in protein levels are illustrated in figure
6.13. IL-15 had no effect on IL-10 mRNA levels relative to controls and this was
consistent with the IL-10 ELISA data (figure 6.13).
268
Figure 6.11
The relative IL-10 mRNA expression levels in uNK cells following a 24 hour incubation
with IL-15, PGE2 and IL-15 plus PGE2. Same letters denote significant difference, a p




















IL-10 release in pg/ml over 24 hours from uNK cells in the four separate cultures as
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Figure 6.13
Summary of the mean values of IL-10 released from uNK cells over 24 hours (from the






6.3.5 IL-10 mRNA Expression and Release by PB NK Cells
IL-10 mRNA levels were increased approximately 7-fold in relation to controls
following a 24 hour treatment with PGE2, although this was not significant {p < 0.067)
(figure 6.14). IL-15 had no appreciable effect on IL-10 mRNA levels. The ELISA data
(figure 6.15) was, however, variable and inconsistent with the mRNA levels. There
were no significant differences in IL-10 protein levels relative to controls with either
PGE2 or IL-15 treatment.
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Figure 6.14
The relative IL-10 mRNA expression levels in PB NK cells following a 24 hour




IL-10 release in pg/ml over 24 hours from PB NK cells incubated with IL-15, PGE2 and


















The results detailed in this chapter have shown the ability of IL-15 to stimulate a
significant rise in IFN-y mRNA levels in uNK cells in vitro compared with PGE2-treated
uNK cells. In addition, IL-15 treatment gave rise to a significant increase in CD40L
mRNA levels in comparison to controls and equivalent PGE2-treated cultures. IL-15
had no effect on the EP2 receptor expression levels. However, IL-15 induced a
significant rise in the EP4 receptor mRNA levels relative to controls and uNK cultures
treated with PGE2. PGE2 stimulated a significant rise in IL-10 mRNA levels in uNK
cells compared with controls and the same trend was apparent when IL-10 secretion was
assayed although due to variability of IL-10 levels secreted, this was not significant. IL-
15 had no effect on IL-10 mRNA expression. In the PB NK cell cultures, PGE2
appeared to be having a stimulatory effect on IL-10 mRNA levels and in all cultures
PGE2 stimulated a rise in IL-10 expression. However, due to the variability between
samples this was not significant.
The preparations of separated uNK cells were on average 75% CD56 positive. The
remaining 25% of the cells were not identified. It is unlikely that they are ESCs because
they are adherent and the cells cultured were non-adherent. The other possibilty is that
they are macrophages since these immune cells constitute approximately 20% of the
decidual leukocyte population (Loke et al., 1995). These cells may be contributing to
some extent to the results attained in this chapter since they are a potential source of
IFN-y (Gessani and Belardelli, 1998). This should be taken into account when
considering the results although it has been confirmed that the predominant cell in the
cultures is the uNK cell. The viability of the cultured cells was not examined and it may
be that some of these cells may have been dead. Culture time was kept to a minimum of
only 24 hours and evidence of alterations in cytokine production after different
treatments implies the presence of living cells. However, in future studies it may be
important to confimi the viabiltiy of the cells.
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The role of uNK cells in reproductive functions has been proposed and explored in
several review papers and have been implicated in decidualisation, implantation and
menstruation (King et al., 1990; King, 2000; Loke et al., 2000; Croy et al., 2002).
Animal studies have demonstrated that mice lacking uNK cells are fertile and become
pregnant without complications (Greenwood et al., 2000; Miyazaki et al., 2002). They
do, however, experience defective decidualisation and it is possible that this would be of
greater consequence in humans where decidualisation is a pre-requisite for successful
embryo implantation. Additionally, inadequate conversion of the decidual vessels was
observed in these mice. One strain of uNK cell-deficient mice, tge26, exhibit reduced
placental size and the offspring have reduced birth weight (Greenwood et al., 2000).
The deficient decidualisation and reduced placental growth could potentially have
effects on fetal programming and thus lead to systemic effects later in life as with
increased cardiovascular risk factors in adults with dysfunctional growth in utero
(Barker, 1997a). NK cells have been postulated to have importance in early pregnancy
maintenance in humans. High activity and raised levels of PB NK cells are associated
with recurrent spontaneous abortion (RSA) of an unknown aetiology (Ntrivalas et al.,
2001; Yamada et al, 2001). When women with received massive intravenous
immunoglobulin (MlVIg) treatment, a decrease in activity and number of CD56+ PB NK
cells was observed followed by successful pregnancies (Morikawa et al., 2001). In the
uterus, a significant rise in CD56 positive cells is apparent in women suffering from
RSA (Quenby et al., 1999) suggesting raised levels are either detrimental to early
pregnancy or a failed attempt to maintain pregnancy. In contrast, lowered cytotoxicity
of PB and uNK cells has also been implicated in endometriosis as discussed in
Somigliana et al 1999 (Somigliana et al., 1999). The conclusions drawn from these
studies should, however, be viewed with caution. The uNK cells represent a distinct
sub-class of NK cells and whether peripheral NK cells have any influence on uNK cells
and pregnancy outcomes has yet to be established. In other studies the number of uNK
cells was assessed in decidua following spontaneous miscarriage in comparison to
normal decidua (Vassiliadou and Bulmer, 1996; Kodama et al., 1998). Both studies
281
reported a rise in uNK cells in the miscarriage decidua versus controls although these
results may actually represent post-miscarriage inflammatory alterations.
PGE2 has been proposed to inhibit the anti-trophoblastic action of decidual leukocytes
via inhibition of the IL-2 receptor (Parhar et al., 1989). In studies on mice NK cells
activated with IL-2, PGE2 supplementation decreased their lytic activity, prevented
proliferation and increased the size and granularity of the cells (Linnemeyer et al.,
1993). They proposed that the PGE2 could be differentiating NK cells at the
implantation site via the same mechanism and would allow successful implantation. The
results in this chapter have shown the ability of PGE2 to increase IL-10 levels in uNK
cells in vitro. PGE2 has been implicated in inhibition of IL-15-mediated IFN-y
production in human PB NK cells via the common y-chain of the IL-15 receptor. PGE2
also acted to decrease the cytotoxicity of IL-15 activated NK cells (Joshi et al., 2001).
The results from this study and in this chapter suggest that PGE2 is having the effect of
inhibiting the Th-1 response and favouring the Th-2 pathway. In a study of patients
undergoing IVF, serum IL-10 levels were raised in the period following successful
implantation, thus implying IL-10 in sustaining normal pregnancy (Wu et al., 2001).
However, the simplistic theory that Th-1 cytokines are detrimental to pregnancy and that
a Th-2 response is critical to pregnancy maintenance (Wegmann et al., 1993) has been
questioned and it appears to be far more complex. Work on mice has demonstrated that
IL-10 and IL-4 from either maternal or feto-placental sources are not essential to
pregnancies as was previously thought (Svensson et al., 2001). However, this study did
not examine if there were any compromising effects on fetal and post-natal development
but does suggest that the classical Th-l/Th-2 hypothesis is too basic. It is also possible
that other cytokines may be compensating for the deficiency in IL-4 and IL-10 which
further complicates the situation. In a detailed study the immuno-expression of a wide
range of cytokines was assessed in the uterus, within the peri-implantation embryo and
in decidual and placental tissues in mice (Chaouat et al., 2002). They demonstrated that
Th-1 cytokines, such as IL-12, are present at the implantation site in normal pregnancies.
If a similar finding is confirmed within humans this implies that the Th-l/Th-2 theory is
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an over-simplification and it is probable that the situation is complex with fine-tuning
necessary.
The results in this chapter noted variability in the levels of IL-10 secreted from the uNK
cells. Previously, uNK cells have been demonstrated to express both IL-10 and the IL-
10 receptor mRNA. In addition, the proinflammatory cytokines, IL-2 and IL-12, were
shown to increase IL-10 production (Vigano et al., 2001). In a study of IL-10 and IFN-y
levels in decidual and blood mononuclear cells from elective first trimester terminations,
levels were found to be variable between patients. However, in women with relatively
high IL-10 levels the IFN-y levels were also raised (Ekerfelt et al., 2002). This implies
that it is the ratio of these two cytokines that is important to the stability of early
pregnancy. In IL-10 -/- mice placental deformities are apparent and it is possible that
IL-10 has a role in modifying placental growth and structure and therefore fetal
programming (Roberts et al., 2003). In women with missed abortions, decreased levels
of IL-10 immunostaining was observed in seven out of ten patients compared with
elective terminations. The levels of CD56+ cells were comparable between the groups
as was IFN-y staining intensity, suggesting the importance of the cytokine profile in
pregnancy maintenance (Plevyak et al., 2002). When post-miscarriage decidua is used
in a study it is important to be aware that inflammatory alterations and necrosis may be
factors affecting the results obtained. Abnormally raised levels of IL-10 can also be
detrimental outside the decidua to normal pregnancy functions. Raised IL-10 levels in
mid-trimester amniotic fluid are associated with small for gestational age (SGA) babies
in first pregnancies (Heybome et al., 1994).
The results in chapter 5 have illustrated the expression of IFN-y mRNA across the
menstrual cycle. Immunohistological studies have localised IFN-y to the lymphoid
aggregates (Stewart et al., 1992a) although this is in contrast to the results of another
study that identifies polymorphonuclear neutrophils and intraepithelial lymphocytes as
the source of IFN-y (Yeaman et al., 1998). First trimester decidual NK cells have been
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shown to express IFN-y in addition to LIF and GMCSF (Jokhi et al, 1994a). In this
chapter the Th-1 cytokine, IL-15, has been shown to raise significantly uNK cell IFN-y
mRNA levels. In chapter 5 IFN-y was shown to be essential to IL-15 secretion by ESCs.
This offers a potential mechanism by which ESCs and uNK cells may be functionally
linked (figure 6.16). Regulation of IFN-y levels appears to be critical to normal
endometrial function since women with endometriosis express raised levels of this
cytokine compared with healthy controls (Klein et al., 1993). Mice studies offer a
further potential role for IFN-y in uterine function. IFN-y -/- and IFN-y receptor -/- mice
show abnormal granulation of uNK cells at the implantation site and abnormal decidual
transformation of the decidual arteries (Ashkar et al., 1999). This has been shown to be
uNK-derived IFN-y by further experiments involving bone marrow grafts (Ashkar et al.,
2000).
The expression of CD40L has not been studied with regard to uNK cells previously. In
this chapter CD40L levels were raised by IL-15 treatment. ESCs express CD40, as
shown by immunohistochemistry and cell culture experiments (King et al., 2001). ESCs
and uNK cells are believed to exist in close proximity to one another (King, 2000) and
this provides the contact needed for the ligand to bind CD40 on ESCs providing another
link between these distinct cell types.
In summary, the cytokine IL-15 is able to raise expression of CD40L mRNA and also
IFN-y levels in uNK cells thus providing possible links with ESC function. In contrast,
PGE2 is acting to raise IL-10 expression, thus maintaining the Th-l/Th-2 balance
essential for a normal pregnancy. It is possible that PGE2 is acting via its EP2 receptor
upon rising levels following IL-15 stimulation but this is yet to be confirmed.
284
Figure 6.16
Illustration of how the actions of IL-15 and PGE2 may be modifying uNK cell function.
PGE2 appears to have immunosuppressive actions via raising IL-10 levels and inhibiting
the IL-15 receptor. IL-15 is stimulating IFN-y and CD40L expression and in turn, these




7.1 Synopsis of Results
These studies have demonstrated some of the unexpected changes that are occurring in
ESCs during decidualisation. These may represent important modulations that are
critical in regulating both the progression of decidualisation and the functions of other
endometrial cell types such as the uNK cell. Here, the cytokine IL-15 has been linked to
both ESC decidualisation and to regulating the functions of uNK cells with regard to
their pro-inflammatory pathway response. In addition, the actions of PGE2 and cAMP
on aspects of the prostaglandin cascade have been analysed. The direct influence of
PGE2 on uNK cells has also been studied.
The effects of cAMP at various stages of the prostaglandin pathway during
decidualisation in ESCs have been demonstrated here. mRNA levels of both COX
enzymes are raised in response to cAMP, implying that this may result in an increase in
PG production in these cells. PGE2 has been shown to have a role in decidualisation
(Frank et al., 1994) and this present study has also shown that cAMP induces a rise in
the expression of the EP2 receptor which would provide a potential target for PGE2 to act
on, to allow progression of decidualisation. However, this rise in cAMP also raises
mRNA levels of the phosphodiesterase enzymes, PDE3a and PDE4b, which are
responsible for the breakdown of cAMP. This may be a self-regulating mechanism to
prevent excessive levels of intracellular cAMP building up. In addition, relaxin may
also target the pathway at the phosphodiesterase level to inhibit the action of
phosphodiesterases and prevent cAMP destruction (Bartsch et al., 2001). One of the
major products of this pathway, PGE2, has been shown herein to raise both its own
receptor, EP4, and IL-10 mRNA levels in uNK cells and may be important in
maintaining the balance of Th-1 and Th-2 cytokine levels in the endometrium with
regard to a successful pregnancy (Wegmann et al., 1993). However, this production of
IL-10 is unlikely to effect the production of IFN-y by uNK cells (Vigano et al., 2001).
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As detailed previously, IL-15 mRNA levels increase in human ESC cultures after IFN-y
and PGE2 treatment. In addition, the presence of IFN-y was found to be essential to
induce secretion of IL-15 protein from these cells in the presence of decidualising
stimuli. The results of this study implicate both cAMP and IFN-y as having central roles
in IL-15 production. IL-15 is tightly regulated at the post-transcriptional level (Tagaya
et al., 1996) and this study has demonstrated that different factors are required to allow
the optimal increase in mRNA expression in addition to facilitation of protein release,
thus representing divergent and complex control mechanisms. It has previously been
hypothesised that cells retain a pool of translationally inactive IL-15 mRNA to allow a
rapid and effective response to stimuli when required to activate NK cells (Tagaya et al.,
1996). This has implications in both an immune response in the endometrium and for
the reproductive functions of uNK cells.
It has been shown that IL-15 can induce a rise in both IFN-y and CD40L mRNA in uNK
cells in vitro. Additionally, PGE2 acts on uNK cells to raise mRNA levels of the EP4
receptor and IL-10. These results will be discussed in more detail in section 7.3 below.
IL-15 mRNA in ESCs rises in concordance with increasing levels of the decidualisation
markers, prolactin and IGFBP-1, during ESC decidualisation in vitro. In a simulation of
early pregnancy, IL-15 protein levels in vivo were found to be raised in relation to the
luteal phase in both the glandular and stromal compartments. This is not unsurprising in
the stroma since it will have been transformed into its decidualised state. However, the
increase of IL-15 immunostaining intensity in the epithelial cells is less accountable.
This study examined two human epithelial cell lines and confirmed that the factors
regulating IL-15 mRNA expression in the primary ESCs were not the same. This
distinct control over IL-15 in the two separate endometrial compartments may suggest
separate functions of this cytokine. The rise in IL-15 in the simulation of early
pregnancy group implies progesterone-directed control over its expression. If this is the
case, then it is likely that the ESC, due to its persistent PR-A expression (Wang et al.,
1998), will provide this link between progesterone and the epithelial IL-15 production.
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7.2 The Relevance of IL-15 in Normal Endometrial Function
Endometriosis affects around 10% of women of reproductive age presenting with the
symptoms of pelvic pain and infertility (Giudice et al., 1998). Using a microarray it has
been demonstrated that endometrium from women with endometriosis have lower levels
of IL-15 compared with control endometrium (Kao et al., 2003). This evidence
implicates IL-15 in having an impact on fertility beyond the confinements of
decidualisation. In contrast, elevated levels of uterine IL-15 expression are present in
women suffering from recurrent spontaneous abortion compared with healthy controls
(Chegini et al., 2002). It appears that the balance of IL-15 levels within the
endometrium can be critical to uterine normal function and early pregnancy
maintenance. The significance of IL-15 in the secretory phase is implicated by raised
levels of this cytokine (Carson et al., 2002), and the a chain of the IL-15 receptor, in the
mid secretory phase compared with the early secretory and proliferative phases and
specifically during the implantation window (Kao et al., 2002).
IL-15 levels of mRNA expression have been demonstrated here to rise alongside
decidualisation of ESCs in culture. The implications of this may be of particular
relevance to uNK cell functions since they proliferate upon IL-15 treatment in vitro
(Verma et al., 2000) and mice lacking the IL-2 receptor y chain, utilised by IL-15, had
no uNK cells (Miyazaki et al., 2002). Since these mutated mice that lack uNK cells
exhibit abnormal decidualisation and blood vessel transformation, it is possible that uNK
cells have significant roles in implantation and placentation in humans. The mRNA
level of IL-15 has been shown in chapter 5 to be raised in the mid secretory phase and
this is likely to correlate with the necessity to regulate the functions of uNK cells at this
critical stage in the reproductive cycle.
There are conflicting reports as to whether hCG receptors are present within the human
endometrium. One study has demonstrated that treatment of ESCs in vitro with hCG is
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unable to induce decidualisation (Kasahara et al., 2001) whereas other studies contradict
this, demonstrating a raise in intracellular cAMP levels (Chattel]ee et al., 1997) and
PGE2 levels (Han et al., 1999) with hCG treatment. For hCG to be exerting these effects
a functional receptor must be present on ESCs and immunohistochemistry has located
hCG/LH receptors in the human endometrium in both glands and stroma with a rise
being apparent in the secretory phase (Reshef et al., 1990). Systemic hCG may
therefore exert effects on the endometrium and this knowledge could have relevance to
endometrial receptivity in women taking hCG as a fertility treatment to hyperstimulate
the ovary (Fanchin et al., 2001). The circulating hCG secreted by the trophoblast will
potentially be having effects on the endometrium during the early stages of pregnancy.
In vivo IL-15 immunostaining increases in women treated with hCG in a controlled
simulation of early pregnancy study described herein. A rise in IL-15 levels in both the
glandular and stromal compartments were observed. hCG is therefore likely to be
producing these effects via the corpus luteum and possibly by direct action on the
endometrial stroma. The effects of hCG on the corpus luteum will be to maintain
progesterone production and stimulate the release of relaxin. These potential
interactions are summarised in figure 7.1 below.
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Figure 7.1
The potential mechanisms by which hCG may be influencing ESC decidualisation and
IL-15 expression. hCG acts on the corpus luteum stimulating the secretion of
progesterone (P) and relaxin (R) and may additionally be acting directly on the stromal
cells. Relaxin is also produced within the endometrium by ESCs and by glandular
epithelial cells (EPC). Relaxin may be having paracrine and autocrine effects on the
ESCs alongside the action of progesterone inducing decidualisation in these cells. Upon
decidualisation both prolactin and IL-15 levels increase in the ESCs thus forming
decidualised stromal cells (DSC). In addition to the details of this figure, there are other
factors that will be influencing decidualisation.
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7.3 The Relationship Between the ESC and the uNK Cell
In a study of uNK cells it has been demonstrated here that IL-15 stimulates a rise in IFN-
y and CD40L mRNA levels. As discussed above, IFN-y is able to trigger IL-15 release
from ESCs and this may be a mechanism by which feedback occurs to ESCs. IFN-y has
been shown to inhibit activity of the prolactin promoter, therefore antagonising cAMP-
mediated prolactin mRNA and protein in differentiating ESCs (Christian et al., 2001).
Since IL-15 production appears to be linked to decidualisation and thus prolactin
production, IFN-y may be providing additional regulation of this pathway at this level.
Previous studies have shown that CD40 ligation on human cortical tubular epithelial
cells (Weiler et al., 2001) and peritoneal mesothelial cells (Basok et al., 2001) stimulates
IL-15 production. In this study the rising expression of CD40L in uNK cells upon IL-15
treatment may therefore also be contributing to ESC IL-15 production via direct cell-cell
contact. It was also shown that IFN-y and TNF-a can induce CD40 mRNA and protein
expression in peritoneal mesothelial cells which would provide a ligation target for the
CD40L. Figure 7.2 summarises this and hypothesises how these may be linked. Within
the human endometrium immunoexpression of CD40 has been located to the
perivascular and stromal cells (King et al., 2001). The stromal cells are therefore targets
for CD40L which the present study has shown to be a product of uNK cells in vitro. The
role of the CD40-CD40L system in provision of a functional connection between
resident endometrial cells and invading immune cells has been proposed (King et al.,
2001). They demonstrated that activation of human ESCs in culture with IFN-y plus
CD40L increased the secretion of IL-6, IL-8 and MCP-1. The results of the current
study propose that the CD40-CD40L system may be a link between ESCs and uNK cells
in the human endometrium.
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Figure 7.2
A summary of the hypothesised interactions between ESCs and uNK cells and how
control over the decidualisation pathway may be modified. The relevant receptors for
the separate ligands are designated by (R). The blue arrows illustrate the potential
downstream effects of IL-15 produced by the ESCs on uNK cells. The orange arrows
represent the possible feedback mechanisms from uNK cells to ESCs in response to IL-
15. Control mechanisms to regulate this pathway include PGE2 and the arrows coloured
green represent the potential actions of PGE2. IFN-y may be modulating ESC functions
in a number of ways: by facilitating the secretion of IL-15 protein, inhibition of prolactin
expression and therefore exerting control over decidualisation and by controlling uNK
cell and ESC interactions via the CD40-CD40L system. CD40 may be having effects on
IL-15 levels either via decidualisation or by a separate pathway to induce a direct
influence over IL-15 production. Prolactin receptors have been demonstrated on uNK
cells (Gubbay et al., 2002) but the effects of prolactin on these cells has not yet been
clarified.
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^ Indicates facilitation of CD40L
binding CD40 via IFN-y
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7.4 Suggestions For Future Study
1. The current study has concentrated on IL-15 production in the ESC with regard
to decidualisation. What is apparent is that IL-15 is also produced by the
endometrial epithelial cells and the results here demonstrated a rise in IL-15
immunoexpression in conjunction with a simulation of early pregnancy. How
IL-15 is being regulated is these epithelial cells and its function needs to be
addressed to fully understand the impact of IL-15 on normal and pathological
endometrial function. A dysregulation of IL-15 levels has been reported in
pathological states such as endometriosis (Kao et al., 2002) and women suffering
from recurrent spontaneous abortion (Chegini et al., 2002) and therefore the
exact regulation of IL-15 in both stromal and epithelial compartments are likely
to be critical to fertility. Experiments using primary endometrial epithelial cells
should be conducted with treatments as described in chapter 5 to assess the
regulation of IL-15 using ELISA and Q RT-PCR.
2. Prolactin is another potential regulator of uNK cell function and provides another
connection to imply the intimate link between ESCs and uNK cells and their
functions. The effects of prolactin on uNK cell cytokine production would be an
interesting area to explore.
3. CD40L mRNA was shown to be both expressed by uNK cells and to be
upregulated by IL-15 treatment in vitro. The implications of this on IL-15
production by ESCs should be explored in conjunction with IFN-y to fully
establish whether ESCs and uNK cells are linked via this mechanism. In
particular, cultures of ESCs should be treated with IFN-y and CD40L alone and
in combination. The levels of CD40 mRNA expression should be assessed
following these treatments by Q RT-PCR and protein production could be
confirmed by immunohistochemistry. In addition, IL-15 levels and prolactin
levels should also be examined. To further determine the CD40L expression by
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uNK cells the cells could be analysed by FACS after being treated with IL-15
and PGE2 as described in chapter 6. This would provide a further means to
measure changes in CD40L expression on the uNK cells.
4. This study has begun to address how the PG pathway can be modified by cAMP.
Exploration of these modifications will aid our understanding of decidualisation
and its regulation at the intracellular level. It would be of value to explore
further how PGE2 secretion is regulated, possibly via the MRP4 transmembrane
transporter. The secretion of PGE2 by ESC cultures could be confirmed by
ELISA and the levels of MRP4 expression examined by FACS and Q RT-PCR to
determine whether a correlation is present.
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Abstract A greater knowledge of IL-15 regulation within human endometrium is important in understanding key
reproductive events and uterine Natural Killer cell function. In the present study, expression of IL-15 mRNA was shown to
be up-regulated by both PGE2 and IFN-y in cultures of human endometrial stromal cells (ESC). Release of IL-15 protein
was also shown to be under the control of PGE2 and IFN-y using an enzyme-linked immunosorbent assay for IL-15. In
addition, 8-Bromo cAMP was able to increase IL-15 release from ESCs (P < 0.0005) implying the actions of PGE2 may be
via this second messenger. Addition of a progestin appeared to enhance these effects. Real-time quantitative PCR has
demonstrated an up-regulation in IL-15 mRNA expression in the late secretory phase of the menstrual cycle (P < 0.005) and
a progressive rise in IFN-y expression throughout the secretory phase and into first trimester decidua. These results suggest
that IL-15 regulation in the human endometrium is complex and that hormonal control may be indirect.
Cellular interaction in the uterus is critical in
reproductive events, such as implantation, menstruation
and placental formation. Natural Killer (NK) cells of the
CD56bri6hl CD 16" phenotype are a major leukocyte
population located in endometrium and first trimester
decidua. Implied involvement of uterine NK cells at the
time of endometrial decidualisation and in endometrial
breakdown at menstruation (1) suggests a dynamic role for
this cell type in uterine physiology. IL-15 has also been
shown to be a potent stimulator of uterine NK cell
proliferation (2). CD56b"8hl NK cells produce
immunoregulatory cytokines and chemokines such as
GMCSF, IL-10, IL-13 and INF-y. IL-15 is reported to be
essential for type 2 cytokine production by these cells (3).
Immunohistochemistry has confirmed the localisation
of IL-15 in human endometrium both perivascularly in
secretory phase stromal cells and in glandular epithelial
cells during the proliferative phase (4). Immunoreactivity
for IL-15 persists in the stromal compartment in first
trimester decidua (4). Previous studies have demonstrated
the ability of progesterone to increase IL-15 expression and
release by both endometrial stromal cells (ESCs) and
decidual cells (4, 5) and a relationship between IL-15 and
stromal cell decidualisation has been proposed (6). A
combination of Medroxy progesterone acetate (MPA), a
synthetic progestin, and the second messenger cAMP, has
been shown to be an effective inducer of the decidualised
phenotype (7, 8). This second messenger is involved in
PGE2 signal transduction through the EP2 and EP4
receptors (9) and PGE2 causes differentiation of human
endometrium (10).
Studies in mice show that IFN-y is not only produced
by uterine granular lymphocytes and is necessary for their
development, but also is essential for appropriate blood
vessel growth at implantation (11).
Received 12/04/01. Accepted 02/05/02.
In the present study the control of IL-15 expression and
secretion by IFN-y and PGE2 in human ESCs is examined
and expression of IL-15 and IFN-y across the menstrual
cycle determined using real-time quantitative PCR.
Materials and Methods
Tissue collection
Human endometrial specimens were collected from
women of reproductive age (n=34) undergoing
gynaecological procedures for benign indications. All
women had regular menstrual cycles between 25-35 days
and had not taken hormonal treatment within the 3 months
prior to surgery. Specimens were dated according to the
patient's last menstrual period (LMP) and were consistent
with histological examination and circulating sex steroid
concentrations.
Decidual (n=5) and trophoblast (n=4) specimens were
obtained from women who had undergone surgical
termination by vacuum aspiration, described previously
(12), during the first trimester of pregnancy. The
endometrial tissue was collected in sterile Roswell Park
Memorial Institute (RPMI) 1640 medium (Sigma, Poole,
Dorset, UK) and divided, whilst the decidual tissue was
processed for messenger RNA (mRNA) extraction only: (i)
homogenisation in tri-reagent to allow mRNA extraction;
(ii) fixation in 10% neutral buffered formalin (NBF)
overnight at 4°C followed by storage in 70% ethanol
preceding wax embedding; and (iii) separation of cell types
and culturing the endometrial stromal cells (ESCs).
Informed patient consent was obtained prior to tissue
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Cell culture
Endometrial specimens (n= 11) were separated into
epithelial and stromal cell populations by sedimentation.
Specimens were washed in phosphate buffered saline and
digested in collagenase for 80m at 37°C. An 18 gague
needle was used to aid tissue breakdown. The cells were
pelleted by ccntrifugation and rc-suspendcd in 12ml RPMI
1640 and left for 5min to settle. The top 10ml were
removed as the population of ESCs. Immunocytochemistry
for vimentin and cytokeratin had been undertaken to verify
the purity of cells separated by this technique. The ESCs
were further cultured in RPMI 1640 medium (Sigma)
supplemented with 10% fetal calf serum (FCS) (Mycoplex;
PAA, Teddington, UK), penicillin (50 pg/ml; Sigma),
streptomycin (50 pg/ml; Sigma) and gentamycin (5 pg/ml;
Sigma). Cells were cultured in 75cm3 culture flasks
(Corning Incorporated, Corning, NY) for a minimum
period of 5 days and allowed to reach confluence in the
presence of estradiol (10"7 M), MPA (10"6 M) and basic
fibroblast growth factor (bFGF) (5ng/ml).
Culture treatments and IL-I5 ELISA
Once passaged, cells were seeded at a concentration of
1.4xl05 cells/ml in 12-well plates (Corning Inc., Costar®)
and incubated for 24h to allow cell adherence. Two
separate ESC culture experiments were designed. In the
first, ESC cultures (n=4) were divided into four treatment
groups: (i) Control; (ii) PGE2 (10"6M); (iii) IFN-y
(25ng/ml); (iv) PGE2+IFN-y. Each well contained RPMI
1640 medium supplemented with 2% FCS and
indomethacin (5pM). Extraction of mRNA was carried out
at 4, 24, 48 and 72h and cDNA produced by reverse
transcription. In the second culture experiment cells were
divided into 7 treatment groups, each in quadruplicate
wells: (i) Control; (ii) Control (without IFN-y); (iii) MPA
(10"6M); (iv) 8-Bromo cAMP (O.lmg/ml) (Sigma); (v)
MPA+8-Bromo cAMP; (vi) PGE2; (vii) MPA+ PGE2. All
wells contained RPMI 1640 medium supplemented with
2% FCS and estradiol (10'7M). After 24h, IFN-y (25ng/ml)
was added to all groups except (ii) and medium was
harvested after a further 48h and stored at -20°C. Fresh
medium and treatments were provided as before and again
collected after 3 days of treatment. All medium samples
were assayed for IL-15 in duplicate using a commercial kit
(R&D Systems, Minneapolis, MN). The IL-15 ELISA
inter-assay variation was calculated as a relative standard
deviation and found to be 9.86% whilst intra-assay
variation was 6.68%.
Real Time Quantitative PCR (RT-Q-PCR)
Real-time quantitative PCR was used to examine IL-15
and IFN-y expression in human endometrial samples
collected across the menstrual cycle, in first trimester
decidua and in trophoblast (IL-15 only). IL-15 expression
in cultured ESCs was also measured. Primers and probes
for IL-15 and IFN-y were designed using the PRIMER
express program (PE Biosystem). Primers and probe for
IL-15 were initially optimised and the linearity of the
results validated via serial dilution of a cDNA pool.
Calculation of the within assay variation was measured by
amplification of six cDNA replicates. The PCR reactions
were run on AB1 Prism 7700 in duplicate and the same
positive control was present in all runs to allow
comparison. To determine genomic DNA contamination
the 3-actin signal was measured in all mRNA samples used
in detection of IL-15/IFN-y across the cycle and in
representative control groups in the culture experiments.
Samples were excluded from analysis if their (3-actin signal
fell below the arbitrary level of 27 cycles. The variability
in the quantity of total mRNA in samples was measured by
determining the relative standard deviation between 18-S
values in the PCR results. This was found to be 1.77% in a
single run, selected at random, containing 34 samples.
Statistical analysis
Analysis of Variance (ANOVA; Statview 3.0) was
conducted to determine significant difference and Fisher's
protected least squares differences (PLSD) test used to
allocate individual differences.
Results
IL-15 expression by cultured ESCs
IL-15 expression increased across the time course from
0 to 72h with both PGE2 and IFN-y stimulating an increase
in expression (figure 1). Control levels remained low
across all time points. When compared to controls the
IFN-y-treated group increased IL-15 mRNA expression at
4, 24 and 72h (P < 0.05). The same was the case with the
IFN-y+PGE2-treated group at all time points (P < 0.05). At
72h the PGE2 treatment increased IL-15 mRNA expression
above the control group {P < 0.005).
Figure 1. Time course of mRNA IL-15 expression
measured by RT-Q-PCR in cultured ESCs (n=4).
IL-15 release from ESCs
Addition of 8-Bromo cAMP created a significant rise
(P < 0.01) in IL-15 release from ESCs after 3 days and
release rose further after 6 days in culture (figure 2).
Addition of MPA appeared to augment this response on
both days, although not significantly. Cells cultured in
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the presence of PGE2 released higher levels of IL-15
protein into the medium compared to controls on days 3
and 6 but this only became significant when PGE2 was
added in combination with MPA (P < 0.05). MPA alone
had no effect on IL-15 release compared to controls. IFN-y
alone stimulated a moderate release of IL-15 protein.
Figure 2. IL-15 protein release from IFN-y treated human
ESCs after 3 and 6 days of treatment. (n=7) * Depicts
group with no IFN-y stimulation. Same letters denote
significant difference. "•d P < 0.01;b'e P < 0.0002; c'r'6 P
<0.05.
IL-15 expression across the cycle
IL-15 mRNA was detected in all stages of the menstrual
cycle and in first trimester decidua but was not present in
trophoblast (figure 3). Levels were lowest in the
proliferative phase of the cycle. A progressive increase in
IL-15 mRNA expression from the proliferative phase to
early and mid secretory phases was observed with a
dramatic rise in the late secretory phase expressing
significantly more than each of the cycle phases (P <
0.005). Levels of expression were raised in both menstrual
and decidual tissue compared to proliferative tissue
although not significantly.
6 5 5 5 5 5 4
Figure 3. Relative amounts of IL-15 mRNA in
proliferative (P), early secretory (ES), mid secretory (MS)
and late secretory (LS) endometrium, first trimester
decidua (D) and trophoblast (T). a P < 0.005.
IFN-y expression across the cycle
Expression of IFN-y mRNA was detected across the
menstrual cycle and in first trimester decidua (Figure 4).
Highest levels of expression were found in decidual tissue
with a significant elevation in expression (P <0.05) when
compared to the early secretory phase.
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Figure 4. Relative amounts of IFN-y mRNA in
proliferative (P), early secretory (ES), mid secretory (MS)
and menstrual (M) endometrium and first trimester decidua
(D). a P < 0.05.
Discussion
The present study demonstrated that PGE2 and 8-Bromo
cAMP were able to increase IL-15 release in vitro in the
presence of IFN-y and these responses appeared to be
enhanced by addition of a progestin. IFN-y was essential
for this effect and alone could stimulate a small level of IL-
15 release from ESCs. However, a progestin alone was not
capable of increasing IL-15 protein release from ESCs in
vitro. Stimulation of ESCs with PGE2 or IFN-y separately
or in combination, led to an increase in IL-15 mRNA
expression in vitro. In addition, expression of IL-15
mRNA in first trimester decidua and endometrium across
the menstrual cycle was demonstrated. The late secretory
stages expressed significantly greater levels (P < 0.005) in
comparison to all other cycle phases. Expression of IFN-y
mRNA across the menstrual cycle and in decidua was also
confirmed. Expression in decidua was significantly greater
than that in the early secretory phase (P < 0.05).
The expression of IL-15 in a broad spectrum of tissue
and cell types, including kidney epithelial cells (13),
skeletal muscle (14) and placenta (15) implies that the
functions of IL-15 stretch beyond that of the immune
system. The possible role of IL-15 in uterine physiology
has also recently been explored and the idea of hormonal
control over this cytokine proposed (4, 5). The
involvement of IL-15 in placental establishment has also
been identified (16, 17).
The results of this study suggest that, at the intra¬
cellular signalling level (at least in vitro), cAMP is a key
regulator of IL-15 release from ESCs and that this response
is likely to be linked to the action of IFN-y. The role of
IFN-y in IL-15 release by cells has also been described in
the kidney (13, 18). The presence of IFN-y in human
endometrium is a contentious issue although IFN-y
immunoreactivity in lymphoid aggregates and in cells
dispersed throughout the stroma has been established (19).
In this study we report, quantitative expression of IFN-y
throughout the menstrual cycle and first trimester decidua
and demonstrated a rise in expression in first trimester
decidua by RT-Q-PCR. Uterine NK cells are a potential
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source of IFN-y and are situated both perivascularly and in
close proximity to glands. There is a further infiltration of
uterine NK cells throughout the stroma in the late secretory
phase (20). This pattern of rising uterine NK cell numbers
post-ovulation parallels the 1L-15 expression demonstrated
across the cycle in this study. It has been proposed that IL-
15 is the stimulator of this proliferation (2). These cells arc
believed to undergo apoptosis prior to menstruation.
However, they appear to be "rescued" if pregnancy is
established and full decidual transformation completed thus
implying a link between uterine NK cells and
decidualisation (1).
The present study demonstrated that PGE2 is able to
stimulate IL-15 expression and release by ESCs. PGE2 can
act via the second messenger cAMP and this supports the
present observations (9). The responses of both PGE2 and
8-Bromo cAMP appear to be enhanced by addition of a
progestin. This is in agreement with other studies that have
suggested progesterone is involved in IL-15 regulation in
human endometrium (4, 5). One of the roles of
progesterone in this circumstance may be stimulation of the
EP2 receptor in ESCs (21). Studies using endometrial
explant cultures have compounded evidence for hormonal
control of PGE2. Secretory endometrium released greater
levels of prostaglandins than proliferative endometrium and
from these results an involvement of PGE2 in menstruation
has been proposed (22, 23). Additionally, synergistic
actions between MPA and estradiol plus PGE2 on the
process of in vitro decidualisation have previously been
reported (10). An up-rcgulation of IL-15 mRNA
expression during in vitro decidualisation (6) supports the
link between IL-15 and decidualisation. Previous studies
have demonstrated a central role for cAMP in increasing
prolactin expression, a marker of decidualisation (24, 25).
In conclusion, this study provides evidence of a role for
PGE2 in IL-15 regulation in concert with the actions of
EFN-y and supports the view that IL-15 is closely linked to
decidualisation and uterine NK cell function. A greater
knowledge about stromal and uterine NK cell interactions
in human endometrium will benefit our understanding of
key reproductive processes such as decidualisation,
menstruation, placental formation and the establishment
and maintenance of early pregnancy.
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Abstract
The coordination of events and cellular interactions within the uterus is vital to the
establishment of pregnancy, a process constrained to a narrow window of time within
the ovarian cycle. The transformation of the endometrium into decidua is one such
event and is considered essential to embryo implantation and to the maintenance of
pregnancy. In humans these changes are most dramatic in the stromal compartment and
are influenced by progesterone, secreted by the Corpus Luteum (CL). This hormone is
believed to be the main factor inducing such differentiation in the oestradiol-primed
stroma. However, mediators with the ability to activate the protein kinase A/cAMP
pathway, such as Prostaglandin E2 (PGE2) and relaxin, are potent inducers of
decidualisation when administered alongside progesterone in endometrial stromal cells
(ESCs) in vitro. Uterine Natural Killer (uNK) cells increase in number in secretory
phase endometrial stroma, implying the control of progesterone on their expansion.
However, they lack the nuclear progesterone receptor and growth and differentiation
may depend on interactions with ESCs. uNK cells replicate upon Interleukin-15 (IL-15)
administration in vitro and this cytokine is expressed in the epithelial and stromal cells.
The aims of this research project have been to investigate in vitro decidualisation of
ESCs and regulation of IL-15 and uNK cells in order to extrapolate how ESCs and uNK
cells may interact during the secretory phase and early pregnancy.
The present study has explored the factors involved in decidualisation using primary
human ESC cultures. Quantitative real-time PCR (Q RT-PCR) and Enzyme-linked
Immunoabsorbant Assays (ELISA) have been used to investigate effective in vitro
stimuli of decidualisation. A combination of treatment with a progestin and either 8-
Bromo cAMP or PGE2 was capable of stimulating decidualisation in ESC cultures as
determined by increases in two markers of this process, prolactin and insulin-like growth
factor-binding protein-1 (IGFBP-1). Further analysis has revealed the changes taking
place within the PGE2 pathway in decidualising ESCs, including an upregulation in the
1
EP2 prostaglandin receptor messenger RNA (mRNA) upon treatment with 8-Bromo
cAMP plus a progestin.
The results present here have demonstrated a rise in IL-15 mRNA levels in parallel with
in vitro decidualisation. It appears that both progesterone and the intracellular
messenger, cAMP, are involved in decidualisation and IL-15 expression. IL-15
secretion from the cells is shown to be IFN-y dependent. The expression of IL-15 and
interferon-y (IFN-y) mRNA across the menstrual cycle has been established.
Immunohistochemistry was used to determine IL-15 expression during simulated early
pregnancy compared with normal luteal controls and has shown that secretions of the
CL, including progesterone and/or relaxin, have the ability to increase IL-15 expression
in vivo. Primary cultures of human uNK and peripheral blood NK cells have been used
for studying the T helper 2-type cytokine IL-10 which is believed important for the
support of early pregnancy. In response to PGE2 treatment, uNK cells expressed and
secreted raised levels of IL-10, an anti-inflammatory cytokine.
Further investigation into the interactions between the convergence of the cAMP and
progesterone intracellular pathways and their receptors would be important in clarifying
the exact mechanisms controlling ESC decidualisation and IL-15 regulation. The
interactions between ESCs and uNK cells need to be clarified further to assess the roles
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EDTA ethylenediaminetetracetic acid
EGF epidermal growth factor
ELISA enzyme linked immunoabsorbant assay
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EPm PGE2 receptors 1-4
ER-a/p oestrogen receptor-a/p
ESC endometrial stromal cell
FACS fluorescent activated cell sorter
FAM 6-carboxy-fluorescein
FCS fetal calf serum
FSH follicle stimulating hormone
FITC fluorescein isothiocyanate conjugate
G-CSF granulocyte-colony stimulating factor
GM-CSF granulocyte/macrophage-colony stimulating factor
GPCR G-protein coupled receptor
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IRF-1 interferon regulatory factor-1
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KDR Type 2 receptor of VEGF
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LIF leukaemia inhibitory factor
LMP last menstrual period
LNG-IUS levonorgestrel-releasing intra uterine system
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MHC major histocompatibility complex
MlP-la macrophage inflammatory protein-la
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1.1 The Uterus and the Menstrual Cycle
The uterus has the role of supporting and retaining the fetus throughout pregnancy. The
organ is lined by a glandular tissue layer termed the endometrium and in the non¬
pregnant state the functional layer of the human endometrium undergoes cyclical
regeneration and degeneration. This takes place over a 28 day period and is primarily
determined by the ovarian hormones, oestrogen and progesterone. A progressive and
sequential maturation of the endometrium is essential preparation for implantation of the
blastocyst. There are three major phases, namely menstruation, proliferation and
secretion (figure 1.1). The secretory phase is surprisingly highly regular in length, even
if there is individual variation in proliferative phase length. The functional layer of the
endometrium is shed via the process of menstruation if implantation fails to occur. This
layer is then replenished from the basal endometrial layer and the process begins once
more. The major cyclical changes in response to progesterone and oestrogen have been
described by Noyes et al 1950 (Noyes et al., 1950) (figure 1.2).
1.1.1 The Proliferative Phase
The proliferative phase lasts from day 4 to day 14 of the cycle and is oestrogen
dominated. Oestrogen receptors are present in the glandular and stromal compartments
as are progesterone receptors during the follicular phase (Lessey et al., 1988; Snijders et
al., 1992; Wang et al., 1998). The primary source of oestrogen is the developing
Graaffian follicle. Follicle stimulating hormone (FSH) released from the pituitary gland
stimulates maturation of one or more of these follicles. The oestrogen released
stimulates proliferation of the endometrium and this is reflected by a variety of changes.
New glands form and are straight and tubular in structure and along with the stroma,
regenerate from the residual basal endometrium. The nuclei of the glands become
prominent and increase in mitotic activity. In the compact stromal compartment mitoses
are also abundant. The stroma becomes highly vascularised and the arteries become
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spiral in formation. As the luteinising hormone (LH) surge on day 14 approaches the
glands become pseudo-stratified and tall and columnar in shape.
1.1.2 The Secretory Phase
The secretory phase commences from day 16 to 25 and is progesterone dominated. The
continued release of LH from the pituitary induces the luteinisation of the theca and
granulosa cells of the corpus luteum (CL). The granulosa lutein cells secrete
progesterone, maintaining the secretory transformation of the endometrium.
In the early secretory phase the glands develop subnuclear vacuoles of glycogen and
they become convoluted. The gland mitoses decrease at this point and are absent after
day 18. The glandular glycogen deposits begin to appear on the apical side of the cells
around day 18 of the cycle and continues to increase with maximal secretions being
released around days 20 and 21 before exhausting their stores. The tortuosity of the
glands increases in the mid to late secretory phase. Stromal oedema increases across the
secretory phase, peaking in the mid-section. During the mid to late secretory phase the
stromal cells begin to change both structurally and functionally. This predecidual
change is initially observed around the spiral arterioles before it spreads to other regions
of the stroma. The stromal cells undergo a decidual reaction in preparation for
implantation and progressively forms the decidua during pregnancy. Pinopodes are
expressed on days 19-21 on the apical surface of the luminal uterine epithelium. The
timing of their appearance is progesterone-dependant and they appear around the time of
implantation (Martel et al., 1991; Nikas et al., 1995; Nikas et al., 1997).
In the late secretory phase, an infiltration of leukocytes invades the endometrium.
Although macrophages and lymphocytes accumulate, the major leukocyte cell type in
the secretory phase is the uterine Natural Killer (uNK) cell. These cells remain abundant
in the first trimester ofpregnancy and will be discussed in more detail in section 1.2.2.
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Figure 1.1
Diagrammatic representation of the cyclical nature of degeneration and regeneration of
the functional endometrial layer with the major stages being highlighted. This is based
on the "classic" 28 day cycle in humans.
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Figure 1.2
The changes that take place in the human endometrium across the menstrual cycle based
on the "classic" 28 day model as described by Noyes et al 1950 (Noyes et al., 1950).
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1.1.3 Oestrogen and Progesterone
The co-ordinated actions of the steroid hormones, oestrogen and progesterone, are
pivotal to succinct female reproductive functions. They act throughout the reproductive
tract, including the hypothalamus, pituitary, uterus and ovary. The effects of oestrogen
are not restricted to the reproductive system proving to be crucial in bone remodelling
(Prior, 1990) and is involved in peripheral vasoreactivity (Hashimoto et al, 1995). The
effects of hormones and hormone replacement therapy on vascular function is discussed
by Ganz (Ganz, 2002).
Oestrogens act on the uterus to increase cellular proliferation across the proliferative
phase and also act to prime progesterone receptors (PR) during this phase. The presence
of a functioning PR is crucial to fertility in mice with PR knockouts being infertile
displaying defective ovulation, implantation and stromal cell decidualisation (Conneely
et al., 2002). The actions of oestrogen and progesterone are mediated via their cognate
receptors located intracellularly in the nuclear compartment primarily, and in turn, the
ligand may act to control levels of receptor expression. Thus, the hormones themselves
are capable of modifying the concentration of receptors at the end-organ and this will
partly determine the extent of their actions. Hormone-bound receptors interact to
modulate gene transcription resulting in a function change. There are two types of
oestrogen receptor (ER), ERa (Green et al, 1986) and ERp (Kuiper et al, 1996;
Mosselman et al, 1996), and two isoforms of the progesterone receptor (PR) exist, PR-
A and PR-B (Horwitz et al, 1983; Lessey et al, 1983). PR-A and PR-B arise from
different promoters of the same gene located on chromosome 11 (Clarke et al, 1990;
Kastner et al, 1990). PR-B is identical to PR-A with the exception that it differs in
length by being an additional 164 amino acids in length than PR-A (Horwitz et al,
1983). Upon binding its receptor, progesterone triggers a conformational change and
receptor dimerisation. Heat shock proteins also become dissociated from the receptor in
the binding procedure. A third PR has been identified and termed PR-C and may be able
to alter the transcriptional activity of PR-A and PR-B (Wei et al, 1990; Wei et al,
19
1996). In addition, more recently a fourth novel, truncated PR has been cloned from
human adipose and aortic cDNA libraries and is believed to have a non-genomic action
(Saner et al., 2003). The functional importance of this receptor with context to the
endometrium is currently under investigation.
1.1.3.1 Receptor Cross-talk
Communication also takes place between the oestrogen and progesterone receptors. PRs
are under the dual control of both oestrogen and progesterone. Experiments involving
rat uterine cells demonstrated that when either a progestin or anti-progestin is bound to
either PR-A or -B a resulting inhibition in oestradiol's ability to stimulate ER activity is
reported (Katzenellenbogen, 2000). Exposure of the endometrium to high dose
progestins, as with the Levonorgestrel-releasing intrauterine system (LNG-IUS), down-
regulates the ER and PR-A and PR-B in both the glands and stroma (Critchley et al.,
1998b) implying a dependency of ER levels on progesterone and its receptors.
1.1.3.2 Immunohistochemical Localisation
Immunohistological studies within the human endometrium have described the cyclical
variation of oestrogen (ER) and progesterone receptor (PR) levels in both functional and
basal regions and within the epithelial and stromal compartments (Garcia et al., 1988;
Lessey et al., 1988; Critchley et al., 1993; Snijders et al., 1996; Wang et al., 1998)
(Summarised in table 1.1). They have demonstrated the nuclear locality of both steroid
receptors. PR-A and PR-B are located in the glands and stroma during the proliferative
phase but only the PR-A isoform is present in the functional layer across the secretory
phase and early pregnancy and is localised to the stromal cells (Wang et al., 1998). This
implies that PR-A is responsible for the luteal phase actions of progesterone within the
stroma and in particular on decidualisation. Immunoexpression of ERa increases in the
functional layer across the proliferative phase and reaches a peak in the late proliferative
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endometrium. The ER in the glands is down-regulated in the secretory phase by the
rising progesterone levels. This reduction of ER can be blocked by administration of the
anti-progestin, RU486, when applied early in the secretory phase confirming the role of
progesterone (Maentausta et al., 1993; Cameron et al., 1996). A decline in ERa occurs
in glandular and stromal compartments of the functional layer across the secretory
phase. In situ hybridisation has located the two ER isoforms within the human
endometrium (Matsuzaki et al., 1999). The same expression pattern for ERa was
observed as with the immunohistological studies. ER(3 mRNA was detected in both
glands and stroma with decreased expression in the glandular region in the late secretory
phase functional layer (Critchley et al., 2001a; Lecce et al., 2001). The ERP was also
localised to endothelial cells implying an influence on vascular regulation. In women
with compromised fertility and receiving clomiphene citrate "anti-oestrogen" therapy,
the low pregnancy rates achieved were correlated with low oestrogen receptor
concentrations in the preovulatory endometrium (Ohno et al., 1998).
A study in vitro has shown that during decidualisation the PR-A is more abundant than
PR-B. However, they found a reduction in the PR-A with progression of the
decidualisation process and this reduction was accelerated by addition of a synthetic
progestin (Brosens et al., 1999). In addition, transient transfection of either PR-A or
PR-B caused an inhibition of decidual prolactin (Prl) promoter-reporter construct in
response to cAMP. Following insertion of LNG-IUS both isoforms of the PR are
downregulated in the glands and the stroma (Critchley et al., 1998b) implying regulation
of both isoforms by their ligand. It appears to be PR-A that is essential to uterine and
ovarian reproductive processes, at least in the murine uterus (Conneely et al., 2002).
They discovered that in the chick oviduct PR-A and PR-B are produced by translation at
two distinct AUG signals encoded by a single gene and could therefore selectively ablate
either of these isoforms (Conneely et al., 1987). Mouse knock-outs for PR-A exhibited
infertility, whilst the necessity of the PR-B isoform is restricted to the mammary gland
(Conneely et al., 2002).
21
Proliferative phase Secretory phase
Glands Stroma Glands Stroma
Functional
PR-A+B ++ ++ - ++




ERp ++ ++ ++
Basal
PR-A+B ++ ++ + ++
ERa ++ ++ + +
ERp ++ ++ ++ ++
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Table 1.1
Relative immunostaining intensity for oestrogen and progesterone receptors in the
functional and basal endometrium across the proliferative and secretory phases of the
cycle. Negative immunostaining is represented by (-), positive immunostaining is
represented by (+) or (++) depending on intensity. Adapted from Critchley 2000
(Critchley, 2000).
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Proliferative phase Secretory phase
Glands Stroma Glands Stroma
Functional
PR-A+B ++ ++ - ++
PR-B ++ ++ - -
ERa ++ ++ - -
ERp ++ ++ ++(+) ++
Basal
PR-A+B ++ ++ + ++
ERa ++ ++ + +
ERp ++ ++ ++ ++
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1.1.4 Regulation of Menstruation
If implantation fails to occur, the functional layer of the endometrium is shed by the
process of menstruation in response to declining progesterone levels as a result of CL
demise. The work of Markee 1940 on the rhesus monkey provides much of our present
understanding of the vascular changes occurring during menstruation with the
determination that progesterone and oestrogen are major controlling factors over these
structural changes. It was known that progesterone acts following oestrogen priming
and then is withdrawn in the lead up to menstruation. The effects of these hormonal
changes were studied in endometrial fragments transplanted into the eye of the rhesus
monkey, where changes in the vasculature could be observed (Markee, 1940). Vessels
become coiled across the luteal phase to form the spiral arterioles and upon withdrawal
of progesterone these become vasodilated followed by vasoconstriction (Markee, 1940).
This results in lesions and breakdown of the tissue. The vasoactive products found in
menstrual fluid have been identified as being PGE2 and PGF2a (Lumsden et al., 1983).
Hormones have been implicated in regulating production of these prostaglandins (PG) in
the human endometrium via explant studies (Abel et al., 1980; Abel et al., 1983) and a
more detailed account of their regulation is discussed in section 1.4.1. PGF2a is a
vasoconstrictive agent and has been implicated in the initiation of menstruation (Baird et
al., 1996). During the mid luteal phase prostaglandin dehydrogenase activity (PGDH) is
high relative to the proliferative phase and therefore mediates metabolism of PGE2 and
PGF2a (Casey et al., 1980; Critchley et al., 1998a).
1.1.4.1 Menstruation and Inflammation
The process of menstruation appears to be multi-factorial and in addition to hormonal
control, the process is considered to be an inflammatory event (Finn, 1986; Kelly et al.,
1994). Leukocytes infiltrate into the endometrium in the pre-menstrual phase, in
addition to providing defence against pathogens at this vulnerable time, they are also
likely to be involved directly in tissue breakdown via production of proteases, and
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indirectly by the release of chemokines and cytokines. Infiltration and the roles of these
different cells will be discussed in section 1.2.1. These leukocytes include macrophages,
neutrophils and uNK cells and all lack genomic steroid receptors (Poropatich et al.,
1987; Henderson et al., 2003) and therefore paracrine control over these cells must be
occurring. Neutrophils are expressed across the cycle in very low numbers but rise
dramatically in the immediate premenstrual phase to sites of uterine inflammation
(Noyes et al., 1950; Kamat et al., 1987; Poropatich et al., 1987). An important
chemotaxis stimulus for neutrophils is IL-8 (neutrophil chemotactic factor) (Rampart et
al., 1989; Colditz et al., 1990).
1.1.4.2 Matrix Metalloproteinases (MMPs)
Matrix metalloproteinases (MMPs) are enzymes released by both the invading immune
cells and by the stromal cells. The breakdown of the extracellular matrix has been
attributed to the actions of MMPs (Schatz et al., 1997; Lockwood et al., 1998;
Salamonsen et al., 1999) and their role in menstruation implied by the timing of their
expression within the human endometrium (Rodgers et al., 1993; Hampton et al., 1994;
Rodgers et al., 1994). MMPs are likely to be under progesterone-control since
withdrawal of progesterone in cultures of endometrial stromal cells (ESCs) enhances
proMMP-2 (Irwin et al., 1996) and proMMP-3 (stromelysin-1) production (Schatz et al.,
1994). A culture system of human ESCs was used to mimic the luteal phase and
demonstrated upregulation of MMP-1, -2, -3 and -4 in latent form upon progesterone
withdrawal (Salamonsen et al., 1997). Their tissue inhibitors (TIMPs) were also
analysed and showed no regulation of TIMP-1, -2 and -3 upon withdrawal of
progesterone, thus implicating a greater complexity to MMP regulation beyond that of
being solely progesterone-determined. Leukocytes are another source of MMPs and via
stromal and epithelial interactions, MMP release and action from this source may be
being controlled (Salamonsen et al., 2000).
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1.1.4.3 Vascular Endothelial Growth Factor (VEGF) and Hypoxia
The type 2 receptor for vascular endothelial growth factor (VEGF), KDR, is expressed
only in endometrial endothelial cells until the premenstrual phase when expression is
observed in the superficial stroma (Nayak et al., 2000). VEGF is expressed across the
menstrual cycle (Zhang et al., 1998a) and is upregulated during the menstrual phase via
a.hypoxic stimulus (Sharkey et al., 2000). Hypoxia has been shown to raise VEGF
levels in cultures of human ESCs (Popovici et al., 1999) and the presence of the
response element for the hypoxia inducible factor has been located on the VEGF
promoter (Goldberg et al., 1994). In vitro decidualised ESCs express greater levels of
VEGF compared with controls using Microarray Technology (Popovici et al., 2000).
VEGF has been shown to increase the expression of MMPs (Unemori et al., 1992; Wang
et al., 1998) and may be acting as an additional control on MMP production during the
premenstrual phase (Nayak et al., 2000; Critchley et al., 2001b).
As discussed by Salamonsen et al 1999 menstrual degeneration is focal and not
ubiquitous throughout the endometrium, with the regeneration and repair of the
endometrium beginning to occur 36 hours after the onset of menstruation. During this
repair process no scarring is evident as with normal tissue repair although the exact
mechanisms are not yet understood it may be relevant in understanding pathologies such
as menorrhagia (Salamonsen et al., 1999).
1.1.5 Decidua and Pregnancy
Decidualisation is unique to species that undergo haemochorial placentation and in the
human endometrium is considered an essential pre-requisite for establishment of
pregnancy. The decidua is the transformed endometrium that is morphologically and
functionally distinct. The endometrial cells differentiate and an infiltration of lymphoid
cells occurs. Specific products are secreted by decidual cells, for example prolactin and
IGFBP-1, and their potential functions, with regard to pregnancy, are discussed in
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section 1.3.1.1. With regard to humans it is difficult to assess the direct necessity of
decidualisation to implantation. However, it occurs in every menstrual cycle in advance
of implantation and it may be that products of decidua are involved in this process.
Conditions involving disturbance of stromal differentiation, such as endometriosis and
luteal phase defect (LPD) can result in reduced fertility and menstrual irregularity
(Vanrell et al., 1986; Ronnberg, 1990; Lessey, 2002) and this evidence implicates
decidualisation in being critical to the implantation process. LPD affects 3-4% of
infertile women and can be defined as a lag of greater than 2 days histological
development compared to the cycle day. This condition is believed to be due to either
inadequate action or secretion progesterone, an essential stimulus for decidualisation.
Decidual cells may play significant roles in controlling the extent of trophoblast invasion
(Pijnenborg et al., 1981). If implantation occurs in regions deficient of decidua, due to
scar tissue, over-invasion occurs and conversely if under-invasion occurs the result
could be the development of pre-eclampsia. Recently alpha-2 macroglobulin (a-2M), a
product of endometrial endothelial cells, has been shown to be involved in decidual
regulation of trophoblast invasion in mice (Esadeg et al., 2003).
A 50% pregnancy loss occurs at the time of implantation and therefore it is apparent that
this is a critical time for the endometrium to either continue with decidualisation or to
breakdown by the process of menstruation. Decidual cells are also thought to be
important in preventing uterine bleeding in the peri-implantation phase of the cycle and
have been associated with spontaneous abortion and pre-term birth (Schatz et al., 2001).
Decidualisation initially occurs in the perivascular stromal cells and it may be that these
decidual cells are involved in the control of menstruation (Kelly et al., 2002). This close
association with the blood vessels may allow control over the vasculature and the
decision to stabilise or degenerate. These cells have been shown to produce IL-8
(Critchley et al., 1994) thus stimulating neutophil influx and tissue breakdown via
production of enzymes. The decision of the endometrium to breakdown or to fully
differentiate is likely to be related to secretion of cytokines and other factors during
implantation.
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1.2 The Uterine Immune Environment
1.2.1 Leukocyte Infiltration in the Endometrium
According to the criteria of Noyes et al 1950, there is an infiltration of leukocytes in the
late secretory phase (Noyes et al., 1950) (figure 1.2). The major leukocyte populations
located in human endometrium and decidua are macrophages, T cells, B cells and uNK
cells and the uNK cell numbers alter in a cyclical manner (Loke et al., 1997). The
proliferative phase and early secretory phases have a relatively low abundance of
leukocytes, as demonstrated by immunohistochemical staining with the surface marker,
CD56, with an increase in the late secretory phase and into early pregnancy (Bulmer et
al., 1991). In addition to these CD56 positive leukocytes, an influx of neutrophils
occurs in the perimenstrual period at which point they comprise approximately 6-15% of
total cells, and they are thought to be important in menstruation (Salamonsen et al.,
1999). Eosinophils also rise immediately prior to menstruation and make up around 3-
5% of endometrial cells at this point (Salamonsen et al., 2000). Macrophages show a
small rise in number from the proliferative phase to the secretory phase (Bonatz et al,
1992) although their expression of MHC class II does not appear to vary (Bulmer et al.,
1988). Macrophages are also raised in number in endometrium taken from women 48
hours after controlled progesterone withdrawal compared to decidua from pregnant
women (Critchley et al., 1999). T and B lymphocytes are located in the basal layer in
lymphoid aggregates and do not vary in number across the menstrual cycle (Bulmer et
al., 1991). In addition, T lymphocytes are also located throughout the functional layer in
intra-epithelial locations (Loke et al., 1995). These cells become activated during
pregnancy at the site of large lymphoid cell clusters and it is possible they are acting to
provide constitutive immune defence at this critical time or control trophoblast invasion
(Mincheva-Nilsson et al., 1994).
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How these immune cells are regulated with regard to their recruitment in the human
endometrium has not been fully established. Cells may be migrating from peripheral
blood (Marzusch et al., 1993) or be proliferating within the tissue itself (Klentzeris et
al., 1992). Endometrial chemokines may be responsible for the up-regulation of
monocytes in the secretory phase (Kamat et al., 1987) and high numbers of these cells
are observed around the time of implantation (Bonatz et al, 1992). Chemokines are
chemotactic cytokines that act via G protein-coupled receptors (GPCRs) (Murphy, 1996)
and their roles as chemoattractants for leukocytes will be discussed in this section.
Chemokines consist of four cysteine residues and two disulphide bonds and are split into
four sub-groups according to the separation of the first two cysteines by amino acids: C,
CC, CXC and CXXXC (Zlotnik et al., 2000).
1.2.1.2 Interleukin-8 (IL-8)
In addition to chemotaxis, IL-8 is implicated in angiogenesis (Koch et al., 1992) and
mitogensis of epidermal cells (Tuschil et al., 1992). In the human uterus, IL-8 has been
located to the perivascular cells in the late secretory phase and first trimester decidua
(Critchley et al., 1994; Critchley et al., 1996; Critchley et al., 1999; Milne et al., 1999).
It is also present in choriodecidual cells (Kelly et al., 1992) and in amniotic fluid
(Laham et al., 1993). In endometriotic tissue it fails to vary with the menstrual cycle
implicating persistent recruitment of leukocytes in this pathological tissue that may be
under IL-8 control (Akoum et al., 2001). Cultures of human ESCs and epithelial cells
have demonstrated that IL-8 production can be regulated by IL-la and TNFa (Arid et
al., 1993). Cell surface peptidases such as aminopeptidase N (APN) are expressed in
human endometrium and their regulation of growth factors, peptide hormones and
growth factors has been suggested previously (Imai et al., 1992; Imai et al., 1996). It
has been proposed that IL-8 levels in vivo may be controlled via APN (Seli et al., 2001).
Progesterone is thought to be a main regulator of IL-8 expression. In human
endometrial explant studies, progesterone acted to inhibit IL-8 secretion (Kelly et al.,
1994). This is in agreement with in vivo data that demonstrates an increase in IL-8
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immunostaining in human endometrium 48 hours after progesterone withdrawal in a
study designed to mimic the late secretory phase (Critchley et al., 1999). This
implicates IL-8 for a role in menstruation but it has also been proposed as a cervical
ripening agent (Kelly et al., 1992). IL-8 is able to synergise with PGE2 to recruit
neutrophils (Rampart et al., 1989; Colditz et al., 1990) which in turn aid the breakdown
of collagen therefore softening the cervix at labour (Junqueira et al., 1980).
1.2.1.3 Monocyte Chemotatic Protein-1 (MCP-1)
Monocyte chemotactic protein-1 (MCP-1) is an example of a CC chemokine and is a
product of an array of cell types including fibroblasts (Yoshimura et al., 1990),
endothelial cells (Sica et al., 1990) and monocytes (Yoshimura et al., 1989) and, as its
name implies, is chemotactic for monocytes (Rollins et al., 1991). MCP-1 is co-
expressed along with IL-8 in perivascular cells in the human endometrium in the late
secretory phase (Jones et al., 1997). This study also confirmed that the expression of
these two chemokines coincides with COX-2 expression and implicates these factors in
perimenstrual functions. Cultures of human ESCs and epithelial cells secrete MCP-1
(Arici et al., 1995) and have been shown to respond to the T helper-1 cytokine, IFN-y,
by releasing MCP-1 after 24 hours of treatment (King et al., 2001). Oestrogen has been
shown to inhibit its secretion by ESCs (Arici et al., 1999). MCP-1 production by
choriodecidual cells and the breast cancer cell line, T47D, is suppressed by progesterone
(Kelly et al., 1997) further implicating a hormonal control over MCP-1. However, a
more recent study failed to show the inhibitory effects of progesterone on either MCP-1,
-2 or -3 mRNA levels in cultured human ESCs or epithelial cells (DeLoia et al., 2000).
1.2.2 Uterine Natural Killer (uNK) Cells
Natural Killer cells are lymphocytes and have been shown to be critical in innate
immune host defence (Bancroft, 1993; Scharton-Kersten et al., 1997; Biron et al., 1999;
Cooper et al., 2001b). They are present in peripheral blood, accounting for
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approximately 10% of total blood lymphocytes (Robertson et al., 1990). There is one
important division with category according to their cell surface marker expression as
either CD56bnght CD16" or CD56Dim CD16+. However, the CD56bnght variety is scarce,
comprising of less than 2% of total blood lymphocytes and approximately 10% of total
blood NK cells (Lanier et al., 1986). Upon activation CD56bnght NK cells produce an
array of cytokines such as IFN-y and GM-CSF, (Cooper et al., 2001a) and also develop
cytotoxic activity upon IL-12 or IL-2 activation (Ellis et al, 1989; Gately et al., 1991;
Robertson et al., 1992). It has been demonstrated that the CD56bnght NK variety produce
far greater levels of cytokines compared with CD56Dim cells (Cooper et al., 2001a).
1.2.2.1 Uterine Expression and Functions of uNK Cells
Within the uterus, NK cells were originally termed Large Granular Leukocytes (LGLs)
due to their size and abundance of cytoplasmic granules (King et al., 1991). They
express CD56 on their cell surface making them distinct from the major blood NK cell
population. However, a study comparing cytokine production by peripheral NK cells
and decidual NK cells reported a very similar cytokine repertoire (Saito et al., 1993).
Through their secretion of cytokines it is likely they are having immunoregulatory
effects. Their density is low throughout the proliferative phase but their abundance
increases across the secretory phase, particularly around the time of implantation (Loke
et al., 1997). In the late secretory phase they comprise approximately 15-25% of the
ESCs (King et al., 1989b). Peripheral NK cell number is raised in women with recurrent
spontaneous miscarriage of unknown aetiology, and this implies a role in controlling
pregnancy maintenance (Ntrivalas et al., 2001). uNK cell levels remain high into the
first trimester of gestation but then decline and they also disappear in the non-pregnant
endometrium prior to menstruation, possibly undergoing apoptosis (King, 2000). The
first trimester appears to be a critical time for a successful pregnancy with highest
miscarriage rates prevailing in this stage with approximately 50% of total human
conceptions failing before the first missed menstrual period. The exact functions of
these uNK cells in humans have yet to be elucidated.
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How uNK cells are regulated is not yet fully understood. Their expansion across the
secretory phase when progesterone levels are rising implicates progesterone as a central
regulator of their growth and this is compounded by evidence that ovariectomised
women lack uNK cells (Loke et al., 1995). However, uNK cells lack the genomic PR
and the ERa (King et al., 1996), although they do express ERP and the glucocorticoid
receptor (Henderson et al., 2003). This absence of the genomic PR suggests they are not
controlled directly by progesterone across the secretory phase but that it is likely that
regulation is via paracrine signalling with non-leukocyte ESCs since these cells persist
to express the PR-A isoform at this stage of the cycle (Wang et al., 1998). Studies in
vitro have demonstrated that uNK cells proliferate upon treatment with IL-15 but other,
as of yet, unidentified products of ESCs appear to increase their proliferation further
(Verma et al., 2000). Murine uNK cells express mRNA for an array of cytokines
including CSF-1, TNF-a, IL-1, LIF and TGF-p (Croy et al., 1991). A study on isolated
human decidual NK cells revealed these cells express mRNA and secrete the protein for
G-CSF, GM-CSF, M-CSF and LIF (Saito et al., 1993). This demonstrates that a role, in
addition to or in place of an immune function, exists for uNK cells although the function
of these cytokines remains unclear. A close association exists between uNK cells and
trophoblast cells in vivo providing circumstantial evidence for a role in trophoblast
invasion (Loke et al., 1997). In culture experiments, isolated human cytotrophoblast
cells have been shown to attract CD56bnght cells via secretion of Monocyte Inflammatory
Protein la (MlP-la) and implies a role for MlP-la in attracting uNK cells (Drake et al,
2001). This is in contrast to the situation in mice where those genetically-ablated for
MlP-la show no difference to wild type mice with regard to uNK cell density at the
implantation site (Chantakru et al., 2001). However, in mice, uNK cells are present only
in the metrial gland (Croy et al., 1993), the triangle at the apex of the placenta where
blood vessels feeding the placenta are close together. In contrast, in humans uNK cells
are present throughout the endometrium and it may therefore be necessary to "attract"
these cells specifically towards the implantation site.
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1.2.2.2 uNK Cells and Decidualisation
uNK cells may be linked with decidualisation. These cells were found to be specifically
located in regions of stroma exhibiting pseudodecidual alterations (Bulmer et al., 1988).
It has been proposed that uNK cells are required in mice for maintenance of the decidual
reaction rather than its initiation (Croy et al., 2002). Evidence from studies on mice
lacking IFN-y implicates this cytokine, a major product of uNK cells, in the decidual
reaction and conversion of the uterine vasculature (Ashkar et al., 1999; Ashkar et al.,
2000). Rat splenocytes can be primed by prolactin to express the IL-2 receptor and
therefore allows these cells to respond to IL-2 stimulation (Mukheijee et al., 1990). In
the human endometrium prolactin is secreted by decidualised stromal cells and mRNA
expression of its receptor on these cells is under progesterone control (Tseng et al.,
1999). A recent study has illustrated uNK cells as a novel target for prolactin action by
detection of the prolactin receptor and this may represent a functional link between uNK
cells and ESCs, which produce prolactin upon decidualisation, and provide the indirect
connection between progesterone control on uNK cells (Gubbay et al., 2002). PGE2 has
inhibitory actions on NK cell IL-15 receptors via down-regulation of the common y-
chain (Joshi et al., 2001). PGE2 has also been shown to reduce IL-2 receptor expression
on NK cells and reduce their proliferation and activity (Parhar et al., 1989). Using IL-2
activated mouse uNK cells, PGE2 stimulated an increase in the size and granularity of
the cells and enhanced the proportion of 4H12 expressing cells (Linnemeyer et al,
1993). The uNK cells accumulating at implantation sites immuno-stain for the 4H12
antibody and they were able to demonstrate in culture that these cells were less cytotoxic
than NK cells negative for 4H12. The described effects of PGE2 are likely to be
mediated via cAMP since this second messenger was able to augment the same
responses.
Angiogenesis is a critical process in the human endometrium and ensures that vascular
remodelling of the spiral arterioles and regeneration of the vasculature following
menstruation can take place. A major angiogenic stimulus is VEGF and it is a member
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of the vascular endothelial growth factor family, of which there are six members. VEGF
protein and mRNA have been localised within the endometrium across all phases of the
menstrual cycle in both the glandular epithelial cells and in the stroma (Charnock-Jones
et al., 1993). In cultures of human ESCs progesterone treatment resulted in a rise in
VEGF, isoform VEGF189, secretion (Ancelin et al., 2001). Hypoxia and cAMP have
also been identified as stimuli for VEGF production in ESCs in vitro as demonstrated by
ELISAs and Northern Blot analysis (Popovici et al., 1999). uNK cells are present in the
stroma across the menstrual cycle and increase in number across the secretory phase and
into the first trimester of gestation (Loke and King, 1997). Across the secretory phase
uNK cells have been shown to express VEGF-C and placenta growth factor (PIGF)
mRNA (Li et al., 2001). Additionally, in the late secretoy phase uNK cells express
mRNA for the angiopoietin, Ang2. This study also demonstrated the ability of IL-15 to
up-regulate VEGF-C mRNA levels in uNK cells. The specific locality of uNK cells
within the stroma is in close proximity to the glands and the blood vessels and therefore
their production of angiogenic factors may be having a direct influence on the blood
vessels. This supports a possible involvement in menstruation or in the stabilisation of
blood vessels during implantation and early pregnancy (King and Loke, 1990).
1.2.3 Glandular Cells in Immune and Reproductive Functions
The epithelium is considered central in intestinal immune function (Gewirtz et al., 2002)
and in the control of lymphocyte trafficking in, for example, the skin and small intestine
(Kunkel et al., 2002). Within the endometrium the glands are composed of epithelial
cells and they undergo cyclical variation as described in sections 1.1.1 and 1.1.2. Figure
1.3 illustrates the structure of a gland in the early secretory phase. Infiltrating
leukocytes in the mid and late secretory phase are situated immediately adjacent to
glands in the human endometrium (Bulmer et al., 1985). Macrophages send long
processes into the epithelium of the glands of human endometrium (Kamat et al., 1987)
and intraepithelial T-lymphocytes have been identified (Loke et al., 1995). The
glandular cells are also HLA-DR-positive in the secretory phase but not in the
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proliferative phase (Chiang et al., 1997) and an increased accumulation of extracellular
immunoglobulin is apparent within glands with progression of the menstrual cycle
(Bjercke et al., 1993) implying a specific immune function in secretory endometrium.
Lymphocytes have been characterised in early human decidua and located as either
clusters, forming aggregates, near to the glands or as intraepithelial lymphocytes within
the glands themselves (Mincheva-Nilsson et al., 1994).
In addition to the leukocyte populations, endometrial epithelial cells are believed to be
important in host defence. Defensins are small cationic proteins that confer anti¬
bacterial, anti-fungal and anti-viral properties and human beta-defensins 1-4 (HBD1-4)
mRNA is expressed in the human endometrium (Valore et al., 1998; Fleming et al.,
2003; King et al., 2003). Secretory leukocyte protease inhibitor (SLPI) is also a product
of human endometrial epithelial cells (King et al., 2000) and has been reported to have
antibacterial, antiviral and antifungal effects (Tomee et al., 1998). Both HBD-1 and
SLPI increase in the mid secretory phase although SLPI expression rises further in the
late secretory phase and into pregnancy (King et al., 2000; Fleming et al., 2003). They
may have important functions at the time of implantation and in early pregnancy but
since the glands lack the progesterone receptor at this time, stromal-derived factors may
be important in controlling their production since the stroma in the functional layer
retains the PR-A receptor (Wang et al., 1998).
The COX enzymes are involved in regulation of PGE2 synthesis and are discussed in
section 1.4.1. Both isoforms have been located in the human endometrium with COX-1
expression being predominant in the luminal and glandular epithelial cells (Rees et al.,
1982) and COX-2 being expressed in the glands and perivascular cells in the luteal
phase (Jones et al., 1997; Marions et al., 1999). Treatment with the antiprogestin,
RU486, in the luteal phase reduced the expression of both isoforms in the epithelial cells
and a role in endometrial receptivity was proposed (Marions et al., 1999). Studies on
mice knock-outs for the COX enzymes have implicated COX-2 in ovulation,
fertilisation, implantation and decidualisation (Lim et al., 1997). In the COX-1 knock-
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Photomicrograph of a gland in the early secretory phase endometrium at high power
magnification in human endometrium stained with toluidine blue and acid fuschsin. G =




Photomicrograph of a gland in the early secretory phase endometrium at high power
magnification in human endometrium stained with toluidine blue and acid fuschsin. G -
gland; S = stroma; GL = glycogen deposits. Scale bar represents 40pm.
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Figure 1.3
Photomicrograph of a gland in the early secretory phase endometrium at high power
magnification in human endometrium stained with toluidine blue and acid fuschsin. G =
gland; S = stroma; GL = glycogen deposits. Scale bar represents 40pm.
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1.3 Establishment of Pregnancy
1.3.1 Decidualisation
The transformation of the human 'endometrium into decidua begins around post-
ovulatory day 9 in oestrogen-primed stromal cells surrounding the spiral arterioles. This
reaction then spreads throughout the stroma completing the pre-decidual transformation
of the 'endometrium. If pregnancy is established, these decidual changes become more
widespread creating three layers: decidua compacts, decidua spongiosa and a basal
undifferentiated layer, allowing regeneration following menstruation or birth. Studies in
rats and mice identified three types of decidual cell: anti-mesometrial decidual cells,
mesometrial decidual cells and granulated metrial gland cells (De Feo, 1967). However,
decidualisation differs between humans and rodents with regard to its stimulus and
locality. In humans, the stromal differentiation is spontaneous and occurs in preparation
for implantation across the secretory phase whereas in rodents it is initiated only upon
the physical stimulus of implantation. Decidualisation is apparent throughout the human
endometrium but only occurs at the implantation site(s) in mice and rats.
1.3.1.1 Decidualisation Markers
Term decidual fibroblasts from humans have been shown to express desmin (Oliver et
al., 1999). In addition, decidualised ESCs express raised levels of fibronectin and
laminin compared with control cultures (Irwin et ah, 1989). Rat decidual cells contain
large quantities of intermediate fibres. These are made up of vimentin, which is also
present in non-decidualised stromal cells, and desmin, specific to decidualised cells
(Glasser et at, 1986). However, two other products of the decidual reaction, prolactin
and IGFBP-i, are more commonly used to mark this process in culture experiments
using human ESCs. In addition to this a further marker of this process is tissue factor
and these will be discussed each in turn.
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Prolactin is an anterior pituitary hormone, but was first detected being produced outside
the pituitary, by decidualised endometrial cells (Riddick et al., 1978). It was then
confirmed that prolactin synthesis correlated with the extent of stromal decidualisation
in a study of human endometrial explants from the various stages of the menstrual cycle
(Maslar et al., 1979). Prolactin is widely expressed and has been located in dermal
fibroblasts, epithelial cells of the prostate and breast, Leydig cells of the testis and by
certain immune cells as summarised in Ben-Jonathan et al 1996 (Ben-Jonathan et al.,
1996). Mouse gene knock-outs have confirmed that prolactin is critical to reproductive
processes and fertility and particularly with regard to implantation and pregnancy
maintenance (Binart et al., 2000). Within the endometrium, prolactin protein is
expressed primarily in stromal cells in the late secretory phase but epithelial cells were
also immunoreactive for prolactin at this point in the cycle (Bryant-Greenwood et al.,
1993). Whilst the protein has also been confirmed in both stromal and epithelial cells,
mRNA has only been detected in the stromal cells (Dimitriadis et al., 2000). Prolactin is
considered to be important in human implantation and early pregnancy, as discussed in
Jabbour and Critchley 2001 (Jabbour et al., 2001). A novel target cell of prolactin has
been identified as uNK cells since these cells express the prolactin receptor (Gubbay et
al., 2002). Prolactin has also been shown to regulate the expression of interferon-
regulatory factor (IRF-1), which is located in the glands and upregulated in the secretory
phase (Jabbour et al., 1999).
The insulin-like growth factor system consists of peptide growth factors (IGFs) and their
receptors but also specific binding proteins (IGFBPs) that regulate the availability of
IGFs to their receptors (Lamson et al., 1991). Six types of soluble IGFBPs exist and
these have a degree of tissue specificity (Shimasaki et al., 1991). Within the human
endometrium, mRNA for all six IGFBPs were located and with the exception of IGFBP-
5, all increased in the secretory phase compared with the proliferative stage (Zhou et al.,
1994). The production of IGFBP-2 and -3 by cultures of ESCs with oestrogen and
progesterone treatment has been demonstrated (Giudice et al., 1991).
Immunohistochemical studies have demonstrated an increase in IGFBP-1 levels in
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human endometrium in the secretory phase (Bryant-Greenwood et al., 1993) and
IGFBP-1 was found to be a secretory product of secretory phase endometrium and early
decidua (Bell et al., 1989). IGFBP-1 is considered a marker of decidualisation and is
used to assess this process in cultures of ESCs (Irwin et al., 1989; Bell et al., 1991;
Giudice et al., 1992). The specific function of IGFBP-1 in the uterus in unknown
although it may be regulating IGF-1, a stimulator of cell growth, and IGF-1 mRNA
levels are up-regulated in the rat uterus following oestrogen treatment (Murphy et al.,
1987). In women using LNG-IUS mRNA levels of IGFBP-1 are upregulated, consistent
with immunohistochemical stromal staining, and IGF-1 levels were found to be
decreased (Rutanen, 2000). It was speculated that the inhibitory action of IGFBP-1 on
IGF-1 levels could partially account for the progestogenic and anti-oestrogenic effects of
LNG-IUS.
Tissue factor is a membrane-bound glycoprotein. It has an extracellular domain that acts
as a receptor for factor VII that is involved in the thrombin pathway and it thought to
maintain an equilibrium between haemostatic and fibrinolytic pathways as discussed in
Schatz et al 2001(Schatz et al., 2001). This knowledge, along with in utero
haemorrhage of tissue factor knockout mice, (Carmeliet et al., 1996) implies a role for
tissue factor in regulation of bleeding. In women using Norplant, the observed decline
in endometrial tissue factor protein and mRNA levels may partially account for their
irregular bleeding patterns (Runic et al., 1997). Tissue factor has also been implicated in
angiogenesis via induction of VEGF (Abe et al., 1999). Experiments on human ESCs in
culture have confirmed hormonal control over the increase in tissue factor expression
and withdrawal of oestrogen and progesterone resulted in a return of tissue factor levels
to those similar to pre-treatment levels (Lockwood et al., 1993). Cyclical changes in
tissue factor mRNA and protein are observed in humans with greatest levels of
expression in luteal phase stroma and in decidua (Lockwood et al., 2001). Its presence
may be important in having a primary stabilisation function during the destructive
process of trophoblast invasion and paralleled vascular remodelling (Schatz et al., 2001).
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1.3.1.2 Progesterone and cAMP
Progestins stimulate the production of prolactin and its receptor in stromal cell primary
cultures and this can be inhibited by addition of the anti-progestin, RU486 (Tseng et al.,
1999). Studies on ESC decidualisation in vitro have demonstrated that progesterone
treatment alone is a weak inducer of the decidual transformation and can only achieve
this conversion after prolonged exposure (Huang et al., 1987; Zhu et al., 1990; Tseng et
al., 1992; Mizuno et al., 1998). It has also been reported that women with low serum
progesterone levels at four weeks gestation can have successful pregnancies following
assisted reproductive technologies (ART) treatment (Azuma et al., 1993) and it may be
the case that other factors are important, in addition to progesterone, to decidualisation.
Synthetic progestins, such as medroxyprogesterone acetate (MPA), are usually used in
place of progesterone because they are metabolically stable and thus more effective at
inducing prolactin expression (Zhu et al., 1990). However, addition of cAMP in
combination with progesterone produces this conversion on a greatly reduced time scale
(Tang et al., 1993a; Tang et al., 1993b; Brar et al., 1997) and these actions are probably
via the protein kinase A pathway (Brar et al., 1997).
1.3.1.3 Relaxin
Relaxin is similar in structure to insulin and insulin-like growth factors (Blundell et al.,
1980) and consists of two chains, A and B chains, which are covalently linked by two
disulphide bonds (Schwabe et al., 1978; Schwabe et al., 1978). It is synthesised as a
precursor form, preprorelaxin (Kemp et al., 1984). Relaxin is primarily a product of the
corpus luteum in reproductive tissue but has been isolasted from human decidua by
chromatographic elution (Bigazzi et al., 1980). It has been localised to the glands and
stroma of human endometrium and decidua, as shown by immunohistochemistry
(Bryant-Greenwood et al., 1993). Relaxin is secreted by the ovary and is present in the
blood and therefore some of the immunoreactivity for relaxin in the endometrium may
be from this source. However, if the sole source of relaxin in this tissue was from
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outside of the endometrium it may be expected that highest concentrations of relaxin
immunoreactivity would be observed surrounding the blood vessels. In fact, highest
immunoreactivity intensity is found in the glandular cells. In addition, two molecular
forms of relaxin exist, HI and H2 and are encoded by different genes (Hudson et al.,
1983; Hudson et al., 1984). H2 is the main form produced by the ovary whereas HI and
H2 are produced by decidua (Bryant-Greenwood, 1991; Hansell et al., 1991). Within
the stroma, relaxin was immunolocalised in decidualised cells in the late secretory phase
and throughout early and late gestation. ESCs themselves have very few receptors for
relaxin, approximately 1000 per cell (Osheroff et al., 1995), however, in cultures of
human ESCs relaxin both acutely and permanently elevates intracellular cAMP levels in
concert with induction of prolactin secretion (Telgmann et al., 1998) and produces
maximal stimulus on prolactin production when added in combination with a synthetic
progestin (Huang et al., 1987; Zhu et al., 1990). In these early studies porcine relaxin
was used in the treatment of human ESCs. Whether this is an exact mimic of human
relaxin actions has not been confirmed due to a lack of availability. However, relaxin
does have the effect of raising cAMP and the direct application of cAMP to cultures
results in prolactin secretion by human ESCs in a similar fashion (Tang et al., 1993a;
Tang et al., 1993b; Brar et al., 1997). It has further been demonstrated that the induction
of raised cAMP levels by relaxin treatment is due to its action to inhibit
phosphodiesterase activity and therefore inhibit cAMP destruction (Bartsch et al., 2001).
1.3.1.4 Interleukin-11 (IL-11)
IL-11 is a member of the gpl30 cytokine family along with LIF (Gadient et al., 1999).
It has actions in a wide range of environments from haematopoietic cells to the nervous
system (Hawley, 1994) but also has anti-inflammatory actions in the gastrointestinal
tract (Sands et al., 1999). Within the human endometrium IL-11 is expressed in all cell
types with greatest immunostaining intensities apparent in decidualised stroma and
appears in these cells before prolactin (Dimitriadis et al., 2000). Human ESCs produce
IL-11 and express IL-11 receptor a (IL-llRa) in culture during progesterone-induced
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decidualisation and upon treatment with an anti-human IL-11 antibody a reduction in
prolactin and IGFBP-1 levels were observed implicating IL-11 in induction of
decidualisation (Dimitriadis et al., 2002). Production of IL-11 by cultured human
epithelial cells and stromal cells was enhanced by IL-la, TNF-a and TGF-P and these
results suggest a role for IL-11 in implantation (Cork et al., 2001). In the murine uterus
IL-11 is essential to female fertility as shown by IL-llRa gene knockout studies in
which a defective uterine response to blastocyst fails to trigger normal maternal decidual
transformation (Bilinski et al, 1998; Robb et al., 1998).
LIF may also have a role in the process of decidualisation since LIF null mice fail to
exhibit decidualisation (Stewart et al., 1992b). The reproductive roles of LIF are
discussed further in section 1.3.2.2. Recently, mRNA and protein for ghrelin, a peptide
hormone, have been shown to increase in human decidualised stroma and in addition,
enhanced cAMP-induced decidualisation of cultured human ESCs (Tanaka et al., 2003).
The mechanisms and factors involved in decidualisation are complex and it is likely that
other factors that are involved have not yet been identified.
1.3.1.5 Decidualisation and Cell Growth
Decidualisation treatments affect the growth rate of ESCs. For example, MPA
stimulates cell growth and prolactin production in human ESCs in culture whereas
relaxin does not promote cell growth (Zhu et al., 1990). IL-11 increases tritiated
thymidine uptake by human ESCs in culture (Karpovich et al., 2003). In rat ESCs both
progesterone and prostaglandins have been postulated to exert effects on the rate of
DNA synthesis with progesterone stimulating it and PGE2 reducing it (Peleg, 1983).
This is consistent with the finding that in rats treated with RU486, division of stromal
cells during pregnancy was inhibited compared with untreated controls (Rider et al.,
1994). The proliferative effects of basic fibroblast growth factor (bFGF) are dependent
on the presence of progesterone in cultures of human ESCs (Irwin et al., 1991). In
addition to this the insulin-like growth factor (IGF) system has been directly implicated
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in human ESC decidualisation (Irwin et al., 1994). This study demonstrated the
necessity of IGF plus epidermal growth factor (EGF) in combination for promotion of
cellular proliferation. However, the presence of growth factors was not essential to
stimulate prolactin and IGFBP-1 production. It has been shown that term decidua
contains undifferentiated ESCs that can be stimulated in vitro to decidualise and it is
speculated that these represent a proliferating population of ESCs that are maintained




The main influences on the sequential maturation of the endometrium are oestrogen and
progesterone with the latter being dominant in the luteal phase of the cycle. Imbalances
of these hormones and/or their receptors can result in an out-of-phase development that
may be significantly detrimental to the implantation process (Bonhoff et al., 1990).
Studies in rodents demonstrated a maternal implantation window controlled by the
steroid hormones (Psychoyos, 1986). In humans, implantation occurs around day LH +
6 and LH + 7 (Hertig et al., 1956; Bergh et al., 1992) and the concept of the
"implantation window" specifies that the blastocyst can only implant whilst the
endometrium is in a receptive developmental stage (Navot et al., 1989; Li et al., 1991;
Tabibzadeh, 1998). The processes of implantation and decidualisation are likely to be
closely linked, although in humans decidualisation begins prior to implantation on day
LH + 8. However, these two events are likely to be closely coordinated and one
important feature of a receptive endometrium is decidualisation. In a review of oocyte
donation success, the optimal window for transferring the fertilized oocyte was between
cycle days 16 and 19 (Rosenwaks, 1987). After this period, no pregnancies were
established. Ultrastructual changes in the luminal epithelial cells are also thought to be
correlated with this receptivity status (Sarani et al., 1999). However, implantation has
been shown to be dependent on embryonic age rather than endometrial maturation in
another study involving IVF treatment of women (Bergh et al., 1992). The receptive
endometrium is thought to balance implantation with excessive trophoblast invasion by
providing appropriate signals (Tabibzadeh et al., 1995) and embryonic signalling may be
essential for the implantation process and maternal acceptance (Edwards, 1994).
The implantation process itself is quite unique in humans in comparison to other species
and is haemochorial (Pijnenborg et al., 1981). The first stage of implantation is
fertilisation of the oocyte within the fallopian tube. The fertilized oocyte then undergoes
successive cleavages during the week-long peri-implantation period. These cleavages
must generate sufficient cell numbers prior to blastocyst formation to allow completion
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of inner cell mass and trophectoderm formation and are followed by proliferation and
migration towards the uterine cavity around 72-96 hours post fertilisation. On day 5,
the blastocyst hatches from the zona pellucida. The actual process of implantation
occurs in three stages, the first of these being apposition. This is followed by adhesion
of the blastocyst to the luminal epithelium via the trophectoderm and allows the
trophoblast to burrow between the luminal epithelial cells, leaving these luminal
epithelial cells undisturbed. Placenta formation starts once the trophectoderm has
invaded and become embedded in the decidua. Some of the cytotrophoblast cells then
extend into the peripheral syncytium and join to form the cytotrophoblastic shell.
Villous trophoblast cells will eventually form a layer over the placenta and have the
function of nutrient and oxygen transport from maternal blood to the fetus. The
extravillous trophoblast cells penetrate deep into the decidua and transform the spiral
arteries, destroying the muscular walls and converting them into larger vessels allowing
delivery of greater volumes of blood. This is essential for an adequate blood supply for
the fetus and in cases of under-invasion of the trophoblast pathologies such as
miscarriage, pre-eclampsia and fetal intrauterine growth restriction can result (Loke et
al., 1995). This is not only relevant to the short-term with regard to pregnancy
complications but can lead to the development of problems in adult life (Barker, 1997b).
Conversely, when over-invasion of the trophoblast occurs a phenomenon of placenta
percreta, or uterine rupture, can develop. Therefore, it is important for this process to be
under stringent control and a synchrony between the blastocyst and endometrium is
required for it to be implemented successfully.
1.3.2.1 Colony Stimulating Factor-1 (CSF-1)
Signalling between the blastocyst and the endometrium are likely to be essential prior to
adhesion to the epithelium and several soluble factors have been implicated. Colony-
stimulating-factor-1 (CSF-1) is a growth factor and is expressed within the endometrium
in the stroma and epithelial cell and also by the trophoblast along with its receptor, c-fms
(Daiter et al, 1992). Mutant mice lacking CSF-1 are infertile due to implantation failure
46
(Pollard et al., 1991). The cyclical variation of CSF-1 and c-fms in humans is
characterised by rapid rises in expression in the late secretory phase and early pregnancy
(Kauma etal., 1991).
1.3.2.2 Leukaemia Inhibitory Factor (LIF)
LIF is a glycoprotein expressed in endometrial glands just prior to implantation in mice
(Bhatt et al., 1991) and may be involved in blastocyst growth and implantation (Bulletti
et al., 1994; Polan et al., 1995). A targeted mutation of the maternal LIF gene resulted
in impaired implantation in mice. The blastocysts however were viable and able to
implant in wild-type pseudo-pregnant mice implicating LIF specifically in implantation
(Stewart et al., 1992b). In contrast, LIF is not critical to implantation in sheep and cows
as determined by experiments in which animals were immunised against LIF (Vogiagis
et al., 1997). In humans, LIF is present within endometrium and at highest levels during
the time of implantation (Charnock-Jones et al., 1994; Kojima et al., 1994). Isolated
first trimester trophoblast is negative for LIF but positive for its receptor (King et al.,
1995) and it could be speculated that endometrial LIF is acting on its receptors located
on trophoblast cells. Some of the actions of LIF may be via human chorionic
gonadotrophin (hCG) since anti-hCG antibodies have been shown to block LIF-
mediated trophoblast differentiation (Sawai et al., 1995). hCG is secreted by the embryo
and by preventing demise of the CL and therefore maintains luteal progesterone
production. The actions of hCG may not be confined to the CL since hCG receptors
have also been located in the human endometrium (Reshef et al., 1990) and in support of
this, human endometrial stromal cells treated with hCG decidualise (Han et al., 1999).
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1.3.2.3 Cell-matrix Interactions
Interactions between the extracellular matrix and cells provide an essential
communication route. The interactions between extracellular matrix constituents and the
surface of cells are predominantly mediated by integrins. Integrins are a family of cell
surface heterodimeric a/p glycoproteins and are able to bind matrix molecules and to
cell surface receptors (Hynes, 1992). They participate in adhesion, migration,
proliferation, differentiation and cell survival. Several integrins are expressed within the
human endometrium (Lessey et al., 1992; Tabibzadeh, 1992). The expression of many
of these fluctuates in a cyclical manner and those with expression confined to the
window of implantation are aiPi, a4Pi and avp3 (Tabibzadeh, 1992; Lessey et al.,
1994a). Expression of the fibronectin receptor is delayed in luteal phase defect (Lessey
et al., 1992) and aberrant expression of this receptor has also been associated with
endometriosis (Lessey et al., 1994b).
Matrix metalloproteinases (MMPs) are enzymes that have a range of specificity for
extracellular matrix molecules and are invloved in their degradation. MMPs are
generally considered pathological when detected in connective tissue, however, they
have been localised in human trophoblast (Polette et al., 1994) and are considered to
have a role in the uterus of physiological tissue remodelling (Hulboy et al., 1997).
Tissue inhibitor of MMPs (TIMP) inhibits the invasiveness of trophoblastic cells in situ
(Graham et al., 1991). MMP2 and MMP9 are members of the gelatinase subfamily and
are secreted by the invasive human trophoblast (Shimonovitz et al., 1994). They act to
digest collagen type IV, the major constituent of the uterine basement membrane, and
would be important in uterine invasion during implantation. MMPs are discussed in
more depth in section 1.1.4.2.
The interactions between leukocytes and ESCs via the production of cytokines and
growth factors, such as VEGF, the interferons and TNF-a, are believed to be important
in endometrial tissue breakdown and remodelling (Fraser, 1999). These immune cells
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are believed to play a significant role in establishment of microenvironments via their
production of such factors (Tabibzadeh et al., 1993; King, 2000). uNK cells are located
in the stroma in high concentrations around the blood vessels and are a source of VEGF
and their potential effects on the blood vessels are briefly assessed in section 1.2.2.2. In
addition, uNK cells are also located at the implantation site and this is their only location
within the mouse endometrium (Croy et al., 1991). They may be involved in
modulating trophoblast invasion in humans (King and Loke, 1990) and in mice have
been proposed as having a role in the regulation of placental development whereby
knockout mice for uNK cells exhibit reduced placental size (Croy et al., 2002).
However, a more crtical role in mice is the stabilisation of the vasculature and complete
differentiation of the endometrium into decidua (Ashkar et al., 2000). IFN-y-producing
immune cells, in particular uNK cells, are thought to be involved in modulating ESC
decidualisation in humans (Christian et al., 2001). They demonstrated the ability of
IFN-y to antagonise prolactin protein and mRNA expression in primary ESC cultures.
This provides a role for IFN- y as a modifier of ESC function.
1.3.3 The Role of Cytokines
Cytokines are small glycoproteins with autocrine and paracrine interactions and are
predominantly associated with immune functions. They can be involved in both the
induction and resolution of an inflammatory response and can generally be termed "pro¬
inflammatory" or "anti-inflammatory". Studies on CD4+ T-cells showed that responses
of these cells are polarised and they have been classified on their cytokine production as
either T-helper-1 (Th-1) or T-helper-2 (Th-2) (Mosmann et al., 1986). The Th-1
cytokines include IFN-y, IL-2 and TNFa and whilst examples of Th-2 cytokines are IL-
4, IL-10 and IL-13. In the human endometrium during the peri-implantation phase, a
reduction or absence of Th-1 and a dominance of Th-2 cytokines is observed (Lim et al.,
1998). The general hypothesis with regard to pregnancy that has been derived from
mice studies is that a Th-1 response is considered detrimental and a Th-2 response is
thought to be beneficial and supportive of pregnancy and the balance of these responses
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is likely to be critical (Wegmann et al., 1993; Hill et al., 2000), although it is now
apparent that this is an over-simplification (Chaouat et al., 2002). Some of the








Chemotaxis and induction of lymphoid infiltration
Oedema
Induction of PGE2
Activation of T cells
TGF-p Gland formation and Angiogenesis
IFN-y




Chemotaxis and induction of lymphoid infiltration
Induction of menstruation
Induction ofHLA-DR and ICAM-1
TNF-a




Chemotaxis and induction of lymphoid infiltration
Oedema
Induction of PGE2
Injury to endometrial vessels
Activation ofpolymorphonuclear leukocytes
Table 1.2
Cytokine functions in the human endometrium. Table adapted from Tabibzadeh 1994
(Tabibzadeh, 1994a).
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This section will examine IL-1, IL-10 and IFN-y and their functions within the uterus.
IL-8 and IL-15 are discussed in more detail in sections 1.2.1.2 and 1.4.3 respectively.
1.3.3.1 Interleukin-1 (IL-1)
IL-1 is a multifunctional cytokine and exists in two forms: IL-1 a and IL-ip with a low
sequence homology between them. They have similar action and act on the same
receptor, IL-1 type-1. A second receptor sub-type exists, IL-1 type-2, but it is non¬
functional. In humans, the IL-1 receptor antagonist is located in decidual glands, and in
isolated cells in chorionic villi, the intervillous space and in maternal decidua (Simon et
al., 1994). These decidual cells staining positive for the IL-1 receptor antagonist are
thought to be macrophages (Tabibzadeh et al., 1992). IL-ip is the dominant form and is
secreted by activated murine peritoneal macrophages (Chensue et al., 1989). In the
human endometrium both IL-1 a and IL-P are expressed in the epithelial and stromal
cells (Tabibzadeh et al., 1992) and IL-P mRNA expression is raised in pregnancy
(Kauma et al., 1990). Human serum IL-1 levels vary according to the menstrual cycle
and are found to be highest in the secretory phase, post-ovulation (Cannon et al., 1985).
In contrast, IL-1 receptor antagonist levels decline in the secretory phase (Simon et al.,
1995). IL-1 has also been connected to blastocyst implantation and is found expressed
along with its receptor in both trophoblast and decidual cells (Simon et al., 1994; Simon
et al., 1995). ESCs produce an immune-related response upon treatment with IL-1 a by
evoking an enhancement in phagocytosis of latex particles and E.coli (Ruiz et al., 1997).
This cytokine may also be involved in menstruation since in cultures of human ESCs,
IL-1 a stimulates production of MMP-1, a key enzyme in menstruation initiation (Singer
et al., 1997). IL-1 P acts to raise PGE2 levels in decidual and endometrial ESCs (Cole et
al., 1995; Ishihara et al., 1995). IL-la stimulates PGE2 and PGF2aproduction in ESCs
(Kawano et al., 2001). These data support a role for IL-1 in the regulation of
menstruation since PGE2 and PGF2a are believed to be involved in vascular changes
associated with endometrial tissue degradation (Baird et al., 1996). IL-1 has also been
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study was also assessing NK cells from blood and whether they have any impact on
uNK cells has not been confirmed.
1.3.3.3 Interferon-y (IFN-y)
The interferon family are cytokine mediators that are involved in alterting the immune
system to the presence of viral infections. The family comprises of three members in
humans: IFN-a, -P and -y. Components of the same receptor are shared by IFN-a and
IFN-P and they are therefore referred to as type I interferons. Since IFN-y uses a
separate receptor system it is termed a type II interferon. In addition to distinct
receptors, type I and II interferons also differ with regard to which chromosome they are
located on and their structure differs. IFN-y is distinct due to its sensitivity to pH and
temperature extremes (Arai et al., 1990) and is expressed by many cell types including
Natural Killer cells and macrophages, but predominantly by T cells (Sugawara et al.,
1986). In contrast, type I interferons are secreted by vims-infected cells (Le Page et al.,
2000).
IFN-t is a member of the interferon I family. It is not present in humans but is
expressed by ruminant trophoblastic cells although it has structural and biological
functions similar to those of IFN-a and -P, both present in humans (Roberts et al.,
1999). IFN-t is believed to be the maternal recognition of pregnancy signals in
ruminants. IFN-t is also secreted by the bovine conceptus and is considered to be
involved in rescue of the corpus luteum via limitation of PGF2a release (Thatcher et al.,
1995).
The source of IFN-y within the human endometrium is thought to be the lymphoid
aggregates (Tabibzadeh, 1994b) but is also synthesised by uNK cells in first trimester
decidua (Saito et al., 1993) and by macrophages (Gessani and Belardelli, 1998). IL-12
can stimulate IFN-y production in cultures of uNK cells and acts synergistically with IL-
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2 to provide this response (Marzusch et al., 1997). IFN-y levels remain consistent across
the menstrual cycle in non-pregnant endometrium (Yeaman et al., 1998) but during
pregnancy it can only be detected in supematants from first trimester decidua and not in
the later pregnancy stages (Lin et al., 1993). IFN-y acts on the epithelial cells to induce
human leukocyte antigen (HLA)-DR molecules of MHC and triggers morphological
changes in addition to a reduction in growth (Tabibzadeh et al., 1986; Tabibzadeh et al.,
1988). This cytokine also has actions on ESCs to induce an increase in the levels of IL-
6, MCP-1 and MCSF production and reduce IL-8 levels (Nasu et al., 1998).
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Table 1.3
Summary of the reproductive phenotypes exhibited by mutated mice genetically
deficient in endometrial cytokines or their receptor. This table is adapted from
Robertson and Hudson 2002 (Robertson et al., 2002).
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Seymour et al 1997
(Seymour et al., 1997)
Robertson et al 1999
(Robertson et al., 1999)
IFN-y
Dysregulation of uNK cells
Decidual necrosis
Inadequate transformation of endometrial
vessels during decidualisation
Increased fetal reabsorption
Ashkar and Croy 1999
(Ashkar et al., 1999)
IL-1R Reduced litter size
Abbondanzo et al 1996




Robertson et al 2000




Robb et al 1998 (Robb et
al., 1998)
IL-2 Ry Fail to develop uNK cells
Miyazaki et al 2002





Stewart et al 1992
(Stewart et al., 1992b)
Ware et al 1995 (Ware et
al., 1995)
TGF-pl Lethal in embryogenesis
Shull and Doetschman
1994 (Shull et al., 1994)
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1.3.3.4 The mouse as a model
In order to evaluate the relevance of different pathways and compounds to an overall
system the mouse proves to be a versatile tool to use. In this respect, knockout mice
offer exploration to the function of specific genes and their products whereby such an in
depth study cannot be carried out on humans. Examples of mouse knockouts that are
relevant to reproductive processes are summarised in table 1.3. Although these
knockouts give an insight into a physiological situation, these findings in mice cannot be
directly applied to the human situation. With regard to the uterus there are many
differences between the mouse and the human. The process of decidualisation in
humans occurs in anticipation of pregnancy whereas in mice the physical stimulus of
implantation is the trigger. This implies that the control of this process in humans is
divergent to that in mice. In addition, decidualisation only occurs at the sites of
implantation in mice, which is highly specific compared to the dispersed decidual
transformation within the human endometrium. Therefore to what extent, for example,
IL-11 is essential to decidualisation and implantation in humans may not directly
correlate to that occurring in mice (Robb et al, 1998). However, studies using cultures
of human ESCs have also indicated IL-11 having a role in decidualisation (Cork et al,
2001; Dimitriadis et al, 2002) therefore illustrating the use of the mouse model as
starting place. In the case of the COX-1 knock-out mouse it appears that COX-2 is
compensating for the absence of COX-1 and therefore the exact roles of this enzyme
become unclear (Reese et al., 1999). This could be occuring in other mouse knock-outs
and therefore should be taken into consideration when assessing the results.
With regard to uNK cells the mouse has been used as a model to assess their function in
several studies (Ashkar and Croy, 1999; Ashkar et al, 2000; Croy et al, 1991; Croy et
al, 2002; Zhang et al, 2003). These studies have focused on knock-out models in
particular and the possible functions of uNK cells in humans are discussed in section
1.2.2. However, more recently IL-15 knock-out mice, which are deficient in uNK cells,
have demonstrated that these cells are not essential to pregnancy (Barber and Pollard,
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2003; Ashkar et al., 2003). What these studies did show was that birth weight was
compromised, probably the result of inadequate conversion of the uterine vasculature,
(Barber and Pollard, 2003) and this deficiency in weight continued into adulthood
(Ashkar et al., 2003). This could have implications on coronary function in the
longterm. The work of Barker demonstrated a greater incidence of coronary heart
disease and stroke in individuals who had suffered from retarded fetal growth (Barker,
1997a, b and c). In humans the uNK cell may be of greater relevance to the
establishment and maintenance of pregnancy than in mice but it may also have
implications to intrauterine programming due to its role in blood vessel modification.
The distribution of uNK cells is different between mice and humans with them only
located at the metrial triangle in mice whereas in humans they are distributed throughout
the stroma. These uNK cell knock-out mice do exhibit defective decidualisation
(Ashkar et al., 2000) and since this decidual transformation is a pre-requisite to
implantation in humans this lack of uNK cells may have a more significant contribution
to establishment of pregnancy in this species.
As discussed in Enders, 2000, the mouse proves an economic animal to use as a model,
however, differences including the mechanism of implantation and the shape of the
lumen exist (Enders, 2000). The mouse is a useful tool and provides a rational starting
point for the exploration within the human system or within other animal models more
closely related to humans.
1.4 Molecular Contributions to Pregnancy
1.4.1 The Prostaglandin Cascade
Prostaglandin (PG) E2 and PGF2tt are the most abundant PGs in the human
endometrium. The major site of production is the glandular epithelial cells both in the
endometrium and in early pregnancy (Smith et al., 1988). The production of
prostaglandins (PGs) is controlled by two rate-limiting steps, phospholipase A2 activity
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and activity of the two cyclooxygenase enzymes, COX-1 and -2 (figure 1.4). Initially,
arachidonic acid (AA) must be liberated from the phospholipid membrane of the cell via
PLA2. This free AA can then be converted to prostaglandin H2 (PGH2) by COX-1 and -
2. The next stage in the cascade is the action of specific synthases on PGH2 to direct the
production of the five primary prostanoids, namely PGD2, PGE2, PGF2a PGI2 and TXA2
(Smith et al., 1996; Smith et al., 1996). Three PGE synthases (PGES) have been
identified to date, and these include a cytosolic PGES (cPGES) (Tanioka et al., 2000)
and two microsomal PGESs, mPGES-1 (Murakami et al., 2000; Mancini et al., 2001)
and mPGES-2 (Tanikawa et al., 2002). Aberrant expression of mPGES-1 in conjunction
with COX-2 has been postulated to have a role in tumourigenesis (Kamei et al., 2003).
In reproductive tissue, PGES has been located in bovine endometrium and its expression
correlated with that of COX-2 (Parent et al., 2002). Studies in mice have demonstrated
the high expression of mPGES in the stroma that immediately surrounds the blastocyst
and have implied a role for this synthase in decidualisation and implantation in rodents
(Ni et al., 2002). Conversely, PGs are metabolised and thus deactivated by
prostaglandin dehydrogenase (PGDH) enzymes. In the uterus, PGDH has been
speculated to have a role in maintaining low concentrations of PGs in the fetal
membranes during the majority of pregnancy (Cheung et al., 1992). In some cases of
idiopathic preterm labour, a reduction in PGDH expression in the chorionic trophoblast
resulting in reduced PG regulation, has been implicated as a causative factor (Sangha et
al., 1994). In support of a role for PGs in pre-term labour, inhibition of COX-2 can
prevent inflammation-mediated pre-term labour in mice (Gross et al., 2000b). Within
the human endometrium, PGDH is located within the cytoplasm of gland cells and levels
were found to be highest in the secretory phase but lowest pre-menstrually and during
menstruation (Casey et al., 1980). Raised levels in the secretory phase versus the
proliferative phase were confirmed in a later study and it was also demonstrated that
PGDH activity was significantly increased at 12 months post-insertion of a LNG-IUS
and coincided with a rise in PR-A and -B immunostaining (Critchley et al., 1998b).
This correlates with the control of endometrial bleeding, implicating both receptor levels
and PGs in the process. The role of PGs is supported additionally by a further study that
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has demonstrated a decline in PGDH immunostaining in the glands and stroma in
women 36-48 hours after receiving the antiprogestin, mifepristone (Hapangama et al.,
2002).
PGs have a short half-life and are metabolised rapidly. It is therefore likely that their
actions are local to their production site. PGs are classified by their cyclopentane ring
and TXA contains an oxane ring. Each group acts via its own distinct receptors
(Coleman et al., 1994; Narumiya et al., 1999). These receptors are G protein-coupled
receptors with 7 transmembrane domains, located on the plasma membrane. Sequence
homology between the different receptors is low, ranging from 20 to 30%, although
homology of the specific receptors between species is far higher, 76 - 97% (Narumiya et
al., 1999). There are 4 different PGE2 receptors and these are referred to as EPi _4. The
EP2 and EP4 receptors act via Gs proteins and have the effect of raising cAMP levels.
The EP3 receptor exists as 7 splice variants (Adam et al., 1994; Sugimoto et al., 2000)
with the predominant effect of decreasing cAMP levels. EPi acts via a different second
messenger, Ca2+, to exert its effects (Kennedy et al., 1982; Watabe et al., 1993).
COX-1 is constitutively expressed in most tissues and in contrast COX-2 is normally
absent and only present in a pathological state, for example, COX-2-dependent pathways
have been implicated in development of colorectal cancers (Williams et al., 1999) and in
eutopic and ectopic pregnancies (Ota et al., 2001). COX-2 can be induced by factors
such as lipopolysaccharide (Inoue et al., 1995) and IL-1 (Thomas et al., 2000; Tamura et
al., 2002). However, it is becoming apparent that COX-1 can also be induced and it has
been shown to be upregulated in cervical carcinomas (Sales et al., 2002). Both of the
COX isoforms are inhibited by non-steroidal anti-inflammatory drugs (NSAIDs) and it
has been demonstrated in mice and humans that some NSAIDs are preferentially
selective for one or other of the COX enzymes (Meade et al., 1993; Gierse et al., 1995).
The cause of luteinised unruptured follicle from animal and clinical studies may be
related to COX-2 inhibition and a link between NSAIDs and reversible female infertility
has been proposed (Stone et al., 2002). In the human endometrium around the time of
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implantation, COX-1 and COX-2 are expressed in glandular and luminal cells, and in the
luminal and perivascular cells respectively (Marions et al., 1999). When mifepristone
was administered, epithelial immunostaining of COX-1 and -2 declined. In addition to
illustrating a connection between the PG pathway and steroid hormone action, a function
in endometrial receptivity has been suggested (Marions et al., 1999). COX-2
immunoreactivity levels are greater in the premenstrual phase than the mid-secretory
phase and this coincides with the recruitment of leukocytes into the endometrium
immediately prior to menstruation (Jones et al., 1997).
A variety of PG antagonists have been shown to reduce the implantation site number in
mice and it has been suggested that PGs exert effects on both mother and fetus (Biggers
et al., 1981). Many studies have assessed the effects of the PG pathway on female
fertility and reproductive processes by generating gene knockouts for the various aspects
of the cascade. Some of these will be discussed here although it is important to
remember that reproductive events such as decidualisation and parturition (Gross et al.,
2000a) differ between mice and humans. A double knock-out for COX-1 and COX-2 is
lethal, caused by patent ductus arteriosus (Loftin et al., 2001), and therefore it is not
possible to study the reproductive consequences in mice of complete COX absence.
Targeted disruption of COX-2 in mice leads to problems with the key processes of
ovulation, fertilization, implantation and decidualisation (Lim et al., 1997). Studies in
mice show two distinct pathways for COX-1 and -2 within the uterus implying
independent contributions to uterine PG production but these were also shown to overlap
to some extent (Reese et al., 2001). In a previous study on knock-out mice for COX-1 (-
/-), on pregnancy day 4 demonstrate reductions in vascular permeability and PG
concentration (Reese et al., 1999). However, these reductions were less than those
predicted and further investigation revealed a compensatory response by COX-2
demonstrating interaction between the two enzymes. Mice deficient in the EP2 receptor
exhibit a reduced ovulatory number and a reduced fertility rate (Hizaki et al., 1999). No
alterations in uterine development are apparent. The lack of EP4 receptor expression in
mice knockouts proves to be fatal soon after birth due to malfunction of the ductus
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arteriosus. Mice deficient in cytosolic PLA2 have reduced fertility, smaller litter sizes
and delayed initiation of labour (Bonventre et al., 1997; Uozumi et al., 1997).
1.4.1.1 PGE2 as an Immune Modulator
PGs have been implicated as modulators of immunity (Harris et al., 2002) and in support
of this PGE2 can inhibit many immune cells such as T cells (Goodwin et al., 1983) and
neutrophils (Fantone et al., 1983). Within human semen high concentrations of PGE2
are contained and this is believed to aid reproductive success via inhibition of female
immune responses (Kelly, 1991). Decidual stromal cells are a source of PGE2 and this
PG has been shown to have an inhibitory effect on NK cells via the IL-2 and IL-15
receptors (Parhar et al., 1989; Joshi et al., 2001). Addition of indomethacin or anti-
PGE2 antibody to NK cells in situ revealed an up-regulation of the IL-2 receptor a chain,
IL-2 production and an increased anti-trophoblast killer activity (Parhar et al., 1989).
PGE2 also has the ability to alter the cytokine profile of cells and favour a Th-2 response
in preference to a Th-1 reaction by stimulating IL-10 and inhibiting IL-12 production in
blood monocytes (van der Pouw Kraan et al., 1995).
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The prostaglandin cascade illustrating the two rate-limiting stages (i) PLA2 activity to
liberate free arachidonic acid (AA) from membrane phospholipids and (ii) COX-1/-2
activity in the conversion of AA to PGH2. The PGs and TXAs then act on their specific
GPCRs.
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1.4.2 Cyclic Adenosine Monophosphate (cAMP)
Intracellular second messengers allow the transmission of signals to pass within a cell
and produce an amplification of the signal. One of these important messengers is
cAMP. It is produced from ATP when adenylyl cyclase is activated. The original signal
is then amplified via a stimulated protein kinase cascade. Phosphodiesterases act to
breakdown cAMP and thus counteract the effects of this second messenger. Levels of
cAMP can be raised by the presence of phosphodiesterase inhibitors such as rolipram.
Activators of adenylyl cyclase including forskolin also produce the end result of
increasing cAMP levels. Within the endometrium PGE2 is an activator of adenylyl
cyclase and relaxin inhibits phosphodiesterases (Bartsch et al., 2001) thus raising cAMP
levels. The connection between cAMP and the ovarian sex hormones could be partly via
the progesterone receptor. In the breast cancer cell line, T47D, CAT assays have shown
the ability of cAMP to potentiate the progesterone-dependent activation of the
progesterone receptor but only in the presence of progesterone (Edwards et al., 1993).
In post-menopausal women the antiprogestin, RU486, can act as an agonist in the
endometrium but only when in the presence ofprogesterone (Gravanis et al., 1985). The
effects of RU486 on the endometrium of castrate monkeys has been studied, and RU486
was found to have weak progestational effects in the proliferative phase but strong anti-
progestational effects in the secretory phase (Koering et al., 1986). Experiments on
T47D cells also demonstrated that when RU486 was added in combination with cAMP a
partial agonist activity was produced. This implies cross-talk between a second
messenger signal transduction pathway and a nuclear receptor but whether this also
occurs within the endometrium has yet to be established.
Within the human endometrium, cAMP is the main second messenger involved in the
PGE2 signal transduction pathway (Frank et al., 1994). Evidence for the involvement of
cAMP and its analogues in the decidualisation of human endometrium has been
proposed (Tang et al., 1993a; Brosens et al., 1996; Brar et al., 1997; Brosens et al.,
1999). Experiments using cultures of ESCs have shown that prolactin expression is
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dependent on activation of the PKA pathway (Brar et al., 1997; Telgmann et al., 1997).
Direct use of cAMP results in an increase in prolactin mRNA expression and protein
release (Tang et al., 1993a; Brosens et al., 1996; Brar et al., 1997; Brosens et al., 1999)
and this elevation is a permanent response (Telgmann et al., 1998). They demonstrated
the ability of cAMP to synergise with a synthetic progestin to result in stromal
differentiation and an increase in prolactin levels. Progesterone treatment alone proved
to be a weak inducer of the decidualised phenotype. High intracellular cAMP levels
appear essential by sensitising the cells to progestins and thus providing maximal
prolactin expression. Deletion of the region between position -332 and -270 in the dPrl
promoter caused a strong reduction in the ability of cAMP to induce prolactin expression
implying the importance of this particular region in its activation (Telgmann et al.,
1998).
1.4.3 Interleukin-15 (IL-15)
IL-15 was initially discovered as a stimulator of T-cell proliferation (Grabstein et al.,
1994). It has a molecular weight of 14-15 kDa and is a member of the 4 a-helix
cytokine family. The receptor complex for IL-15 is composed of three subunits. The a-
chain is unique to its receptor but both the P- and y-chains are also common to the IL-2
receptor (Carson et al., 1994; Grabstein et al., 1994). Two forms of IL-15 exist due to
alternative splicing resulting in a long signal peptide (LSP), 48-AA in length, and a short
signal peptide (SSP), 21-AA long (Fehniger et al., 2001) (figure 1.5). The SSP IL-15 is
restricted to the nuclear and cytoplasmic compartments of the cell whereas the LSP has
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The generation of the two isoforms of IL-15, SSP and LSP, from the human IL-15 gene
locus. Diagram recreated from Waldmann et al 2001 (Waldmann et al., 2001).
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1.4.3.1 Systemic IL-15
Human IL-15 has 97% sequence homology compared with simian IL-15 and 73%
homology with murine IL-15 (Anderson et al., 1995). This conservation in IL-15
between species suggests an important biological role. This is compounded by its wide
tissue distribution within humans including skeletal muscle, heart, kidney, placenta and
uterus (Grabstein et al, 1994). Inappropriate production of IL-15 can lead to the
manifestation of a number of human diseases. An implied involvement of IL-15 in
autoimmune and inflammatory diseases such as rheumatoid arthritis and inflammatory
bowel disease support an immune connection with IL-15 (Fehniger et al., 2001). In
contrast, the functions of IL-15 stretch beyond the immune system. In skeletal muscle it
appears to have anabolic properties associated with skeletal muscle fiber hypertrophy
(Quinn et al., 1995). However, knockout mice studies have shown no defects in muscle
development implying a non-critical role in this tissue (Kennedy et al., 2000). Detection
of IL-15 has been reported in human cortical tubular epithelial cells. Both the message
and protein levels are increased by the Th-1 cytokine IFN-y and by ligation with CD40
and it has been suggested that this knowledge may be important in kidney
transplantation (Weiler et al., 1998; Weiler et al., 2001).
1.4.3.2 The Reproductive Relevance of IL-15
Although the actions of IL-2 and IL-15 are reported to be similar, their tissue
distribution is distinct. The uterus and placenta were found to be negative for IL-2
(Jokhi et al., 1994b; King et al., 1995) and so further investigation into other cytokines
that could stimulate uNK cells was undertaken. The novel cytokine, IL-15 was
discovered via detection of both the mRNA (Okada et al., 2000b; Verma et al., 2000)
and protein (Kitaya et al., 2000). Gene profiling has demonstrated an upregulation of
IL-15 during the human "implantation window" compared with the late proliferative
phase. The IL-15 precursor, IL-15 and the a chain of the IL-15 receptor are all
increased by at least three-fold (Kao et al., 2002) and this supports the role of IL-15 in
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the process of implantation. Other studies have also confirmed higher levels of IL-15
mRNA expression in the secretory phase versus the proliferative phase with highest
expression levels in the mid-late secretory phase (Kitaya et al., 2000; Okada et al.,
2000b; Verma et al., 2000; Chaouat et al., 2002). Immunohistochemistry localised IL-
15 to the glandular and luminal epithelium during the proliferative phase and in the mid-
late secretory phase to the perivascular stromal cells (Kitaya et al., 2000). Studies on
stromal cells grown in vitro imply that production of this cytokine is partly under
hormonal control (Okada et al., 2000a). However, the presence of IL-15 is not limited
to the menstrual cycle but is also abundant in first trimester decidua (Kitaya et al., 2000;
Okada et al., 2000b).
The human placenta is an important source of IL-15. Studies utilising a trophoblast
invasion model, JEG-3, discovered IL-15 has the ability to enhance trophoblast invasion
and migration in vitro (Zygmunt et al., 1998) and it is postulated to be involved in this
process in vivo. It is apparent that the ratio of IL-13: IL-15 is important in controlling
this process in vivo since it has been discovered that women experiencing recurrent
spontaneous abortion (RSA) expressed raised levels of IL-13 and IL-15 in endometrial
stromal and epithelial cells with the ratio being in favour of IL-13 (Chegini et al., 2002).
In general terms it is accepted that a Th-2 response is beneficial to pregnancy (Wegmann
et al., 1993), however, the rise in IL-13 expression over that of IL-15 in RSA
endometrium implicates complexity to this classification (Chegini et al., 2002). The
general hypothesis that Th-1 cytokines are detrimental and Th-2 cytokines are beneficial
to pregnancy is probably an over-simplification (Chaouat et al., 2002). This is of
particular importance given the role of IFN-y in the establishment of normal pregnancy
in the mouse (Ashkar et al., 1999; Ashkar et al., 2000).
1.4.3.3 Studies on IL-15 Null Mice
Knockout mice for IL-15 (-/-) have no NK cells present and this suggests a role for IL-
15 in the development and maturation of these cells (Kennedy et al., 2000). Studies
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specifically within the uterus have shown with knock-out studies in mice that mutant
mice lacking uNK cells display irregular oestrous, deficient decidual formation and
thickened blood vessel walls (Miyazaki et al, 2002). In addition to these defects, a
reduced placental size occurs in uNK cell deficient mice (Greenwood et al., 2000). This
supports the theory that these cells are involved in transformation of uterine vasculature
(King et al., 1990). In humans, inadequate artery transformation can result in pre¬
eclampsia, intra-uterine growth retardation (IUGR) and still birth and with the case of
IUGR this programming in utero can be associated with cardiovascular diseases in adult
life (Barker, 1997a; Barker, 1997b).
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1.5 Hypothesis and Aims
Previous studies have identified various factors that are involved in the decidualisation
of endometrial stroma, a process that is essential to a successful pregnancy in humans.
The accumulation of uNK cells across the secretory phase coincides with this decidual
transformation of the stromal compartment. The regulation of uNK cells and their
specific functions in the human uterus are not fully understood although it is likely they
are closely linked to the ESC that is under progesterone control. From the results of
previous research discussed in section 1.2.2.1, a hypothesis of these speculative actions
has been summarised in figure 1.6.
Paracrine interactions between uNK cells and ESCs via cytokines are likely to be
essential to the respective development and functions of both cell types. Specific
products of uNK cells, including IFN-y and IL-10, may be modulating the function of
ESCs in addition to maintenance of inflammatory and immune homeostasis. At this
point in time the ESC cell will be transforming via decidualisation and products of the
uNK cells may be modulating this conversion reaction. Reciprocally, cytokine
production by ESCs will provide communication with uNKs and possibly amend their
cytokine production. Feedback between these cell types will be essential to fine-tuning
the control of these actions and thus establish an environment correctly prepared for
pregnancy.
Prostaglandins are considered important to many of the key reproductive events in the
human uterus although their exact effects are not yet clearly defined. Their actions are
controlled at multiple levels within cells by the activity of various enzymes and this
represents a complex cascade of events. PGE2 is involved in decidualisation of the
endometrial stroma, a process in humans essential to successful implantation.
Expansion in our knowledge of the changes occurring to the PGE2 pathway will provide
a greater understanding of the mechanisms controlling the decidual transformation. This
process is likely to be tightly regulated with modifications at a number of control points
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along the cascade. The transport of PGE2 across the cell membrane is a further control
mechanism post-translationally and will be relevant to transport out of and into cells. In
addition to actions on ESCs, PGE2 can act to modify the actions of IL-15 on the cell
surface of NK cells at the receptor level. PGE2 may also be regulating the production of
cytokines by uNK cells via actions on the IL-15 receptor or directly on its own receptors
at the surface of the cell.
The Main Aims of this Research Project:
1. Further investigate decidualisation of human ESCs in vitro and explore the
functional link between IL-15 and decidualisation.
2. Assess the changes in the prostaglandin cascade during decidualisation of ESCs.
3. Assess the potential factors that are involved in the regulation of IL-15 mRNA
expression and protein secretion in ESCs in vitro and in the human endometrium
and decidua.




The hypothesised interactions between uNK cells and ESCs in the human
endometrium/decidua during the secretory phase and in early pregnancy implicating
the indirect action of progesterone on uNK cell function via the ESC. Studies on
blood NK cells demonstrated that it is the CD56bnght NK cells that may be the major
producers of cytokines (Cooper et al., 2001a). uNK cells may therefore represent an





2.1 Collection, Processing of Human Uterine Tissue and Ethics
Human endometrial specimens were collected from women of reproductive age (n = 77)
who were undergoing gynaecological procedures for benign indications. All women had
regular menstrual cycles with a length of between 25-35 days and had not received
exogenous hormones or used an intrauterine contraceptive device in the 3 months prior to
surgery. For all endometrial biopsies analysed, the stage of the menstrual cycle was
consistent with the patient's reported last menstrual period and histological dating using the
criteria of Noyes et al (Noyes et al., 1950). Samples were classified as menstrual (M),
proliferative (P), and early (ES), mid (MS) and late secretory (LS) phases for the purposes of
Taqman Q RT-PCR. Any cases with severe uterine pathology, for example, polyps or large
fibroids, were excluded. All subjects had a serum sample collected at the time of surgery for
the determination of circulating oestradiol and progesterone levels by RIA. All samples
were consistent with the designated cycle stage based on morphological criteria and last
menstrual period (see table 2.1) (Critchley et al., 2002).
Decidual tissue was collected by two different methods for varying experimental
procedures. For the purpose of the analysis of mRNA expression across the cycle
decidual (n = 5) and trophoblast (n = 4) specimens were obtained from women who had
undergone surgical termination by vacuum aspiration, during the first trimester of
pregnancy. All patients had the termination performed under general anaesthesia. Prior
to vacuum aspiration, decidual tissue distant from the implantation site was removed by
gentle curettage of the uterine lining. Presence and absence of decidual parietalis and
trophoblast respectively was confirmed by examination of haematoxylin and eosin
stained tissue sections. Tissue sections were also stained with cytokeratin to confirm the
presence or otherwise of trophoblast cells within the decidual tissue (Critchley et al,
1996). The endometrial tissue was collected in sterile Roswell Park Memorial Institute
(RPMI) 1640 medium (Sigma, Poole, Dorset, UK). The decidual tissue samples were
processed for messenger RNA (mRNA) extraction alone. The endometrial samples
were divided and processed as follows: (i) homogenisation in Tri Reagent® (a
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monophase solution containing phenol and guanidine thiocynate) to allow mRNA
isolation from DNA and protein; (ii) fixation in 10% neutral buffered formalin (NBF)
overnight at 4°C followed by storage in 70% ethanol preceding wax embedding; and
(iii) separation of endometrial stromal cells (ESCs) by sedimentation (see section 2.2).
A second method of decidua collection was utilised in order to collect tissue for the
uterine Natural Killer cell separation procedure. Insufficient amounts of tissue could be
collected via the former method. In order to collect larger volumes of decidual tissue the
total tissue yield from the suction curettage procedure (used to evacuate uterine
contents) were collected. Decidual tissue (n = 15) was selected by macroscopic
inspection from the products of the termination aspiration procedure (this process was
performed by our trained, Research Sister). Thereafter decidual tissue was collected in
sterile RPMI 1640 medium (Sigma, Poole, Dorset, UK) in preparation for the uterine
Natural Killer cell separation procedure. A small section of tissue was placed in RNA
Later (Ambion Europe Ltd., Cambridgeshire, UK) in order that mRNA could be later
extracted. A second small section of tissue was placed into 10% NBF and following
fixation for 24 hours samples were placed in 70% ethanol preceding wax embedding.
Decidua was only collected from women with a pregnancy of gestation age between 7
and 10 weeks.
Informed patient consent was obtained prior to all tissue collection by a dedicated
Research Nurse. Ethical local research approval had been previously granted by the



























































Details of the endometrial and decidual biopsies studied in this research project. The
median and range of serum oestradiol and progesterone concentrations are included.
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2.2 Endometrial Cell Culture
Endometrial specimens (n = 28) were separated into epithelial and stromal cell
populations by a sedimentation procedure. Specimens were initially washed in
phosphate buffered saline and sliced into l-2mm pieces using scalpel blades. These
were re-suspended in 2ml PBS and digested in collagenase (Sigma) for 80 minutes at
37°C. An 18 gauge needle was used to facilitate tissue breakdown. The cells were then
pelleted by centrifugation and re-suspended in 12ml RPMI 1640 and left for 5 minutes
to settle. The top 10ml were removed as the population of endometrial stromal cells
(ESCs). A Fluorescence Activated Cell Sorter (FACS) had been used to verify the
purity of cells separated by this technique (see section 2.3). The ESCs were further
cultured in RPMI 1640 medium (Sigma) supplemented with 10% foetal calf serum
(FCS) (Mycoplex; PAA, Teddington, UK), penicillin (50 pg/ml; Sigma), streptomycin
(50 pg/ml; Sigma) and gentamycin (5 pg/ml; Sigma). The endometrial specimens used
in the cell culture experiments were predominantly from the proliferative phase.
However, due to a shortage of specimens it was necessary to use some from the early
secretory phases also. These specimens will have been exposed to progesterone in vivo
although those from the proliferative phase had not. It was therefore necessary to grow
all of the cultures in the prescence of progesterone prior to being used in the experiments
so that all cultures had been exposed to progesterone. Cells were cultured m 75cm
culture flasks (Coming Incorporated, Coming, NY) for a minimum period of 5 days and
allowed to reach confluence in the presence of oestradiol (10"7 M),
Medroxyprogesterone acetate (MPA) (10"6 M) and basic fibroblast growth factor (bFGF)
(5ng/ml). These supplements also provide optimum conditions for ESC growth (Irwin et
al., 1991).
2.3 Fibroblast Cell Purity
Cultures of ESCs were grown for two weeks before the purity of fibroblasts in the
cultures (n = 6) was determined by a Fluorescence Activated Cell Sorter (FACS)
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(Beckmann Coulter). This was achieved by using a human fibroblast antigen Ab-1
(Oncogene). About 1 million ESCs were taken from an ESC culture following
trypsinisation, re-suspended in 200pl Cell Separation Media (CSM) (PBS 0.5% bovine
serum albumin; 2mM EDTA) and split between three 1.5ml Eppendorf tubes. Into one
tube 2pl of the fibroblast antibody was added and mixed and the tubes were left on ice
for 30 minutes. The tubes were spun at 4000rpm for 1 minute to pellet the cells, which
were re-suspended in 1ml CSM. This wash was repeated twice more. To two tubes
lOOpl CSM and lOpl anti-mouse IgG whole molecule with FITC conjugated (Sigma)
was added and cells re-suspended. The remaining tube is used as a "blank". The tube
exposed to only the anti-mouse IgG whole molecule with FITC conjugated is the
negative isotype-matched control. The tubes were wrapped in foil to prevent light
exposure and kept on ice for 30 minutes. Tubes were washed as before and re-
suspended in 500pl FACs buffer (PBS 0.1% Azide; 1% FCS). Before passing the cells
through the FACS machine the cell suspensions were passed though cell strainers
(Becton Dickinson Labware Europe, France) to ensure a single cell suspension. See
figure 2.1 for an example of the FACS reports.
2.3.1 Fluorescence Activated Cell Sorter (FACS)
A Coulter ® EPICS® XL™ Flow Cytometer was the FACs machine used to measure the
purity of the cells. This machine allows the purity of a specific cell type within a mixed
population of cells to be measured. The cells are passed through an aperture as single
cells. The laser beam detects cells and registers them as an event. The laser beam is
able to determine two properties of each cell: the granularity and cell size. The
granularity is read by the amount of side scatter of the laser beam and the cell size
determined by the degree of forward scatter. The third measurement made by the laser
beam is fluorescence, in this case fluorescein. The three measurements combined
illustrate the distinct populations of cells that are present and the percentage of
fluorescent gives the percentage of fibroblast-positive cells in the sample.
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Figure 2.1
A representative example of the FACS recordings for the fibroblast purity of ESCs after
2 weeks in culture. The isotype-matched negative control (A) and the sample incubated
with the fibroblast antibody (B). On graph (i) the y axis is the log of the forward scatter
and the x axis is the log of the side scatter. The total number of counts is illustrated on
this graph and the region within the red line represents the gated area of cells analysed.
The remainding points that are outside of this region are likely to be cell debris or red
blood cells and are therefore excluded from analysis. On graph (ii) the y axis is the total
cell count and the x axis is the FITC value - the total level of fluorecence detected on
the cells counted within the gated region in graph (i). The region represented by the
green line indicates the number of cells that are positive for FITC. This is minimal in
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2.4 Messenger RNA Extraction and Reverse Transcription-Polymerase Chain
Reaction (RT-PCR)
2.4.1 Messenger RNA Extraction
The medium on the treated cell cultures was pipetted off and either frozen at -20°C or
maintained at 4°C if being used immediately. Cells were washed in PBS twice to
remove the remnants of medium. Onto each well of a 12-well plate, 0.5ml tri-reagent
was added whereas if 6-well plates or small flasks had been used, 1ml of tri-reagent per
well or flask was added. Cells were left for 5 minutes to allow rupture of cell
membranes to take place. The contents of the wells/flasks were then transferred to phase
lock gel tubes (Eppendorf, Hamburg, Germany) and kept on ice for the remaining
extraction. Chloroform was added at 200pl/ml and the tubes shaken vigorously for
several seconds. They were spun in a pre-cooled, refrigerated centrifuge at 4°C,
14000rpm for 20 minutes to remove the organic phase containing protein and DNA that
become trapped beneath the gel layer. The top aqueous phase containing the mRNA
was poured into labelled 1.5ml eppendorfs. Into each tube 500pl of isopropanol was
added and tubes were inverted a couple of times before being left on ice for 1 hour.
They were spun in a pre-cooled, refrigerated centrifuge at 4°C, 14000rpm for 15 minutes
to pellet the mRNA. The majority of the isopropanol was removed using a sterile
Pasteur pipette and 500pl of 70% ethanol added to each Eppendorf. After being
inverted the tubes were spun for 5 minutes in a pre-cooled, refrigerated centrifuge at
4°C, 14000rpm. The ethanol was removed from each tube and between 20-50pl RNA
Storage Buffer (RSB) was added depending on the size of the mRNA pellet. Samples
were left to dissolve in the RSB for a minimum of 30 minutes.
The concentration of total RNA in the samples was then measured using a Biotech
photometer (WPA, Cambridge, UK). Each sample was vortexed and 2.5pl removed,
which in turn was diluted in 2ml distilled water. All tubes were thoroughly mixed
before measuring the wavelength at both 260nM and 280nM on the photometer. A
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blank used to zero the machine consisted of 2.5pl RSB diluted in 2ml of distilled water.
All samples were then diluted in Diethylpyrocarbonate-treated water (Depc water) to a
concentration of lOOng/pl.
2.4.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Messenger RNA samples (at lOOng/pl) were reversed transcribed using a multiscribe
reverse transcriptase (1.25 IU/pl), random hexamers (2.5 pmol/1), MgCh (5.5 mmol/1),
dNTPs (lmmol/1) and an RNAase inhibitor (0.4 IU/pl) was added (PE Biosystems,
Warrington, UK). All reactions consisted of 16pl of reverse transcription mix per tube
and 4pl of mRNA. Once the contents of the tube were mixed, 50pl of mineral oil was
added to prevent evaporation of the reaction mix during the reverse transcription
process. Samples were incubated for 20 minutes at 25°C, 60 minutes at 42°C and then at
95°C for 5 minutes (Omnigene PCR machine, UK). The resulting cDNA was then
diluted 2.5x with TE buffer (10mmol/l Tris pH8.0 and lmmol/1 EDTA in DEPC water)
and were stored at 4°C.
The precision of the reverse transcription (RT) reaction was calculated by a colleague,
Elena Faccenda (laboratory research support). An mRNA sample was taken and 8 RT
reactions set up in 8 separate tubes. These were compared in a single PCR run on one
primer and probe set. The precision was found to be 3.65%.
2.5 Quantitative Real-time-PCR (Q RT-PCR)
This procedure allows the quantitative detection and measurement of a specific sequence
of complementary DNA (cDNA). Primers and probes were designed individually for
each DNA target sequence using the Primer Express computer program. The probe has
a reporter dye and quencher dye attached to the 5' and 3' ends respectively. Whilst
intact, the close proximity of the reporter to the quencher suppresses fluorescence of the
reporter. If the target sequence is present the probe anneals to the cDNA in between the
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blank used to zero the machine consisted of 2.5pl RSB diluted in 2ml of distilled water.
All samples were then diluted in Diethylpyrocarbonate-treated water (Depc water) to a
concentration of lOOng/pl.
2.4.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Messenger RNA samples (at lOOng/pl) were reversed transcribed using a multiscribe
reverse transcriptase (1.25 IU/pl), random hexamers (2.5 p.mol/1), MgCh (5.5 mmol/1),
dNTPs (1 mmol/1) and an RNAase inhibitor (0.4 IU/p.1) was added (PE Biosystems,
Warrington, UK). All reactions consisted of 16pl of reverse transcription mix per tube
and 4pl of mRNA. Once the contents of the tube were mixed, 50pl of mineral oil was
added to prevent evaporation of the reaction mix during the reverse transcription
process. Samples were incubated for 20 minutes at 25°C, 60 minutes at 42°C and then at
95°C for 5 minutes (Omnigene PCR machine, UK). The resulting cDNA was then
diluted 2.5x with TE buffer (10mmol/l Tris pH8.0 and lmmol/1 EDTA in DEPC water)
and were stored at 4°C.
The precision of the reverse transcription (RT) reaction was calculated by a colleague,
Elena Faccenda (laboratory research support). An mRNA sample was taken and 8 RT
reactions set up in 8 separate tubes. These were compared in a single PCR run on one
primer and probe set. The precision was found to be 3.65%.
2.5 Quantitative Real-time-PCR (Q RT-PCR)
This procedure allows the quantitative detection and measurement of a specific sequence
of complementary DNA (cDNA). Primers and probes were designed individually for
each DNA target sequence using the Primer Express computer program. The probe has
a reporter dye and quencher dye attached to the 5' and 3' ends respectively. Whilst
intact, the close proximity of the reporter to the quencher suppresses fluorescence of the
reporter. If the target sequence is present the probe anneals to the cDNA in between the
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forward and reverse primer sites and this is referred to as the polymerisation step. The
sequence of either strand must be complementary to the probe for it to attach. The Taq
polymerase has nuclease activity in the 5' to 3' direction and cleaves the probe in
between the reporter and quencher. This can only take place if the probe has hybridised
to the target sequence of cDNA. Cleavage of the probe allows separation of the reporter
dye from the quencher dye with the result being an increase in fluorescence. This
increase in fluorescence allows the accumulation of PCR products to be measured
directly.
The FAM Ct is the cycle number when the fluorescent signal crosses an arbitrary
threshold value. The 18-S is a measure of the mRNA content of the sample and is used
as an internal control for mRNA variation between samples. The ACt is the difference
between the FAM Ct and the 18-S reading and enables the amplified signal to be
normalised against the total mRNA content. The mean ACt between the duplicates on
the PCR plate was calculated. This was then used to calculate the AACt which is the
difference between the ACt of a treated sample relative to the control in that experiment.
Within each experiment the ACt was related to its own control. The 2"AACt is then
calculated which shows the fold increase or decrease in mRNA expression of the
samples in relation to their control with each control always having a 2"AACt of 1.
All primer and probes sets used on the ABI Prism 7700 PCR machine were purchased
from Biosource (Belgium). The sequences for these are listed in table 2.2. Primers were
diluted to 250pM and probes to 50pM in TE buffer (lOmM Tris; ImM EDTA in Depc
H2O). A PCR master mix was made up using the Stratagene Brilliant Quantitative PCR
Core Reagent kit (Amsterdam, Netherlands) (7.2mM MgCl2; 1.6mM Stratagene dNTP
mix; 1.6mM Boehringer dNTP mix; 0.05U/pl Taq Polymerase; 2x PCR Buffer and
0.06% Reference dye diluted in Depc H2O). Sample to be tested were ran in duplicate
wells on the PCR plate (Applied Biosystems, UK). For each sample, a tube containing
45pi PCR Master Mix and 5pi cDNA was mixed and 23pi pipetted into two separate
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wells on the PCR plate. Two wells containing 5pl of Depc H20 in place of cDNA were
added to each run to serve as a negative control.
The primer and probe sets used were validated with respect to the linearity of the
response. Graphs of the log of total RNA in ng were plotted against the mean ACt value
of three replicates. The regression line of the graph (y) needed to be < 0.1 in order that
the primers and probe could be validated (Figure 2.2). The intra-assay variation was
calculated as a precision value (relative standard deviation) calculated from the mean of
six replicates of identical cDNA ran on the PCR machine in the same run. This value is
expressed as a percentage. (See table 2.3).
85
Table 2.2
Details of the primer and probe sets used in Q RT-PCR in this study. The accession




































































































































































y = 0.062x + 13.82
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log ng total mRNA
Figure 2.2
An example of a linearity plot for the primer and probes used for Q RT-PCR. This
figure is the plot for the prolactin primer and probes. The y value for this particular plot
is 0.062 and is an indication of the linearity.
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Validation and precision values for the primer and probe sets used in the present study.
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To ensure that no genomic DNA contamination was present in the mRNA samples, the
p-actin level was measured in the controls from each experiment and in all the RNA
samples used for analysis across the menstrual cycle. The samples were not processed
for the reverse transcription stage and were measured directly by Q RT-PCR in place of
adding cDNA. An arbitrary level of 27, which was 3 standard deviations away from the
mean of all samples, was set and any endometrial samples falling below this level were
excluded from analysis. One sample was excluded for this reason. Figure 2.3 represents












♦ ♦ 4 ♦
.♦.•v'"V * /.♦/♦*&v^ '
♦ % ♦ ♦
&
0 20 40 60 80 100 120
Sample number
Figure 2.3
The P-actin levels for the experimental control mRNA samples and for the samples used
in across the menstrual cycle analyses. The cycle number represents the fluorescence
threshold level for all of the samples. Any samples with a value below 27 were
excluded from the study. Therefore, the sample circled in red was omitted.
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2,6 Eifiscyitie-lieked ImmmoabsorbantAss^
An enzyme-linked itronun'oabsOrbaM assay;, m BEJSA, can be used to detect and
measure various protein's released by;'cells during: in vWo> culture. The media in which
the cells have been grown and treated whs collected and stored at -20°C. The ELISA
detects the amount of a; particular protein present and measures this against a standard
curve to give the concentration of protein present in the media sample. There are two
types of ELISA that will be discussed: the: Two-site sandwich ELISA (section 2.6.1) and
the Competition ELISA (section 2.6.2). Both types are run on Maxisorp 96-well plates
(Nunc, Denmark). Method files for each ELISA were constructed in Assay Zap and
contained information concerning the range of standards used and the level of non¬
specific binding. This allows a standard curve to be produced against which the samples
can be measured against,
2.6.1 Two-site' Sandwich" ELSXA
Prior to the assay, plates are coated with capture monoclonal antibody that is specific
against the protein of interest Blocking and- protecting medium (2% Polyvinyl
Pyroliidone; 5mg/ml BSA; 0.5ml/litre Preservatives (2G0mg/ml 5-bromo-5-nitro-l, 3-
dione and 200mg/ml 2-methyl-4-isothiazolin-3-one in DMF/DMSO 1:2); 5mM EDTA;
50mM EDTA) is added to prevent non-specific binding and reduce background
recordings aeross all samples. The samples are incubated with the standards, quality
controls (of a set concentration in multiple replicates), non-specific binding wells and
finally the media samples to be assayed. Any free, specific protein in the wells will
spontaneously bind to the capture antibody on the base and sides of the well. Excess
media is discarded and washed away before a biotinylated detection antibody
(secondary) is added. This will bind to the protein already bound on the plate and this is
detected with streptavidin peroxidase conjugate (SPC), diluted in assay buffer (see
specific assays for details). After washing; the plates once more to remove any unbound
SPC, substrate is added.. The peroxidase substrate consisted of 20ml sodium acetate
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(pH 6; lOOmM), 2ml 0.5% urea hydrogen peroxidase (pH 6) and 2ml tetramethyl
benzidine (3mg/ml). Any bound peroxidase will metabolise the hydrogen peroxide
present in the substrate and the tetra methyl benzidine will be converted into a coloured
product. The reaction is stopped by addition of 2N sulphuric acid. The colour is then




The capture antibody is bound to the
base and sides of the wells.
Stage 2:
Any antigens in the media specific to
the capture antibody bind.
Stage 3:
A biotin-labelled detection antibody is
added and it binds to the bound antigen.
Stage 4:
Streptavidin peroxidase conjugate is
added to the wells and this converts the












Description of the stages and principles of a two-site sandwich ELISA.
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2.6.2 Competition ELISA (PGF2ctand PGE2)
A Competition ELISA (see figure 2.5) works on a different basis to the Two-site
sandwich ELISA. Initially plates are coated with a purified donkey anti-rabbit antibody
(Sapu, Scotland, UK). Blocking and protecting medium is added to block any non¬
specific binding and reduce background. For the PGE2 ELISA, a PGE2 anti-sera (AS)
raised in rabbit is added to the wells and this will bind to PGE2. Since the coating
antibody is anti-rabbit, this will also bind with the AS. Biotinylated labelled PGE2 is
added at the same time and this is referred to as the Link. Samples are added in this
same step and this allows the PGE2 protein in the sample to compete with the Link for
binding sites on the AS. As in other ELISAs, a standard curve and quality control wells
are added to the plate. The standard contains unlabelled PGE2 that will compete for
biding sites on the AS in the same way as for the unknown samples. The maximum
binding is measured by addition of the Link and AS in duplicate wells and this is
referred to as the B0 value. The assay works on the principle that the greater the level of
PGE2 in the sample the greater the amount of displacement of the Link. This results in
lower streptavidin binding and thus less colour product in the wells.
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Stage 1:
The PGE2/PGF2a in the sample
competes with the biotin-labelled link













The streptavidin peroxidase binds to the
biotin on the bound link and converts
the substrate into a coloured product
that can be measured. The greater the
level of PGE2/PGF2a in the sample, the











Description of the stages and the principles of a Competition ELISA.
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2.7 Immunohistochemistry
The immunohistochemical method used was a standard avidin-biotin peroxidase (ABC)
method allowing specific proteins within formalin fixed and paraffin embedded
endometrial tissue sections to be detected and visualised. Avidin and biotin have a high
affinity for one another and it is this property that is the basis of the method. A primary
antibody is added and will bind specifically to the protein of interest in the tissue
section. A biotinylated secondary antibody that is specific to the species in which the
primary antibody was raised is added and will thus bind to the primary antibody.
Addition of an avidin-biotin and horseradish peroxidase enzyme complex will result in
any free sites on the avidin molecule binding to the biotin on the secondary antibody.
When 3,3 diaminobenzidine (DAB) is added it becomes oxidised the resulting colour
change of the chromagen causes an insoluble brown precipitate to form at the site of the
protein of interest.
2.7.1 Preparation
Tissue sections and cultured cells embedded in agarose and then in paraffin wax were
dewaxed in histoclear for 5 minutes. Slides were transferred into a second vial of
histoclear for a further 5 minutes. The sections were dehydrated in an alcohol series
starting in absolute ethanol for 20 seconds, then into 95% ethanol and finally 70%
ethanol, each for 20 seconds. Slides were transferred into dt^O and washed once in
PBS.
2.7.2 Scoring of Immunohistochemistry
A semi-quantitative scoring system was used to measure the location and intensity
immunostaining. The sections were scored blind and individually by two observers.
The following system was employed: 0 = no immunoreactivity; 1 = faint
immunoreactivity; 2 = moderate immunoreactivity; 3 = strong immunoreactivity. All of
the slides analysed were included in the same immunohistochemical run and therefore a
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fair comparison could be made between them. Initially all of the slides were examined
briefly to assess the extremes in staining intensity. The staining intensity and area of
staining across each slide was considered as a whole before deciding on the score value
to give it. The two observers then came together and compared the scores they had
asigned. If there were any discrepancies the slides were re-examined and a mutal
decision made on the score that should be given.
2.8 Statistical Analysis
Significant difference of the Q RT-PCR and ELISA data was determined by analysis of
variance (ANOVA) using the computer package Statview 3.0. Individual differences
were assigned using Fisher's protected least square differences (PLSD) test.
The IL-15 immunohistochemistry results were analysed by Kruskal-Wallis analysis and
Dunn's Multiple Comparisons Test used to assign significance (Instat 2.03). This
approach was necessary since the data is non-continuous.
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3. Features of Endometrial Decidualisation - in vitro studies
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3.1 Introduction
The sequential development of the human endometrium is a prerequisite for successful
implantation and continued pregnancy (Wilcox et al., 1999; Lessey, 2000). In humans,
the stromal compartment of the endometrium experiences a transformation across the
mid- and late-secretory phases of the menstrual cycle referred to as decidualisation.
This begins within the perivascular stromal cells and spreads throughout the stromal
region contributing to the formation of decidua in pregnancy. The cells become larger
and more rounded in appearance (figure 3.1) with intracellular structural rearrangements
and increasing stromal oedema. The major in vivo trigger of these adaptations is
considered to be progesterone acting upon oestrogen-primed cells (Milligan et al., 1995;
King, 2000). The differentiation of these cells runs parallel with the rise in progesterone
levels across the secretory phase. Studies in vitro on primary cultures of human
endometrial stromal cells (ESCs) have revealed that this process is complex implicating
the involvement of other factors such as PGE2 (Frank et al., 1994), relaxin (Tabanelli et
al., 1992; Lane et al., 1994) and cAMP (Tang et al., 1993a; Yee et al., 1993; Brar et al.,
1997) in addition to progesterone. More recently, Activin A, a member of the TGF-P
superfamily, has been implicated as another inducer of decidualisation in ESC at least in




Diagrammatic illustration of the various factors thought to be involved in decidualisation
of human ESCs to decidualised stromal cells (DSC), highlighting the multi-factorial
nature of the process.
102
PGs are synthesised from the intermediate, PGH2, (see sections 1.4.1 and 2.1 for details)
by specific PG synthases (Smith et al., 1996; Smith et al., 1996; Murakami et al., 2003).
PGE2 and PGE2 synthase are located in glandular, stromal and epithelial cells in the
functional layer of the human endometrium at all cycle stages with a reduction in
stromal staining in the late secretory phase (Milne et al., 2001). Prostaglandins may be
important in the secretory phase and specifically during the implantation window since
the EP2 receptor is up-regulated 4-fold compared with the late proliferative phase as
shown by gene profiling (Kao et al., 2002). There are four sub-types of the PGE2
receptor, EP1-4 and activation of the EP2 and EP4 receptors (section 1.4.1) leads to
stimulation of adenylate cyclase and the cAMP/protein kinase A pathway (Narumiya et
al., 1999). Relaxin is a phosphodiesterase inhibitor and therefore has the ability to
maintain intracellular cAMP levels by inhibiting the action of phosphodiesterases, which
breakdown cAMP. The principal source of relaxin in the female reproductive tract is the
corpus luteum in the luteal phase and throughout pregnancy (Weiss et al., 1978;
Blankenship et al., 1994; Bani, 1997; Sunder et al., 2000). Relaxin is also expressed in
the endometrium and decidua (Bryant-Greenwood et al., 1993). Epithelial and stromal
cells have been reported to display immuno-reactivity for relaxin with an increase in
intensity across the secretory phase and throughout pregnancy.
It is not only the morphology of the stromal cells that transforms with decidualisation,
but also their function. The stroma provides more extensive functions than a mere
supportive structural role. It is believed that decidualised stromal cells are important in
providing homeostasis during implantation and trophoblast invasion (Lockwood et al.,
1999). Progesterone receptor knock-out mice fail to exhibit decidualisation and this is
associated with implantation failure (Rider, 2002). Trophoblast invasion in humans is
significantly deeper in areas where the uterus is deficient in decidua caused by scar
tissue. Imbalances in implantation and placentation can result in uterine rupture or the
later development of pre-eclampsia (Loke et al., 1997) highlighting the necessity for
tight regulation of these events. The depth of trophoblast invasion in humans is under
the influence of hCG, progesterone and oestradiol (Mitreski et al., 2003) and in ectopic
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pregnancies, the extent of trophoblast infiltration has also been shown to be influenced
by hCG levels (Natale et al., 2003). In humans, whether the process of decidualisation
is irreversible is a matter for discussion and will be addressed in this chapter. Relaxin
has previously been shown to acutely and permanently raise intracellular cAMP levels in
cultured ESCs, resulting in prolactin secretion (Telgmann et al., 1997).
Documented markers of the decidualisation process include prolactin (Maslar et al.,
1979; Tseng et al., 1999) and IGFBP-1 (Bell et al., 1991; Bryant-Greenwood et al.,
1993; Lee et al., 1997) and these can be used as guidelines to observe and identify
decidualisation in vitro. In humans, prolactin levels start to increase in early secretory
phase endometrial stroma reaching maximal levels in decidua as shown by
immunohistochemistry (Bryant-Greenwood et al., 1993). This study also revealed a rise
in IGFBP-1 immuno staining with a different timing of appearance to that of prolactin.
IGFBP-1 was absent from proliferative and early secretory phase endometrium but
began to appear in the mid secretory phase followed by a dramatic rise in the late
secretory stroma (Figure 3.2). Other markers of decidualisation that have been
identified in human and rat decidual stroma include vimentin, desmin, laminin and
fibronectin (Glasser et al., 1986; Glasser et al., 1987; Van Muijen et al., 1987) and
these represent structural rearrangements within the cells.
The number of uNK cells present in the human endometrium increases across the
secretory phase, particularly in the mid-secretory phase. This implies hormonal control
over these cells (King et al., 1989b) although they do not express the nuclear
progesterone receptor (King et al., 1996; Henderson et al., 2003). Studies on uNK cells
have demonstrated the ability of the cytokine IL-15 to stimulate proliferation of these
cells in vitro (Verma et al., 2000). A relationship between IL-15 and progesterone-
induced decidualisation of human ESCs in vitro has been proposed (Okada et al.,
2000a). This provides a link between the functions of ESCs and uNK cells within the
endometrium that may be important to successful embryo implantation and early
pregnancy maintenance.
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This chapter examines decidualisation in ESC cultures in vitro, studying the effects of
treatment with a synthetic progestin, PGE2 and 8-Bromo cAMP on the expression and
release of prolactin and IGFBP-1. Using these data as an indication of decidualisation in
these cultures a comparison between IL-15 mRNA expression and decidualisation in
vitro has been made. Levels of the genomic progesterone receptor expression in these
cells have been established. The effect of withdrawing decidualisation treatment on




Photomicrographs of non-decidualised ESC (a) and decidualised ESC (b) primary
cultures. The decidualised ESCs were treated for 6 days with a synthetic progestin,
MPA, (10"6 M) plus 8-Bromo cAMP (250pM) and have become much rounder in
appearance compared with the non-decidualised ESCs. Scale bar represents 300pm.
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Figure 3.3
Schematic diagram of the variation in stromal immuno staining intensity of prolactin and
IGFBP-1 across the human menstrual cycle and throughout pregnancy. Based on data
from Bryant-Greenwood et al 1993 (Bryant-Greenwood et al., 1993).
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3.2 Materials and Methods
3.2.1 Human Uterine Tissue Collection
Proliferative (n = 5) and early secretory (n = 4) endometrial biopsies were collected and
processed as described earlier (section 2.1). All samples were processed to separate the
ESCs from the glands, as described in section 2.2. The cells were grown for a period of
two weeks prior to commencing experiments in the presence of Medroxyprogesterone
acetate (MPA) and bFGF.
3.2.2 in vitro Primary Cell Culture Studies - Decidualisation
ESCs were seeded in 12-well plates at a concentration of 1.4x10s cells/ml and allowed to
adhere overnight. The following treatment regimes were employed as detailed in tables
3.2 and 3.3. The experiments were designed to study in vitro decidualisation of ESCs.
MPA is a synthetic progestin and is relatively stable. It was selected as a treatment to
analyse the effects of a progestin alone on in vitro decidualisation. Both PGE2 and
synthetic cAMP analogues have previously been acknowledged as stimulators of
decidualisation in vitro and were therefore included in the treatment regime (see section
3.1). 8-Bromo cAMP is a cAMP analogue and was selected because it is readily
absorbed by cells and partially resistant to phosphodiesterases. In addition, the
combined effects of MPA plus PGE2 or 8-Bromo cAMP were assessed. The experiment
detailed in table 3.3 was designed to determine whether a continuous supply of
treatments was required to sustain decidualisation in ESCs in vitro. Relative levels of
prolactin mRNA will be analysed to assess this (see 3.2.5).
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Table 3.2
Experiment 1: Decidualisation of ESCs (n = 4)
Treatment Concentration Incubation time
Control n/a





pge2 + mpa io~6m+ io-6m
8-Bromo camp 250pm
8-Bromo camp + mpa 250pm + 10~6m
Table 3.3
Experiment 2: Decidualisation of ESCs and treatment removal (n = 5)
Treatment Concentration Incubation time
Control N/A 5 days, 5 days followed
by 5 days with treatment
withdrawal, 10 days
continuous treatment
PGE2 + MPA 10~6M+ 10"6M
8-Bromo cAMP + MPA 250pM+ 10"6M
3.2.3 Prolactin ELISA
Media collected from experiment 1 at the termination of the time-points, (4, 8 and 12
days), was assayed on a commercial Wallac DELFIA® Prolactin kit (PerkinElmer™
Life Sciences, Wallac Oy, Turku, Finalnd). The kit instructions were adhered to with
the exception that 150pl of sample media was added in place of the suggested 25pl to
increase the sensitivity of the assay.
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3.2.4 IGFBP-1 ELISA
Media collected from experiment 1 at the termination of the time-points, (4, 8 and 12
days), was assayed for IGFBP-1 using a two-site sandwich ELISA (section 2.6.1) (R &
D Systems). Plates were coated with the IGFBP-1 capture antibody and incubated
according to the IL-15 ELISA method. The antibody was added at 2pg/ml and lOOpl
per well. The plates were washed prior to use and a standard curve added in single wells
to each plate consisting of eight standards starting with a top standard of 8ng/ml. 1:2
dilutions were performed until the bottom standard of 0.06ng/ml was obtained. Buffer
plus Tween (B+T) was used to dilute samples and NSB wells were added as lOOpl of
B+T. A quality control was made up at 700pg/ml from the IGFBP-1 standard and added
in quadruplicate wells to each plate. All media samples to be tested were added in
quadruplicate wells, lOOpl per well. Plates were sealed and incubated for 2 hours on a
plate shaker at room temperature. The plates were washed in wash buffer four times
each and tapped dry. The IGFBP-1 detection antibody was then added at O.lpg/ml and
lOOpl per well and incubated at room temperature for 2 hours on a plate shaker. Plates
were washed as before and tapped dry. Streptavidin peroxidase conjugate (Roche) was
diluted in B+T to 0.125U/ml and lOOpl pipetted into all wells. Plates were sealed and
incubated for 20 minutes on a plate shaker at room temperature. The plates were then
washed as before and lOOpl of substrate added per well. Plates were allowed to develop
for 15 minutes before stopping the reaction with 50pl of 2N sulphuric acid per well. All
plates were read on a plate reader at 450nM. The computer program Assay Zap was
used to analyse the results and construct a standard curve against which the samples
could be judged.
3.2.5 RNA Extraction and Q RT-PCR
The RNA was extracted and cDNA prepared from the ESC experiments 1 and 2.
Prolactin, IGFBP-1, IL-15 and progesterone receptor mRNA levels were measured by Q
RT-PCR as described in section 2.5.
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3.2.6 Statistical Analysis




3.3.1 Decidualisation of ESC Studies
3.3.1a Prolactin mRNA Expression and Release by ESCs
The mRNA expression of prolactin after 4 days is almost 4-fold greater than controls
with MPA or with 8-Bromo cAMP treatment. Treatment with a combination of MPA
and 8-Bromo cAMP stimulated a 22-fold increase in prolactin mRNA levels (P <
0.017). Prolactin protein released into the media after 4 days was below the minimum
detection limit (250pg/ml) of the ELISA. After 8 days of treatment the combined
treatment of PGE2 and MPA had caused a 40-fold rise in prolactin mRNA relative to
controls. A 163-fold increase in prolactin mRNA was produced by treatment with 8-
Bromo-cAMP and MPA in combination (P < 0.006). This was comparable with the
ELISA data that recorded 3-fold and 9-fold increases in prolactin release with PGE2 plus
MPA and 8-Bromo-cAMP plus MPA (P < 0.009) treatment respectively. The same
pattern of prolactin mRNA expression and protein release were observed after 12 days
of treatment. PGE2 plus MPA stimulated an 11-fold rise in mRNA and a 9-fold increase
in protein levels. 8-Bromo-cAMP plus MPA triggered a 29-fold increase in prolactin
mRNA levels (P < 0.03) and a 22-fold increase in protein release (P < 0.028). Modest




Relative levels of prolactin mRNA expression after 4 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, a p< 0.017.
Figure 3.4
}
Relative levels of prolactin mRNA expression after 8 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, bp < 0.006.
Figure 3.5
Relative levels of prolactin mRNA expression 12 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same




Prolactin protein release by human ESCs over 48 hours after 8 days of treatment with a
variety of treatments designed to stimulate decidualisation in ESCs in vitro. Same
letters denote significant difference, a p < 0.009. The lower detection limit of the
ELISA was 0.25ng/ml.
Figure 3.7
Prolactin protein release by human ESCs over 48 hours after 12 days of treatment with a
variety of treatments designed to stimulate decidualisation in ESCs in vitro. Same



























3.3.1b IGFBP-1 mRNA Expression and Release by ESCs
The mRNA expression for IGFBP-1 was increased considerably by treatment of ESCs
with PGE2 plus MPA (1766-fold increase) and 8-Bromo cAMP plus MPA (9075-fold
increase) (P < 0.019) after 4 days. Treatment with PGE2 alone resulted in a 32-fold rise
in IGFBP-1 mRNA expression relative to controls. 8-Bromo cAMP promoted a fold
increase of approximately 800. These results were consistent with the IGFBP-1 ELISA
data, illustrating a 25-fold increase in protein release on day 4 with PGE2 plus MPA
treatment and an 85-fold increase following incubation with 8-Bromo-cAMP plus MPA
(P < 0.034). After 8 and 12 days of incubation with the treatments corresponding
patterns in mRNA expression and release were observed.
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Figure 3.8
Relative levels of IGFBP-1 mRNA expression after 4 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference. a/> < 0.019
Figure 3.9
Relative levels of IGFBP-1 mRNA expression after 8 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, b p < 0.015,
Figure 3.10
Relative levels of IGFBP-1 mRNA expression after 12 days of treatment with a variety
of treatments designed to stimulate decidualisation in ESCs in vitro. The numbers
located above the error bars indicate the fold increase in expression relative to controls.




IGFBP-1 protein release (pg/ml) by human ESCs over 48 hours after 4 days of treatment
with a variety of treatments designed to stimulate decidualisation in ESCs in vitro.
Same letters denote significant difference, a p < 0.034. The lower detection limit of the
ELISA was 60pg/ml.
Figure 3.12
IGFBP-1 protein release (pg/ml) by human ESCs over 48 hours after 8 days of treatment
with a variety of treatments designed to stimulate decidualisation in ESCs in vitro.
Same letters denote significant difference, bp < 0.011. The lower detection limit of the
ELISA was 60pg/ml.
Figure 3.13
IGFBP-1 protein release (pg/ml) by human ESCs over 48 hours after 12 days of
treatment with a variety of treatments designed to stimulate decidualisation in ESCs in
vitro. Same letters denote significant difference, c p < 0.034. The lower detection limit
of the ELISA was 60pg/ml.
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3.3.2 Decidualisation State of ESCs Following Treatment Removal
After 5 days of treatment the mRNA expression of prolactin was 77-fold and 261-fold
greater compared with controls proceeding treatment with PGE2 plus MPA and 8-Bromo
cAMP plus MPA (P < 0.017) respectively. Treatment of ESCs for 5 days and then a
further 5 days of culture with removal of treatments gave rise to a 44-fold increase in
those initially incubated with PGE2 plus MPA and a 139-fold increase following 8-
Bromo cAMP plus MPA (p < 0.04) pre-treatment. After 10 days of continuous
incubation with the treatments, PGE2 plus MPA and 8-Bromo cAMP plus MPA




Relative levels of prolactin (prl) mRNA expressed in ESCs treated for 5 days with
decidualising stimuli. The numbers located above the error bars indicate the fold




Relative levels of prolactin (prl) mRNA expressed in ESCs treated for 5 days with
decidualising stimuli followed by 5 days of treatment withdrawal. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, b p < 0.04.
Figure 3.16
Relative levels of prolactin (prl) mRNA expressed in ESCs treated for 10 days with
decidualising stimuli. The numbers located above the error bars indicate the fold







3.3.3 IL-15 mRNA Expression in ESCs Treated with Decidualising Stimuli in vitro
After 4 days of treatment with PGE2 plus MPA an 11-fold increase in IL-15 mRNA
expression was observed relative to controls and a 22-fold rise in ESCs treated with 8-
Bromo cAMP plus MPA (p < 0.023). After 8 days of treatment with PGE2 plus MPA
and 8-Bromo cAMP plus MPA (p < 0.028) 26- and 60-fold increases in IL-15 mRNA
expression were recorded. Following a further 4 days of treatment on day 12, PGE2 plus
MPA and 8-Bromo cAMP plus MPA (p < 0.028) had stimulated 20- and 168-fold
increases in IL-15 mRNA levels compared with controls. MPA added alone produced a
2-fold increase in expression and 8-Bromo cAMP on its own stimulated 4-, 18- and 25-
fold rises in IL-15 mRNA levels on days 4, 8 and 12 respectively.
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Figure 3.17
Relative levels of IL-15 mRNA expression after 4 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, a p < 0.023
Figure 3.18
>
Relative levels of IL-15 mRNA expression after 8 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, b p < 0.028
Figure 3.19
Relative levels of IL-15 mRNA expression after 12 days of treatment with a variety of
treatments designed to stimulate decidualisation in ESCs in vitro. The numbers located
above the error bars indicate the fold increase in expression relative to controls. Same
letters denote significant difference, cp< 0.028.
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Figure 3.20 Correlation between prolactin and IL-15 mRNA levels on day 4
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 4 and found to be 0.92. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
Figure 3.21 Correlation between prolactin and IL-15 mRNA levels on day 8
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 8 and found to be 0.97. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
Figure 3.22 Correlation between prolactin and IL-15 mRNA levels on day 12
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 12 and found to be 0.97. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
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Figure 3.20 Correlation between prolactin and IL-15 mRNA levels on day 4
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 4 and found to be 0.92. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
Figure 3.21 Correlation between prolactin and IL-15 mRNA levels on day 8
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 8 and found to be 0.97. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
Figure 3.22 Correlation between prolactin and IL-15 mRNA levels on day 12
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 12 and found to be 0.97. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
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Figure 3.20 Day 4

























Log of relative fold increase in prolactin mRNA expression
Figure 3.22 Day 12
Log of relative fold increase in prolactin mRNA expression
129
Figure 3.20 Correlation between prolactin and IL-15 mRNA levels on day 4
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 4 and found to be 0.92. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
Figure 3.21 Correlation between prolactin and IL-15 mRNA levels on day 8
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 8 and found to be 0.97. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
Figure 3.22 Correlation between prolactin and IL-15 mRNA levels on day 12
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 12 and found to be 0.97. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
128
Figure 3.20 Day 4
o>
o 1.5
Log of relative fold increase in prolactin mRNA expression
Figure 3.21 Day 8
' 0.97
Log of relative fold increase in prolactin mRNA expression
Figure 3.22 Day 12
Log of relative fold increase in prolactin mRNA expression
129
Figure 3.20 Correlation between prolactin and IL-15 mRNA levels on day 4
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin niRNA for the different treatments on day 4 and found to be 0.92. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
Figure 3.21 Correlation between prolactin and IL-15 mRNA levels on day 8
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 8 and found to be 0.97. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
Figure 3.22 Correlation between prolactin and IL-15 mRNA levels on day 12
The correlation coefficient was calculated for the relative expression levels of IL-15 and
prolactin mRNA for the different treatments on day 12 and found to be 0.97. This graph
represents the log values of prolactin mRNA expression against the log values of IL-15
mRNA expression for the different treatment groups and illustrates the rise in IL-15
expression along with prolactin levels. The R2 value is stated on the graph.
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